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Multiple sclerosis is among the most frequent neurological diseases, which 
affect seriously the quality of life of a constantly increasing number of patients, 
inducing physical and mental invalidism with indefinite perspectives. The ongoing 
investigation of the pathogenetic background and the inconclusive analysis of many 
pathophysiological mechanisms and serious neuropathological alterations of the disease 
are dominant crucial topics in the field of neurosciences, aimed at tracing a definite 
way to a therapeutic approach. The authors of this volume attempt to throw light on 
the labyrinth of multiple sclerosis, approaching the disease from the viewpoint of 
epidemiology, autoimmune reactions, symptomatology, mental and physical decline, 
diagnostic procedures, prognosis, and treatment. The authors submit herein, along with 
scientific data, their hope of contributing effectively to ameliorating the quality of life of 
those suffering from multiple sclerosis who wait patiently for the day of recovery.
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Preface
Multiple sclerosis (MS) has for years been a crucial unsolved problem in the field of
neurosciences, and is a serious cause of suffering for millions of patients worldwide, 
affecting psychosomatic homeostasis in the majority of patients.
The etiopathological background of the disease, which is presumably a progressive
inflammation of the central nervous system (CNS), inducing demyelination in the
white matter and degenerative alterations in the gray matter, provoking a multitude
of polymorphic clinical phenomena, is still an open field of intensive, constantly
progressive investigation.
The incidence of MS varies across geographic regions, with high rates in high lati-
tude, affecting three times more women than men at any age. Many genetic factors, 
major histocompatibility complex and non-major histocompatibility complex, may
play an important role in the innate immune mechanisms and in the modulation of
the immune system under the influence of the many exterior environmental risk
factors and viral infections.
A large number of patients have from the onset experienced relapses and remissions
of various neurological phenomena, lasting for many years, whereas a substantial 
number of untreated patients face the tragedy of continuous deterioration of their
physical and mental condition, resulting in a serious irreversible disability. 
Energy failure is the substantial cause of functional impairment in the majority of
patients who suffer from MS. That cause is reasonably associated with neuronal
degeneration, demyelination, and axonal loss based on a wide spectrum of innate
autoimmune mechanisms, inflammatory reactions, mitochondrial dysfunction, cyto-
kine interactions, intracellular and interstitial edema, and perivascular cell reactions.
The clinical manifestations of the disease vary from person to person, from time
to time, and from age to age, and most of them are changeable in the majority of
the cases even from the initial stages of the disease. Vertigo, nausea, vomiting,
hiccups, motor deficits, tremors, dysarthria, cutaneous sensory deficits, sensory
phenomena from mucosae, cerebellar dysfunction, gait instability, diplopia,
vision impairment, visual field defects, dyschromatopsia, phosphenes, painful
conditions, autonomic dysfunction, sphincter insufficiency, fatigue, and cogni-
tive decline, such as episodic memory deficits and impaired visuospacial estima-
tion, emerging early in the disease compose a part of the resizing pattern of the
disease. Cognitive decline, which would be attributed to association of gray and
white matter lesions, in addition to disconnection and dissociation syndrome, is
frequently underestimated in the initial stages of the disease, necessitating neu-
ropsychological evaluation by properly designed tools for MS patients. Cognitive
rehabilitation, which is essential for the improvement of the quality of life of
patients, may include various methods and techniques enabling patients to over-
come common problems of everyday life, coping harmoniously with the disease
burden. Language disorders are not rare phenomena in patients who suffer from
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tion, emerging early in the disease compose a part of the resizing pattern of the 
disease. Cognitive decline, which would be attributed to association of gray and 
white matter lesions, in addition to disconnection and dissociation syndrome, is 
frequently underestimated in the initial stages of the disease, necessitating neu-
ropsychological evaluation by properly designed tools for MS patients. Cognitive 
rehabilitation, which is essential for the improvement of the quality of life of 
patients, may include various methods and techniques enabling patients to over-
come common problems of everyday life, coping harmoniously with the disease 
burden. Language disorders are not rare phenomena in patients who suffer from 
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XIV
Diagnostic criteria for MS have been proposed and introduced for many years, and 
have been revised many times. Most of them may simply facilitate the approach 
of the diagnosis of the disease. Among them, diffusion imaging, resting state 
functional magnetic resonance imaging, magnetic resonance spectroscopy, evoked 
potentials, optical coherence tomography (OCT), OCT angiography, and immuno-
logical analysis of the cerebrospinal fluid may lead to a prompt diagnosis of the dis-
ease even in patients with atypical clinical manifestations and course heterogeneity. 
However, in the differential diagnoses of MS a substantial number of other condi-
tions mimicking the clinical manifestations of the disease should be under con-
sideration. Among them neuromyelitis optica spectrum disorder (Devic’s disease) 
would be differentially diagnosed on the basis of anti-aquaporin 4 antibody, acute 
disseminated encephalomyelitis on the basis of the clinical profile and neuroimag-
ing data, myelin oligodendrocyte glycoprotein (MOG) antibody disease on the basis 
of the level of MOG antibodies, and antiphospholipid syndrome by the detection 
of lupus anticoagulant and anticardiolipin antibodies. In addition, systemic lupus 
erythematosus, small vessel disease, and Susac’s syndrome have also a place in the 
expanded spectrum of the differential diagnosis of MS.
There is no definite targeted therapeutic approach for MS. An efficient therapeutic 
strategy should be based on clear knowledge of the pathogenetic mechanisms of the 
disease. Investigation of the role of myeloid cells and the infiltration of the CNS by 
peripheral lymphoid and myeloid cells may be crucial for a deeper understanding of 
the progression of the disease and the chronicity of the clinical phenomena. Novel 
therapeutic attempts aimed at modulating the activities and reactions of myeloid 
cells might be hopeful in treating MS patients at the initial stages of the disease. In 
addition, the application of autologous Epstein-Barr virus-specific T cell therapy 
may improve the clinical condition of patients. Non-pharmacological therapies, 
such as appropriate diet, proper environment, physical exercise, relaxation and 
progressive muscle relaxation therapy, psychotherapy, cognitive behavioral therapy, 
music therapy, and emotional, social, and spiritual support may also play a benefi-
cial role in the amelioration of the quality of life in the large majority of patients.
In this volume, the authors discuss some of the crucial aspects of the MS drama, 
attempting to contribute to finding a way that may lead to catharsis.












Introductory Chapter: Multiple 
Sclerosis
Stavros J. Baloyannis
1. In the labyrinth of multiple sclerosis
Multiple sclerosis (MS) remains a crucial unsolved problem in the field of neu-
rosciences, being also a serious cause of suffering for millions of patients worldwide 
affecting the quality of life, the personal and social economy, and the psychoso-
matic homeostasis substantially in the majority of the patients.
The etiopathological background of the disease, which is a progressive inflam-
mation of the CNS [1, 2], inducing demyelination in the white matter and degen-
erative alterations in the gray matter in various areas of the brain hemispheres, 
the cerebellum, the brain stem, and the spinal cord, may provoke a multitude of 
polymorphic clinical phenomena inducing a variable type of physical, mental, and 
social disability in the suffering people [3, 4].
The incidence of MS varies considerably across geographic regions, with high 
rates in high latitude and low in the tropical zone, affecting three times more 
women than men at any age, though the climax is between 20 and 40 years. 
Approximately 2.5 million people in the world suffer from multiple sclerosis nowa-
days, and 700,000 among them are registered in Europe [5–7].
Many genetic factors, MHC and non-MHC, may play an important role in the 
innate immune mechanisms and in the modulation of the immune system under 
the influence of the many exterior environmental risk factors and viral infections 
[8, 9]. Among the viruses, the infection with Epstein–Barr virus (EBV), which is 
a common human herpes virus, seems to have a considerable association with the 
incidence of MS, particularly among pediatric patients [10–12].
A large number of patients have from onset the experience of relapses and 
remissions of the various neurological phenomena, lasting for many years, whereas 
a substantial number of untreated patients face the tragedy of the continuous 
deterioration of their physical and mental condition, resulting in a serious irrevers-
ible disability eventually, though primary progressive forms starting from the onset 
of the disease may also occur in approximately 10–15% of patients [13, 14].
Energy failure is obviously the substantial cause of the functional impairment 
in the majority of patients who suffer from multiple sclerosis. That cause is reason-
ably associated with demyelination, neuronal degeneration, and axonal loss, based 
on a wide spectrum of innate autoimmune mechanisms, inflammatory reactions, 
mitochondrial dysfunction, cytokine interactions, intracellular and interstitial 
edema, and perivascular cell reactions [15, 16].
2. The multiform suffering
The multiform clinical manifestations of the disease vary from person to 
person, from time to time, from age to age, and most of them are unstable and 
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changeable in the majority of the cases even from the initial stages of the disease. 
Vertigo, nausea, vomiting, hiccups, motor deficits, tremors, dysarthria, cutaneous 
sensory deficits, sensory phenomena from mucosae, cerebellar dysfunction, gait 
instability, diplopia, vision impairment, visual field defects, dyschromatopsia, 
phosphenes, hearing impairment, painful conditions, neuralgia of the trigeminal 
nerve, autonomic dysfunction, sphincter insufficiency, fatigue, and cognitive 
decline, such as episodic memory deficits and impaired visuospacial estimation, 
emerging early in the disease compose a part of the frequently resizing pattern of 
the disease [17].
Particularly, cognitive decline, which would be attributed to the association of 
gray and white matter lesions [18], in addition to disconnection and dissociation 
syndrome, is frequently underestimated in the initial stages of the disease, neces-
sitating neuropsychological evaluation by properly designed tools for MS patients 
[19]. In fact, cognitive phenomena are evident in the same degree of severity during 
all the stages of the disease, concerning all clinical subtypes [20, 21]. Cognitive 
rehabilitation, which is essential for the improvement of the quality of life of the 
patients, may include various methods and technics enabling the patients to over-
come common problems of everyday life and to cope harmoniously with the disease 
burden, improving skills and capacities on the basis of the neuronal plasticity and 
the principle of functional reorganization of the brain [22, 23].
Language disorders are not rare phenomena in patients who suffer from MS [24]. 
The naming deficit, semantic paraphasia, impaired verbal fluency, grammar and 
syntax deficits, and the loss of high-level language skills necessitate the appropriate 
speech therapy [25].
3. Searching for the truth
Diagnostic criteria for multiple sclerosis have been proposed and introduced 
for many years and have been revised over times [26]. Most of them may simply 
facilitate the approach of the diagnosis of the disease. In general, the clinical estima-
tion of the patients and the incorporation of data from the paraclinical investiga-
tion, especially from MRI [27], diffusion imaging, resting state functional MRI, 
magnetic resonance spectroscopy, evoked potentials, optical coherence tomography 
(OCT) [28], OCT angiography, and immunological analysis of the CSF, may lead to 
a prompt diagnosis of the disease even in patients with atypical clinical manifesta-
tions and marked course heterogeneity [29, 30].
In the cases that clinical and neuroimaging data are atypical or inadequate for 
posing the diagnosis of MS, the findings of oligoclonal band and immunoglobulin 
G (IgG) level in the cerebrospinal fluid analysis, in correlation with the serum data, 
would be a strong argument of intrathecal inflammation, advocating in favor of the 
diagnosis of MS [31].
However, in the differential diagnosis of multiple sclerosis, a substantial number 
of other conditions mimicking the clinical manifestations of the disease should be 
under consideration [32]. Among them, the neuromyelitis optica spectrum disorder 
(Devic’s disease) would be differentially diagnosed on the basis of anti-aquaporin 4 
antibody (AQP4-IgG) [33], the acute disseminated encephalomyelitis (ADEM) on 
the basis of the clinical profile and the neuroimaging data [34], the MOG antibody 
disease on the basis of the level of MOG antibodies [35], and the antiphospholipid 
syndrome by the detection of lupus anticoagulant and anticardiolipin antibodies 
[36]. In addition systemic lupus erythematosus, small vessel disease, and Susac’s 
syndrome have a substantial place in the expanded spectrum of the differential 
diagnosis of MS [37].
5
Introductory Chapter: Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.90475
Disease activity is usually estimated by the clinical relapses and the MRI findings 
of contrast-enhanced lesions, enabling the detection of new lesions on T2-weighted 
images. However, a reasonable criticism and a periodic reevaluation of the adopted 
diagnostic criteria would be of substantial importance for the accuracy of the 
prompt diagnosis of MS [38, 39].
4. Perspectives on resolution
There is no definite targeted therapeutic approach for MS [40–42]. The appli-
cation of many current treatments aims at ameliorating the quality of life of the 
patients by reducing the disability progression and stabilizing the clinical condition 
of the patients [43].
The introduction of interferon in 1993 opened the horizons of many potential 
therapeutic options of various efficacy and side effects, which turned to raise many 
reasonable controversies from the viewpoint of the heterogeneity of the disease, the 
obscure etiopathological background, and the complexity of the pathophysiological 
mechanisms [44].
An efficient therapeutic strategy should be based on a clear knowledge of 
the pathogenetic mechanisms of the disease. The investigation of the role of the 
myeloid cells and the infiltration of the CNS by peripheral lymphoid and myeloid 
cells may be crucial for a deeper understanding of the progression of the disease and 
the chronicity of the clinical phenomena [45, 46].
Novel therapeutical attempts aiming at modulating the activities and reactions 
of myeloid cells might be hopeful in treating MS patients at the initial stages of the 
disease. In addition the application of autologous EBV-specific T cell therapy may 
improve the clinical condition of the patients, ameliorating consequently the qual-
ity of life in a substantial number of them [47–49].
Non-pharmacological therapies [50], such as appropriate diet [51], proper 
environment, physical exercise [52], psychological relaxation [53] and progres-
sive muscle relaxation therapy (PMRT), psychotherapy [54], cognitive behavioral 
therapy [55], music therapy [56], and emotional, social, and spiritual support [57] 
may also play a considerable beneficial role in the amelioration of the quality of life 
in the large majority of the patients.
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Abstract
In steady state, the central nervous system (CNS) houses a variety of myeloid 
cells, such as microglia, non-parenchymal macrophages and dendritic cells (DCs), 
and granulocytes. Most of these cells enter the CNS during embryogenesis and are 
crucial for proper CNS development. In adulthood, these resident myeloid cells 
exert crucial homeostatic functions. In neuroinflammatory conditions, like mul-
tiple sclerosis (MS), both lymphoid and myeloid cells from the periphery infiltrate 
the tissue and cause local damage. Although lymphocytes are undeniably important 
players in MS, CNS-resident and CNS-infiltrating myeloid cells have recently 
gained much-deserved attention for their roles in disease progression. Here, we will 
review significant advances made in recent years delineating myeloid cell functions 
within the CNS both in homeostasis and MS. We will also discuss how these cells are 
affected by currently employed therapeutics for MS patients.
Keywords: microglia, macrophages, dendritic cells, monocytes, granulocytes,  
disease modifying treatments, multiple sclerosis, EAE
1. Introduction
Myeloid cells are crucial for central nervous system (CNS) tissue function both 
in development and adulthood. Other than microglia, which are found in the paren-
chyma, CNS meningeal and perivascular spaces along with the choroid plexus, are 
populated by special subsets of macrophages and dendritic cells [1–3]. Additionally, 
granulocyte cells are also present in the homeostatic CNS [4]. Studies in rodents 
have elucidated mechanisms by which these cells promote tissue physiology.
In multiple sclerosis (MS), myeloid cells play a dominant role. Studies in mice 
and human patient samples show that myeloid cells from the periphery enter 
the tissue through a compromised blood-brain barrier (BBB) and together with 
CNS-resident cells perpetuate the inflammatory environment through secretion 
of inflammatory cytokines and reactivation of primed T cells. However, myeloid 
cells may also exhibit anti-inflammatory and pro-reparative functions. The exact 
contribution of each myeloid subset to disease progression is currently the focus of 
thorough investigation.
Here, we will provide an overview of myeloid cell types and functions in homeo-
stasis and how these populations evolve in neuroinflammation. In addition, we will 
review the effects of therapeutics currently employed for MS patients on myeloid 
cell populations and functions.
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2. CNS-resident myeloid cells in homeostasis
The CNS houses a variety of myeloid cell subsets that exert multiple functions 
crucial to homeostasis such as BBB maintenance, sampling of the local milieu, syn-
aptic pruning, and control of neuronal populations in development and adulthood. 
In this section, we will elaborate on the developmental origin and known functions 
of these subsets in the CNS.
2.1 Microglia
Microglia are resident immune cells within the CNS parenchyma proper. They 
derive from Runx1+ erythromyeloid precursors in the extraembryonic yolk sac and 
enter the brain early in embryonic development [5–7]. Before migrating out of the 
yolk sac, these progenitors acquire CD45 and CX3CR1 expression [8] and seed the 
brain parenchyma around embryonic day 9.5 [7, 9, 10], through a process that is 
mediated largely by the metalloproteinases MMP8 and MMP9 [8].
Microglia development relies on transcription factors PU.1, IRF8, and colony-
stimulating factor 1 receptor (CSF1R) signaling [11], whereas transcription factors 
such as MYB, BATF3, and ID2 are not necessary, suggesting that microglia are tran-
scriptionally distinct from bone marrow-derived myeloid cells [6, 10]. Moreover, 
the microglial transcriptional profile changes at each developmental stage, roughly 
divided into early microglia (microglia that seed the brain from E10.5 to E12.5), pre-
microglia (microglia found in the CNS from E12.5 up to P9), and adult microglia 
[10, 12]. Early microglia are highly proliferative, pre-microglia exert functions on 
synapse pruning [10] and excess neuron elimination [13], and adult microglia per-
form immune surveillance but also synaptic refinement [11, 14–16]. During devel-
opment, microglia control the numbers of neural progenitors via phagocytosis. This 
was shown by clodronate-mediated microglia deletion in organotypic brain cultures 
[13] or in CSF1R knockout mice, which lack microglia [17]. However, CSF1R is also 
expressed in other cells including peripheral myeloid subsets and neurons. Specific 
deletion of CSF1R in nestin+ cells recapitulated some of the observed effects in the 
global CSF1R knockout [17].
Complement components C1q and C3 tag extra synapses which are then 
removed by microglia via CR3 receptor-mediated phagocytosis [15, 16]. This 
process is known as synaptic pruning [15]. Neuronally derived CX3CL1 acting 
on microglial CX3CR1 is one of the cues that guide microglia to the synapses 
[15]. Mice deficient in microglia or CX3CR1 exhibit neuronal connectivity and 
behavioral deficits similar to those observed in autism spectrum disorders [4, 10, 
18, 19]. Developing microglia also control neural cells in the cerebellum and were 
shown to induce Purkinje cell death via NADPH activity [5, 20]. On the other hand, 
developing microglia also secrete trophic factors that promote neuronal circuit 
formation and neuronal survival. Microglial-derived insulin-like growth factor 1 
(IGF-1) promotes survival of cortical layer V neurons in postnatal development. 
In addition, it induces the fate of many cell lineages, such as oligodendrocytes, and 
also protects them from glutamate-mediated apoptosis [5]. Basic fibroblast growth 
factor, hepatocyte growth factor, epidermal growth factor, platelet-derived growth 
factor, nerve growth factor, and brain-derived neurotrophic factor are all also 
secreted by microglia and contribute to neuronal development, maintenance, and 
function throughout life [21–23].
As microglia mature, they adopt a ramified morphology characterized by a 
small body and thin, long processes. Interestingly, recent studies suggest that adult 
microglia are not a homogeneous population and their activation state is the result of 
region-specific cues [24–30]. They are self-renewing via a local progenitor [31, 32], 
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but in certain instances and when microglia are depleted for prolonged periods of 
time via genetic or pharmacologic methods, peripheral myeloid cells can enter and 
engraft in the CNS for long periods but remain functionally distinct [33]. Microglia 
in the steady-state CNS depend on CSF1R signaling for survival. Both CSF1R ligands, 
CSF1 and IL-34, are found in the normal CNS and their expression is regionally 
controlled [34]. Interestingly, in the absence of CSF1, microglia numbers decrease by 
30%, while in the absence of IL-34, microglial numbers decrease by 70%. IL-34 in 
particular controls the migration of microglial precursor cells in the CNS via CSF1R 
signaling in development [35]. TGF-β signaling is also necessary for homeostatic 
microglial functions, and in its absence, they assume a transcriptome that is similar to 
that of peripheral macrophages [36].
Defining microglial markers that are distinct from those of peripheral mono-
cytes has been the focus of investigation for many years. New RNA-Seq techniques 
yielded a number of genes that are preferentially expressed by microglia but not 
peripheral myeloid cells in homeostasis [1, 10, 18, 37, 38]. Lately, the most com-
monly employed markers are the purinergic receptor P2Y, G-protein coupled recep-
tor 12 (P2RY12), the transmembrane protein TMEM119, and the transcriptional 
regulator Sal-like 1 (SALL1) [1, 10, 18, 37, 38]. Both P2RY12 and TMEM119 are 
expressed by the vast majority of microglia within the healthy CNS. The function 
of TMEM119 in microglia has not been yet elucidated, but in other cell types, it 
has been implicated with differentiation and proliferation [39–42]. P2RY12 serves 
as a chemotactic receptor that guides microglia to sites of injury [26]. SALL1 is a 
microglia fate-determining factor, vital for expression of essential microglial genes 
and normal microglial morphology [26, 36]. Whether these markers are still able 
to differentiate between microglia and infiltrating myeloid cells in neuroinflam-
mation, when all these cells undergo major transcriptional changes, is still under 
investigation. However, SALL1 and TMEM119 are emerging as the most reliable 
microglial markers.
Adult microglia exert multiple roles in tissue maintenance: they phagocytose 
debris or dead cells, clear toxic amyloid-β, shape neural circuits via phagocytosing 
inappropriate or inactive connections [16], provide trophic support to neurons by 
producing growth factors, and regulate neurogenesis in the hippocampus and the 
subventricular zone (SVZ). Interestingly, microglial-derived CX3CL1 increases with 
exercise and confers a protective effect on neuronal cells, while CX3CR1 deletion 
results in activated microglia with an inflammatory phenotype, leading to decreased 
rates of adult neurogenesis in the hippocampus [43–45]. In addition, microglia 
phagocytose neuronal progenitors in the adult SVZ, thus controlling the local pool 
of neurons [18, 44, 46]. Microglia also influence oligodendrocyte development 
and myelinogenesis both during development and in adulthood. In the adult CNS, 
microglia are necessary for myelin homeostasis and maintenance of adult oligo-
dendrocyte progenitor cells [47, 48], promote BBB function [49, 50], and in case of 
injury, they migrate to the affected site to promote repair [51].
Microglial malfunction is associated with neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease, and neurodevelopmental and psycho-
logical defects such as Rett syndrome and obsessive-compulsive disorder [10]. 
Furthermore, the lack of phagocytosis by microglia results in excess synapses which 
is associated with impaired memory formation [16].
2.2 Tissue-resident macrophages
In addition to microglia, the healthy CNS houses three types of non-paren-
chymal tissue-resident macrophages. They are named based on their location and 
are currently categorized as perivascular macrophages, meningeal macrophages, 
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and macrophages in the choroid plexus [1, 52]. These macrophage populations are 
optimally placed to regulate and interrogate peripheral cell entry, act as sentinels 
by sampling their environment, and quickly respond in the event of an insult. 
Previously thought to be derived from bone marrow (BM) monocytic progenitor 
cells, it is now established that the majority of CNS-resident macrophages are 
long-lived and transcriptionally similar to microglia. As such, most of these cells 
are derived from erythromyeloid progenitors found in the extraembryonic yolk 
sac or the fetal liver, and their generation is dependent on PU.1 and independent 
of MYB and BATF3 [1, 7]. Choroid plexus macrophages are the most distinct 
among these types of CNS non-parenchymal macrophages and originate from 
either embryonic precursors or BM.
Perivascular macrophages are located between the blood vessel endothelium (of 
BBB) and the glia limitans, which form the barrier for the CNS parenchyma. They 
are wrapped around endothelial walls with their elongated cell bodies and monitor 
the perivascular space [2]. Perivascular macrophages provide nutrients to endo-
thelial cells, regulate vascular permeability, maintain BBB integrity, clear toxic 
amyloid-β from the CNS, sample debris to assess the local milieu, and communi-
cate with surrounding cells [52]. Their location is ideal to simultaneously sample 
both the CNS interstitial fluid and the blood [1, 52]. Perivascular macrophages 
infiltrate the CNS at the same time as microglia (E 9.5) and populate the abluminal 
spaces of the newly developed vasculature. Together with microglia, these macro-
phages play significant roles on the refinements of the developing vasculature [53]. 
In adulthood and in response to injury, perivascular macrophages promote anasto-
moses and the repair of vasculature [54].
Meningeal macrophages have a very similar origin and transcriptional control as 
perivascular macrophages. They are located in between meningeal vasculature and 
ER-TR7+ fibroblast-like cells that line the meninges. They also express similar mark-
ers to those of perivascular macrophages and are also long-lived with negligible 
contribution from the periphery [1, 2].
The choroid plexus macrophages reside on the apical side of the epithelium 
facing the cerebrospinal fluid (CSF) in the stroma. The stroma of the choroid 
plexus is highly vascularized and surrounded by a monolayer of cuboidal epi-
thelial cells, which are joined together by tight junctions forming the blood-CSF 
barrier. The choroid plexus is located in all four ventricles of the brain and is 
responsible for producing CSF [52]. It allows trafficking of a variety of immune 
cell types and is an area with an anti-inflammatory environment [55, 56]. In addi-
tion, the choroid plexus is the gateway to the CNS and is an area through which 
pioneering T cells gain access into the CNS in preclinical stages of the MS murine 
model experimental autoimmune encephalomyelitis (EAE) [57]. Unlike the other 
types of CNS macrophages, these macrophages are partially replenished from the 
bone marrow [1].
All of these brain-resident macrophages express the mannose recep-
tor CD206 and scavenger receptor CD163, along with CD11b, CX3CR1, and 
MHC-II. Perivascular and meningeal macrophages also express the lymphatic vessel 
endothelial hyaluronan receptor LYVE1, which is not expressed in choroid plexus-
associated macrophages [1, 2, 58].
2.3 Dendritic cells
At steady state, dendritic cells (DCs) are sparsely distributed within the non-
parenchymal CNS spaces. They are more numerous in the leptomeninges and dura 
mater, less prominent in the choroid plexus, and mostly absent from perivascular 
spaces [3].
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DCs develop from committed DC or monocyte progenitors in the BM and 
are dependent upon FLT3 signaling [59]. They are relatively short-lived and are 
replenished roughly every 1–2 weeks [60]. Mature DCs are divided into con-
ventional DCs (cDCs), plasmacytoid DCs (pDCs), and monocyte-derived DCs 
(moDCs). cDCs are further subdivided into cDC1 and cDC2. cDC1s are associated 
with Th1 responses [61, 62], while cDC2 with Th2 and Th17 [63]. cDC1s are also 
able to cross present antigens and activate CD8+ T cells. cDCs leave the BM in the 
form of committed precursors, while pDCs mature in the BM before entering the 
circulation. In addition, moDCs are not usually found in steady state but are crucial 
mediators on inflammatory responses [64].
IRF4 and IRF8 are transcription factors differentially expressed in the vari-
ous DC subsets. cDC1s are IRF8+IRF4lo/−, cDC2s are IRF8loIRF4+, pDCs are 
IRF8+IRF4+, and moDCs are IRF4loIRF8lo [65]. cDC1s do not express CD11b. 
Within the mouse CNS, the majority of DCs are cDC2 and are mostly located in the 
leptomeninges and dura mater, while in the choroid plexus, the majority of DCs are 
cDC1s [3].
2.4 Granulocytes
Although their presence within the CNS at steady state is commonly ignored, 
various types of granulocytes such as neutrophils, mast cells, basophils, and eosino-
phils are found within perivascular and meningeal spaces and the choroid plexus 
[4]. Mast cells in particular are also found within the parenchyma [66, 67].
Neutrophils exit the bone marrow in a mature state and are thought to be 
short-lived. However, subsets of neutrophils live much longer than previously 
thought and, more importantly, some have been found in various organs likely 
as a local reservoir [68]. It is now acknowledged that neutrophils or neutrophil 
subsets may have different functions. Other than the well-documented inflamma-
tory functions, pro-reparative CD206+ neutrophils, VEGF-responding angiogenic 
neutrophils, and CD11c+Ly6G+ “hybrid” cell types have been identified [69–72]. 
Interestingly, neutrophils were recently detected in the normal murine CNS 
localized within the subdural meningeal spaces, but their contribution to tissue 
homeostasis is still not known [73].
Mast cells (MCs) are derived from CD34+ bone marrow progenitor cells, enter 
the circulation in an immature state, and mature once they reach the tissue in 
response to local cues. They are mostly known for their effects during allergic/
atopic responses mediated by cross-linking of their FcεRI receptor by IgE. MCs are 
a heterogeneous population, and depending on the types of proteases they carry 
within their granules, they are broadly categorized into at least three subtypes: MCs 
that contain only tryptase (MCT), MCs that contain only chymase (MCC), and 
MCs that contain tryptase, chymase, carboxypeptidase, and cathepsin G (MCCT) 
[74, 75]. MCs are loaded with granules containing preformed mediators and can 
synthesize mediators de novo. They are found in many tissues and usually associ-
ated with vascular epithelial cells and nerves. CNS MCs are constitutively active and 
degranulate in response to homeostatic or inflammatory stimuli [67, 76–78]. Their 
preformed granules are released immediately upon activation and contain various 
mediators such as histamine, serotonin, and TNF-α in addition to proteases. They 
can quickly synthesize lipid mediators such as prostaglandins and leukotrienes and 
growth factors. A late-phase MC activation results in de novo production of inflam-
matory cytokines such as IL-6 and TNF-α [74, 79].
Within the healthy CNS, MCs are found within the thalamus, hypothalamus, 
entorhinal cortex, hippocampus, meninges, and perivascular spaces in proximity 
to the BBB. They interact with neurons and microglia, and their granules contain 
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a plethora of mediators including neurotransmitters. Their location allows them to 
modulate BBB permeability, and genetically modified mice that lack MCs display 
decreased BBB permeability both in homeostasis and neuroinflammation [67, 77, 78].
MC activity in stress has been associated with migraines [78, 80]. Moreover, 
histamine released from MCs was shown to promote wakefulness in adult mice [81] 
and microglial synaptic pruning in the developing CNS, which then regulates sexual 
behavior in adulthood [82].
3. Myeloid cells in multiple sclerosis
Pathologically, MS is characterized by focal demyelinating lesions disseminated 
in space and time and neuronal and axonal damage. MS lesions are rich in myeloid 
cells (microglia, infiltrating monocyte-derived macrophages, and DCs), which out-
number lymphoid cells [83]. Below we will discuss current knowledge on myeloid 
cells in MS, which are now emerging as crucial players in disease pathogenesis and 
progression. Some of this knowledge is derived from studies on the animal model 
of MS, experimental autoimmune encephalomyelitis (EAE). Although this model 
has been criticized [84], it mimics most of the CNS pathology observed in MS such 
as tissue infiltration by immune cells, formation of lesions, local inflammation, and 
progressive axonal loss [85, 86].
Monocytes are not found in the healthy CNS but are regularly found in the CNS 
and CSF of MS patients. Once they enter the CNS, monocytes mature into macro-
phages and participate in disease progression. There are three well-characterized 
monocyte subsets categorized based on expression patterns of the LPS receptor 
CD14 and the Fce (greek) RIII receptor CD16: the classical CD14++CD16- 
(similar to the inflammatory monocyte Ly6ChiCCR2+ in mice), the nonclassical 
CD14+CD16++ (similar to the anti-inflammatory CX3CR1+Ly6Clo in mice), and 
the intermediate CD14++CD16+. CD16+ monocytes have been associated with 
inflammation and promoting the generation of Th17 cells. MS patients with active 
disease show increased CD14+ cells both in the blood and the CSF. These cells also 
contribute to BBB disruption [87, 88].
Both conventional and plasmacytoid DCs are increased in the blood and CSF of 
MS patients. cDCs are usually found early in disease, and pDC numbers are highly 
increased in the CSF during relapses. Circulating cDCs in MS patients upregulate 
CCR5 which is a receptor for CCL3 and CCL5, both of which are upregulated in MS 
lesions. However, cDCs in primary progressive MS display an immature phenotype 
[89]. Interestingly, although pDC numbers increase in MS, these cells are found 
to be phenotypically similar to those of healthy controls. Although the data on 
circulating pDCs are still conflicting, imbalances in DC populations may result in 
significant changes in T-cell functionally in MS [90].
3.1 Myeloid cells in MS lesions
MS lesions are found both within the brain and spinal cord and can be formed 
within the white and the gray matter [91, 92]. The most commonly employed 
classification is the four types of lesions described by Lucchinetti and colleagues 
[93]. Type I is characterized by macrophage products, and type II is characterized 
by antibody and complement deposition, while type III lacks complement and 
antibody deposition. Types I and II have clearly demarcated borders, while type III 
is characterized by diffuse demyelination and lacks clear demarcation. Type IV is 
characterized by dystrophic apoptotic oligodendrocytes. In most of these lesions, 
the major cell types are myeloid cells [83].
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Although more pronounced during relapses, infiltrating myeloid cells and 
activated microglia are found within the CNS of MS patients throughout the disease 
and are associated with demyelination, oligodendrocytic loss, and axonal dam-
age [92, 94, 95]. With the exception of rapid progressive MS, in which the CNS 
is intensely infiltrated [94], in progressive forms of the disease, the tissue is not 
massively infiltrated; however, myeloid cells (microglia and/or infiltrating myeloid) 
remain activated [92, 96]. During progressive stages of the disease, axonal loss is 
prominent leading to tissue atrophy in both MS and EAE [86, 92]. These processes 
are likely mediated via the production of oxygen radicals produced by either 
microglia or infiltrating myeloid cells [84].
3.1.1 Microglia/macrophages
The contribution of microglia to MS is still debated. Studies in mice have shown 
that microglia are poor antigen-presenting cells and not likely to activate infiltrat-
ing lymphocytes. Instead, microglia may contribute to the disease process via 
oxidative stress and production of pro-inflammatory cytokines that may activate 
astrocytes or cause oligodendrocytic damage. Microglia are highly phagocytic and 
thus can remove myelin debris and cellular fragments, damaged axons, and dead 
cells. It is clear that microglia are activated in the CNS of MS patients, but whether 
they promote disease or facilitate repair is still not well delineated. One of the main 
hurdles for these investigations is that there is no unique marker to reliably distin-
guish microglia from infiltrating monocytes in neuroinflammation. Additionally, 
activated microglia are morphologically indistinguishable from infiltrating mono-
cytes/macrophages. RNA transcriptome analysis has yielded a number of markers 
that show preferential expression in microglia (see Section 2.1). TMEM119 is the 
only marker so far examined in MS tissue and seems to be expressed by a subpopu-
lation of myeloid cells within lesions and in cells with microglial morphology in 
nonlesional areas [97]. However, there is still not a wide breadth of studies exam-
ining the specificity of TMEM119 in neuroinflammation, when all myeloid cells 
undergo major transcriptional changes [2]. Thus, below we will talk about microglia 
and macrophages as one population in active MS lesions and specify TMEM119-
expressing cells within the MS CNS.
Microglia/macrophages (M/Ms) in active MS lesions are heterogeneous and 
capable of performing a variety of activities that may promote or control inflam-
mation and repair [98, 99]. M/Ms found within active MS lesions usually express 
markers associated with inflammatory macrophage functions, including inducible 
nitric oxide synthase (iNOS), co-stimulatory molecules CD40 and CD86, the Fc 
receptors CD32 and CD64, phagocytosis marker CD68, and p22phox, a subunit of 
NADPH oxidase [100, 101]. In addition, M/Ms may also express anti-inflammatory 
markers such as the mannose receptor CD206 and the scavenger receptor CD163 
[100]. Approximately half of the myeloid cells within active lesions express 
TMEM119, suggesting these cells may be microglia. Interestingly, PY2R12, which is 
usually expressed in homeostatic microglia, is not expressed in these cells, suggest-
ing it is downregulated upon activation [97].
MS lesions are not static and over time grow outward, eventually becoming 
chronically active. These lesions are slowly expanding and have a thin border of 
M/Ms. The center of these lesions appears quiescent and populated by lipid-laden 
(foamy) macrophages, many of them expressing CD206 and CD163 [98, 102]. 
However, M/Ms lining the rim of these lesions express iNOS and HLA-DR, suggest-
ing they are inflammatory and promote T-cell functions [103]. M/Ms at the rims of 
either active or chronically active plaques contain iron which has been suggested to 
promote MS pathology [104, 105]. In the normal CNS, most iron is found within 
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either active or chronically active plaques contain iron which has been suggested to 
promote MS pathology [104, 105]. In the normal CNS, most iron is found within 
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oligodendrocytes or myelin. When iron is released after oligodendrocytic death and 
demyelination, it is internalized by ferritin+ M/Ms which acquire a dystrophic phe-
notype [106]. Interestingly TMEM119+ cells that express low or no P2RY12 (likely 
activated microglia) are found within chronically active or slow-expanding lesions, 
and their density decreases inward. Strikingly, there are no differences between 
overall M/M density and levels of activation between lesion types [97, 100, 103].
Areas of the CNS that are far from the demyelinating lesions and often appear-
ing normal (normal-appearing white matter; NAWM) are also characterized by 
scattered microglial activation. Interestingly, ramified microglia were shown to 
express iNOS and were often close to injured axons [107]. However, microglia 
have also been documented to exhibit a suppressed and anti-inflammatory char-
acter [108]. Clusters of microglia or macrophages, known as microglial nodules, 
have been found in NAWM in close proximity to degenerating axons. These 
nodules appear in the absence of extensive inflammation, astrogliosis, or demy-
elination, and their formation has been argued to be one of the early events in 
MS pathology [109]. Furthermore, P2RY12+ TMEM119+ microglia in the NAWM 
also expressing activation markers CD68 and p22phox are found in both MS and 
healthy controls’ brains, suggesting that certain microglial populations are in a 
pre-activated state [97].
In addition to white matter, demyelination is also observed within the gray 
matter. MS gray matter is characterized by less infiltration by immune cells and less 
activation of M/Ms compared to white matter. This type of demyelination has been 
mostly attributed to aberrant microglia functions such as ROS production via the 
NADPH oxidase activity. This mechanism seems to be more prominent in the gray 
matter compared to white matter lesions. In addition, cortical microglial activation 
can be observed via PET imaging by administering the traditional PK11195 and 
more recently the novel PBR28 ligand [110, 111].
In progressive forms of MS, M/Ms are activated both within the lesions and in 
the normal-appearing white and gray matter, and this has been linked to inflam-
matory cytokines produced in the meninges, likely by infiltrating B cells [112, 113]. 
Activated complement component 3 fragments (C3d) are found within microglia 
clusters of slowly expanding lesions in progressive but not acute MS [114] and in 
close proximity of damaged axons. This suggests that C3 activation and deposition 
are not likely associated with lesion initiation but rather a mechanism that facilitates 
the removal of axonal and cellular debris. Furthermore, the activation/phagocytosis 
marker CD68 is significantly increased in the NAWM in progressive forms of MS 
compared to that of relapsing–remitting MS and healthy controls [97].
3.1.2 Dendritic cells
Both cDCs and pDCs accumulate in the leptomeninges and lesions in MS 
patients. MoDCs, which are not present in the homeostatic CNS, differentiate from 
infiltrating inflammatory monocytes after these reach the CNS of MS patients. 
Studies in murine EAE showed that both cDCs and moDCs are found within 
the CNS infiltrates. cDCs express CD26 and ZBTB46, a transcription factor also 
expressed in human cDCs, while moDCs express CD88 and CD64 [3, 103, 115]. 
Although these markers may be expressed by other cell types, they are useful mark-
ers for identification of DC subsets. cDCs are the most efficient antigen-presenting 
cells and are able to process larger myelin fragments to activate naive and effector 
T cells. Both cDCs and moDCs progressively expand during the onset and peak of 
EAE in every CNS compartment. pDCs are not efficient antigen-presenting cells 
but are equipped to secrete inflammatory cytokines and promote an inflammatory 
environment to support cDCs and moDCs [116].
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3.1.3 Granulocytes
Neutrophils are relatively rare in established MS lesions; thus, their contribu-
tion to disease course has long been debated. Studies in EAE show that neutrophils 
are part of the inflammatory lesions, appear early in disease process [86, 117], and 
are increased in peripheral lymphoid organs and blood [117]. Neutrophils may 
promote early disease progression by increasing permeability of the BBB, pos-
sibly through secretion of matrix metalloproteinases or the release of neutrophil 
extracellular traps (NETs) [118, 119]. Inactivation of neutrophil products, such as 
myeloperoxidase or neutrophil elastase, results in milder EAE course and associated 
optic neuritis [120, 121]. In agreement with the EAE data, CSF of newly diagnosed 
patients shows elevated neutrophil counts [122], and the CSF of patients with 
established disease contains increased levels of the neutrophil chemoattractant 
CXCL8 [123, 124]. Neutrophil elastase and chemokines that promote neutrophil 
recruitment, such as CXCL1 and CXCL5, are systemically elevated in relapsing MS 
patients and correlate with lesion burden and clinical disability [125]. Transcripts of 
the granulocyte colony-stimulating factor (G-CSF) which promotes the prolifera-
tion and differentiation of neutrophils (and other granulocytes) are found within 
lesions but not in NAWM [126], and treatment with G-CSF worsens MS symptoms 
[127, 128]. Thus, lack of neutrophil detection in MS lesions may be due to incorrect 
sampling timing.
Interestingly, mast cells are found in close proximity to MS lesions and were 
initially observed in 1890 by Neuman [129] and later by other groups [66, 130–132]. 
Their numbers are very low compared with those of the other myeloid subsets; 
thus, not much is known about their contribution to disease progression. However, 
the ability of mast cells to secrete histamine and proteases may facilitate disease 
onset or relapses by promoting vascular permeability and tissue infiltration. In 
EAE, mice with spontaneous c-Kit mutations that lead to deletion of mast cells have 
shown that these cells may prevent, promote, or have no effect on disease onset and 
progression [133]. These conflicting data are likely due to the fact that none of these 
mouse strains are specific and efficient mast cell knockouts.
4. Effect of MS therapeutics on myeloid cells
MS therapies are designed to dampen immune system activation. Although most 
of these therapies target lymphocytes, myeloid cells can also be affected directly or 
indirectly. This section will explore how current MS therapies affect myeloid cells.
4.1 IFN-β
IFN-β, the first FDA-approved biologic therapeutic for MS, is a pleiotropic 
cytokine exerting a plethora of effects on a variety of cells [134, 135]. Monocytes 
isolated from MS patients treated ex vivo with IFN-β exhibit impaired inflamma-
tory responses when stimulated with LPS/alum compared to monocytes isolated 
from healthy donors [136]. Ex vivo treatment of DCs derived from MS patients or 
healthy donors with IFN-β reduced the expression of IL-1β and IL-23 and upregu-
lated the expression of IL-12p35 and IL-27p28, which resulted in reduced generation 
of Th17 cells [137]. Additionally, studies in EAE showed that deletion of IFN-α/β 
receptor (IFNAR), the receptor of IFN-β specifically on myeloid cells, resulted in 
aggravated EAE disease [138].
IFN-β is one of the most common first-line MS treatments; however, a large 
proportion of patients is not responsive. Interestingly, non-responders exhibit 
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exaggerated upregulation of type I IFN-responsive genes either at baseline or in 
response to IFN-β treatment compared to responders [139–141]. MS patients that 
upregulated the death-associated receptor TRAIL on monocytes were responsive 
to IFN-b treatment, but those who did not upregulate TRAIL were not respon-
sive to IFN-b treatment. than patients that did not [142]. Additionally, mono-
cytes isolated from MS patients treated with IFN-β for prolonged periods of time 
(9 months to 6 years) upregulated the co-stimulatory molecules CD80, CD86, 
and CD40 [143], and were associated with responsiveness to treatment [144]. 
A different study, however, showed a positive association between monocytic 
CD40 upregulation, early after IFN-β injections (9–12 h) and relapses [145].
About 30% of MS patients treated with IFN-β also develop antidrug antibodies 
and thus are not responsive to treatment. Antidrug antibody generation was associ-
ated with decreased NOTCH2 signaling. NOTCH2, which promotes the conversion 
of patrolling inflammatory monocytes to anti-inflammatory phenotype [146], was 
markedly reduced in CD14+ monocytes of untreated MS patients that developed 
antidrug antibodies 12 months after IFN-β therapy initiation [147].
All the above suggest that defining myeloid cell subset propensities in MS before 
and after treatment initiation will be useful in determining whether IFN-β is a suit-
able treatment for specific patients.
4.2 Glatiramer acetate
Glatiramer acetate (GA) is a synthetic random copolymer, composed of glutamic 
acid, alanine, lysine and tyrosine, employed as a treatment for relapsing-remitting 
MS. MS patients treated with GA show a shift toward Th2 responses and produce 
anti-inflammatory/pro-repair mediators, likely due to GA effects on myeloid 
subsets [148, 149]. Initial studies showed that GA binds to MHC-II, altering the 
myelin antigen presentation capabilities resulting in impaired activation of auto-
reactive T cells [150, 151]. However, it was later shown that GA can also exert its 
anti-inflammatory effects independently of MHC-II [152]. Instead, GA was shown 
to promote the generation of anti-inflammatory monocytes which support regula-
tory T-cell functions [152].
In support of this, monocytes isolated from the blood of GA-treated MS patients 
produced significantly higher amounts of IL-10 and lower amounts of IL-12, and 
the levels of CD16+ anti-inflammatory monocytes were restored to those of healthy 
controls [153, 154]. DCs from GA-treated MS patients exhibit reduced IL-12 pro-
duction [155] and express lower levels of CD40, upregulation of which is associated 
with relapses [156]. Furthermore, the activity of myeloid-derived suppressor cells, 
a population that suppresses inflammatory responses, is augmented in GA-treated 
MS patients [157], and GA-treated human microglia express IL-10 and reduce 
production of pro-inflammatory TNF-α [153]. Increased levels of circulating IL-27, 
a regulatory cytokine produced by myeloid cells in inflammatory conditions, was 
recently linked to better GA therapeutic outcomes [158]. Another study showed 
increased levels of IL-27 in blood, CSF and lesions of MS patients. however, there 
was no association with treatments [159].
4.3 Fingolimod
Fingolimod is the first oral therapy approved to treat relapsing-remitting MS 
and is more effective in reducing relapses than IFN-β [160]. Fingolimod (FTY720) 
is phosphorylated by sphingosine kinase, and its phosphorylated metabolite 
(FTY720-P) binds to the G-protein-coupled sphingosine-1-phosphate (S1P) 
receptors. S1P receptors are expressed on a variety of cells including neural, glial, 
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and endothelial cells in the CNS and most of the immune cells in the CNS and the 
periphery [161]. One of the mechanisms by which fingolimod reduces disease sever-
ity and relapses in MS is that it binds S1PR1, a type of S1P receptor, on lymphocytes 
and prevents their egress from lymphoid tissues [162].
Fingolimod’s immunosuppressive effects are also exerted on myeloid cells. 
Incubation of murine macrophages or human monocytes with either S1P (the 
natural ligand of S1PR1), or fingolimod, respectively, reduced inflammatory 
responses after LPS exposure [163–165]. Although microglia, DCs, and peripheral 
macrophages express similar patterns and levels of S1P receptors, fingolimod 
downregulated ERK phosphorylation only in DCs and macrophages. Fingolimod 
also downregulated expression of the pro-inflammatory cytokine IL-12 and 
upregulated anti-inflammatory IL-10 in DCs and macrophages but not in microglia 
[164]. Fingolimod crosses the BBB [168], and therapeutic administration of fingo-
limod reduced TNF-α production by microglia and monocytes in EAE [163]. Flow 
cytometry analyses of DCs and monocytes isolated from MS patients before and 
during fingolimod treatment showed decreased levels of activation markers (CD83, 
CD150, and HLA-DR). Furthermore, fingolimod treatment reduced pro-inflamma-
tory cytokine production, phagocytic activity of DCs and monocytes, and impaired 
priming of Th1 and Th17 cells [166]. Interestingly, monocytes isolated from 
fingolimod-treated MS patients exhibited reduced expression of pro-inflammatory 
micro-RNA miR-155 but also of antioxidant genes HMOX1 and OSGIN1 compared 
to untreated patients [167]. When monocyte-derived macrophages and microglia 
were examined in vitro, fingolimod reduced LPS-induced inflammatory cytokines 
and increased expression of antioxidants. These data suggest that the effects of 
fingolimod on myeloid cells in vivo may be an indirect effect.
4.4 Dimethyl fumarate
Dimethyl fumarate (DMF) was approved as an oral first-line therapeutic for 
relapsing-remitting MS in 2013. It is a methyl ester of fumaric acid, quickly metabo-
lized to active monomethyl fumarate which activates transcription factor nuclear 
factor erythroid-derived 2 (Nrf2) and suppresses NF-κB to modulate oxidative 
stress [169]. DMF exerts its effects on multiple immune subsets [170].
Monocytes from DMF-treated RRMS patients express reduced levels of the 
pro-inflammatory micro-RNA miR-155, and DMF-treated human microglia and 
monocyte-derived macrophages had reduced production of pro-inflammatory 
cytokines after LPS stimulation, indicating direct regulatory effects [167].
DMF reduces neuroinflammation levels and cognitive deficits induced by 
systemic LPS administration in mice [171]. In EAE, DMF promoted the generation 
of anti-inflammatory monocytes and decreased macrophage infiltration into the 
CNS resulting in milder clinical deficits. Interestingly, these effects were exerted 
independently of Nrf2 [172, 173].
4.5 Teriflunomide
Teriflunomide is a reversible inhibitor of dihydroorotate dehydroge-
nase (DHODH), a mitochondrial enzyme active in proliferating cells [174]. 
Teriflunomide impairs proliferation of lymphocytes, but exerts nebulous effects 
on myeloid cells [175]. In EAE, teriflunomide reduced T-cell and myeloid cell 
infiltration of the CNS [176]. In cultured primary microglia, teriflunomide down-
regulated expression of CD86 and mildly upregulated of IL-10 [177]. Ex vivo, 
teriflunomide treatment decreased production of IL-6 and CCL2 in activated 
monocytes from healthy individuals [178].
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Furthermore, MS patients after 6 months of treatment showed increased IL-10 
production and PD-L1 expression in monocytes, implying that teriflunomide 
induces anti-inflammatory and regulatory responses in these cells [179].
4.6 Monoclonal antibodies
Several recently developed antibody-based MS therapies target lymphocytes. 
Below, we will discuss whether and how these therapies affect myeloid cells.
4.6.1 Natalizumab
Natalizumab (NTZ) is an immunomodulatory antibody that limits immune cell 
infiltration into the CNS by blocking the interaction between the very late activa-
tion antigen-4 (VLA-4), an integrin expressed on lymphocytes and myeloid cells, 
and vascular adhesion molecule-1 (VCAM-1) [180]. As a result, fewer cells are 
able to migrate and infiltrate the CNS [181]. NTZ reduces relapses and lesion load 
but increases the risk for progressive multifocal leukoencephalopathy [182]. NTZ 
reduced the frequencies of mature activated pDCs; however, this activation was not 
a direct effect of NTZ on pDCs [183].
Triggering receptor 2 expressed on myeloid cells (TREM2) is an innate immune 
receptor associated with inflammatory responses and within the CNS expressed 
by microglia [184]. In neuroinflammation, microglia shed TREM2, which can be 
detected in CSF [185, 186]. NTZ reduced CSF-soluble TREM2 to baseline levels, 
indicating dampened microglial activation, which is associated with improved 
clinical outcome after 12 months of treatment [187]. It is not clear however whether 
there is a direct effect of NTZ on microglia.
4.6.2 Anti-CD20 antibodies
There are multiple anti-CD20 monoclonal antibodies shown to ameliorate 
relapses in relapsing-remitting MS including rituximab, ocrelizumab, and ofatu-
mumab [188]. However, ocrelizumab is the only anti-CD20 antibody that exerts 
beneficial effects in relapsing-remitting and also in primary progressive MS [189]. 
A subset of GM-CSF-producing memory B cells, more prevalent in MS patients 
than healthy controls, was shown to activate pro-inflammatory myeloid cells 
in vitro [190]. Following B-cell-depleting therapy in MS patients, the inflammatory 
myeloid response is diminished [190].
4.6.3 Alemtuzumab
Alemtuzumab is a monoclonal antibody that binds CD52 and effectively 
depletes CD52-expressing lymphocytes through antibody-dependent cell-mediated 
cytolysis. Both lymphocytes and myeloid cells express CD52; however, myeloid 
cells are more resistant to alemtuzumab-mediated cytolysis. Thus their numbers 
are not affected by treatment [191]. Neutrophils, however, express CD52 and are 
subject to lysis during alemtuzumab treatment [192], occasionally leading to severe 
 neutropenia [193].
5. Conclusion
The contribution of myeloid cells to MS progression is now widely appreciated. 
Their persistent elevated presence in lesions and activated phenotype, regardless 
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of tissue infiltration load, in both relapsing and progressive MS, suggest they play 
crucial roles in disease progression and chronicity. Although gaps in knowledge still 
exist, recent advances faciltated the efforts by researchers and clinicians to dissect 
the roles of each myeloid subset in the disease process.
Current therapeutics have broad activities or specifically target lymphocyte 
functions. In many instances, however, their efficacy stems from their direct or 
indirect effects on myeloid cell functions. Future research focusing on modulation 
of myeloid populations and their activities will prove useful for the design of novel 
therapeutics for MS patients.
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Diagnosis of Multiple Sclerosis
Joyce Pauline Joseph
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the
central nervous system. Although there are no pathognomonic features to confirm
the diagnosis of this immune-mediated disease, a constellation of clinical, radiolog-
ical, and immune studies can ensure the clinician gets a more definitive diagnosis.
Criteria have been made every few years based on research to clinch the diagnosis.
The most recent criteria which are the McDonald criteria have been formed in 2001
and revised in 2005, 2010, and 2017. Most criteria are to be used only as a guide to
facilitate the diagnosis of multiple sclerosis. Advances in demyelinating disorders
will require diagnostic criteria to be revised every few years with scientists hoping
for a more definitive and confirmative diagnosis. The cardinal features for diagnosis
are dissemination in time and space. There should be no other possible explanation
to the clinical features.
Keywords: multiple sclerosis, diagnosis, criteria, dissemination in time,
dissemination in space
1. Introduction
Multiple sclerosis is an immune-mediated disease involving the central nervous
system predominantly affecting the brain, spinal cord, and optic nerves. There is
no gold standard or pathognomonic features that can distinguish MS from other
neurological conditions with multiple anatomical site involvement. A comprehen-
sive history obtained from the patient, clinical examination with the support of
laboratory investigations with is required to assist in the diagnosis of MS. The key to
diagnosis has always been dissemination in time, which translates into different
time interval of clinical relapse, and dissemination of space, which is a variable
anatomical site in the central nervous system. Hence difference in time and neuro-
anatomical site is essential. Several criteria have been created over the last several
decades such as Schumacher criteria, [1], Poser criteria [2], and McDonald criteria
[3–5]. McDonald criteria has been first established in 2001 and revised in 2005,
2010, and 2017. Revisions are necessary due to evolving research and advances in
the field of demyelinating diseases. Researchers in neuroimmunology diseases
concurred the diagnosis of MS could be made earlier and can be used for paediatric
population and Asian patients [5]. Investigations are done for diagnosis of MS to
ensure there are no other possible explanations for the clinical and radiological
presentation. As the patient can be subjected to lifelong immune modulators and
immunosuppressant, it is highly essential to ensure diagnosis is made accurately and
possible differentials are monitored during follow-up. A clinician’s job does not end
with establishing diagnosis and instituting treatment. Careful surveillance is neces-
sary to ensure we are in the right track as regards to the diagnosis. Misdiagnosis
41
Chapter 3
Diagnosis of Multiple Sclerosis
Joyce Pauline Joseph
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disorder of the
central nervous system. Although there are no pathognomonic features to confirm
the diagnosis of this immune-mediated disease, a constellation of clinical, radiolog-
ical, and immune studies can ensure the clinician gets a more definitive diagnosis.
Criteria have been made every few years based on research to clinch the diagnosis.
The most recent criteria which are the McDonald criteria have been formed in 2001
and revised in 2005, 2010, and 2017. Most criteria are to be used only as a guide to
facilitate the diagnosis of multiple sclerosis. Advances in demyelinating disorders
will require diagnostic criteria to be revised every few years with scientists hoping
for a more definitive and confirmative diagnosis. The cardinal features for diagnosis
are dissemination in time and space. There should be no other possible explanation
to the clinical features.
Keywords: multiple sclerosis, diagnosis, criteria, dissemination in time,
dissemination in space
1. Introduction
Multiple sclerosis is an immune-mediated disease involving the central nervous
system predominantly affecting the brain, spinal cord, and optic nerves. There is
no gold standard or pathognomonic features that can distinguish MS from other
neurological conditions with multiple anatomical site involvement. A comprehen-
sive history obtained from the patient, clinical examination with the support of
laboratory investigations with is required to assist in the diagnosis of MS. The key to
diagnosis has always been dissemination in time, which translates into different
time interval of clinical relapse, and dissemination of space, which is a variable
anatomical site in the central nervous system. Hence difference in time and neuro-
anatomical site is essential. Several criteria have been created over the last several
decades such as Schumacher criteria, [1], Poser criteria [2], and McDonald criteria
[3–5]. McDonald criteria has been first established in 2001 and revised in 2005,
2010, and 2017. Revisions are necessary due to evolving research and advances in
the field of demyelinating diseases. Researchers in neuroimmunology diseases
concurred the diagnosis of MS could be made earlier and can be used for paediatric
population and Asian patients [5]. Investigations are done for diagnosis of MS to
ensure there are no other possible explanations for the clinical and radiological
presentation. As the patient can be subjected to lifelong immune modulators and
immunosuppressant, it is highly essential to ensure diagnosis is made accurately and
possible differentials are monitored during follow-up. A clinician’s job does not end
with establishing diagnosis and instituting treatment. Careful surveillance is neces-
sary to ensure we are in the right track as regards to the diagnosis. Misdiagnosis
41
could still occur, and therefore it must be addressed, and measures should be
undertaken to minimise them.
2. Making the diagnosis: symptoms and signs
Awareness about MS is crucial for the patient to seek attention, and to ask for a
second opinion when necessary is important both for patients and healthcare pro-
viders. A good history with a knowledge of common presentations and bearing in
mind neuroanatomical sites involved will be valuable in coming to a conclusion, and
focused investigations will be needed. Knowledge of subtypes and classification will
be helpful to the clinician.
Four subtypes of multiple sclerosis are used [6].
Active or disease activity is measured by clinical relapses and MRI evidence of
contrast-enhanced lesion or new or enlarging lesion on T2-weighted images by
annual clinical assessment.
Progression-progressive disability by annual clinical assessment
If no annual assessment is done, it is called indeterminate.
• Clinically isolated syndrome
◦ Active
◦ Not active
• Relapsing-remitting multiple sclerosis
◦ Active
◦ Not active
• Primary progressive disease
◦ Active with progression
◦ Active but without progression
◦ Not active but with progression
◦ Not active and without progression
• Secondary progressive disease
◦ Active with progression
◦ Active but without progression
2.1 Optic nerve
Optic nerve involvements are common and often the first presentation in mul-
tiple sclerosis [7]. The severity can vary from being asymptomatic to severe visual
loss, and recovery could be complete, partial, or no resolution. The symptoms could
begin as pain behind the eye and evolve into visual impairment in the centre of the
42
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eye and may worsen till visual acuity is lost. Diminished colour appreciation or
dyschromatopsia may be seen. The pain associated with ON tends to progress over
days. Visual improvement may occur in 3–8 weeks, and most visual recovery occurs
within the first 6 months but can continue for up to 1 year after the acute event
[8–12]. However, many patients may experience residual and variable visual com-
plaints and dysfunction after recovery. Examination on optic neuritis could reveal
no abnormalities, and deficits are present; there may be disc selling, fine
haemorrhages, impaired visual acuity, central or centrocecal oedema, relative
afferent pupillary defect or Marcus Gunn pupil, impaired colour vision, and pale
optic discs [11]. Phosphenes, which are an experience of bright flashes of light
without light entering the eye, Uhthoff’s phenomenon where there is brief blurring
of vision during physical exercise [13].
2.2 Spinal cord
Numbness and weakness of upper and or lower limbs are presentations seen in
spinal cord lesions in MS [14]. Cord lesions also come with urinary incontinence,
frequency, and urinary retention depending on the level and severity involved.
Constipation and diarrhoea could relate to bowel dysfunction. The symptoms are of
corticospinal tract lesion; a clear sensory level might guide the clinician to focus on a
cord lesion rather than a peripheral lesion due to a lower motor neuron lesion.
Clinical assessment may reveal increased tone, monoparesis, hemiparesis and
quadriparesis, abnormal cutaneous and sensory deficit, and sphincter disturbance
[14]. The clinical diagnosis involving the cord is called myelitis.
2.3 Brainstem
Double vision, speech difficulty, swallowing difficulty, nausea, vomiting, hic-
cups, vertigo, unsteadiness, and weakness of limbs are symptoms seen in brainstem
lesions. Examination would reveal nystagmus, ophthalmoplegia, dysarthria, and
facial weakness [14]. Cranial nerve deficits involving III–XII may be seen. Cerebel-
lar connection with the brainstem can cause dysdiadochokinesia, dysmetria, and
ataxia [15]. Brainstem lesions could also cause respiratory failure and locked-in
syndrome. Localization of the neuroanatomical site can be judged based on the
symptoms prior to neuroimaging.
2.4 Cerebellum
Unsteadiness involving upper and lower limbs, gait instability, and dysarthria
are common symptoms seen in structures involving the cerebellum. Tremors,
which are either due to cerebellar or thalamic involvement, could occur, and they
result in tremor affecting limbs, trunk, and vocal cord, and head. Types of tremors
are intention, postural, rest, and rubral (Alistair [16]). Cerebellar signs will be
evident with a significant involvement of the cerebellum. A pure cerebellar
syndrome is rare and other causes must be investigated. Tremors in cerebellar
involvement affect arms, legs, head, and trunk in descending order of frequency.
Face, tongue, and jaw were not affected in a study done by Alusi et al. [17].
2.5 Cerebrum
Symptoms involving the cerebral hemispheres correlate the site of lesion such
as the parietal, temporal, frontal, and occipital lobes. Symptoms are right- or
left-sided hemianaesthesia, hemiparesis, hemiplegia, or monoplegia and visual
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symptoms due to visual field defect. Aphasia or dysphasia and epilepsy are rare
symptoms noted in MS [13].
2.6 Symptoms of multiple sclerosis in chronic disease
Spasticity, cognitive dysfunction, fatigue, affective disorders, and sexual dys-
function are normally seen in chronic disease [13]. An in-depth history during the
first clinical assessment is a valuable asset to establishing the diagnosis.
3. Investigations in MS
3.1 Blood investigations
There are no blood investigations that are pathognomonic for the diagnosis of
multiple sclerosis. However, in order to rule out other neurological conditions that
canmimicMS, a completeworkout is necessary. Screening for connective tissuediseases
such as Systemic Lupus Erythematosus, antiphospholipid antibody, retroviral screen,
other autoimmune condition such as thyroid disease, infectious diseases, Lyme disease
and angiotensin converting enzyme are necessary [18].
3.2 Lumbar puncture
Lumbar puncture for CSF analysis is required as it can further assist in the
diagnosis as its presence reveals a risk of developing MS in patients with clinically
isolated syndrome [3, 5, 19]. In 2017, cerebrospinal fluid (CSF) is done to look for
oligoclonal band and immunoglobulin G (IgG), and a parallel serum sample need to
be taken as no OCB production is noted in the blood in multiple sclerosis.
Oligoclonal band and immunoglobulin G are indicative of intrathecal inflammation
which is B cell modulated from plasma cells seen in CNS inflammatory disease [20].
Distinctive CSF analysis will disclose slightly raised leucocyte count, B cells, or
plasma cells in cytological analysis and raised IgG synthesis [21]. Oligoclonal band
will be highly helpful in the event of other clinical features that are not diagnostic,
and furthermore it depicts dissemination in space. Lumbar puncture is
recommended in the following situations [5]:
• When clinical and MRI evidence is inadequate to make diagnosis of multiple
sclerosis, especially if treatment is considered
• When there are atypical features of clinically isolated syndrome and in
population where MS is less common such as children, older individuals, or
non-white populations
The Panel on Diagnosis of Multiple Sclerosis [5] cautions diagnosis of multiple
sclerosis early on in the disease and in children when OCB is negative in atypical
clinical, radiological, or OCB findings.
There are two methods of analysing the CSF for oligoclonal band agarose gel
electrophoresis/Coomasie Blue Staining and isoelectric focus/silver staining [22].
Oligoclonal bands are positive in up to 95% of patients with clinically definite
multiple sclerosis.
3.3 Evoked potentials
Evoked potentials are electrophysiological tests done to look for evidence of
silent lesions [23]. Abnormal or slowing of electrical conduction along the central
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nervous system pathway can be detected even when there are no obvious clinical
features seen. Visual evoked potentials are visual stimulation, which consists high
contrast black and white checkerboard where these squares, are changed places and
response to this reversal is recorded. Delayed waveform depicts an optic nerve
lesion. Brainstem evoked potentials are when auditory stimulations in the form of
clicks are given for a response obtained from the brainstem. It assesses lower
brainstem auditory pathway. The BAEP are abnormal when demyelination involves
brainstem. Somatosensory evoked potentials are obtained when stimulation from
the peripheral nerves in the upper limbs produces a response. An abnormal
response could translate to demyelination within the central fibres of dorsal
column-medial lemniscal pathways. Evoked potentials may not be useful with
advances in MRI techniques and oligoclonal band, and they have not been included
in McDonald criteria 2017.
3.4 Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a neuroimaging of choice for diagnosis of
MS and plays a key role in research, surveillance, and treatment. Although the
McDonald criteria denote that two clinical attacks depicting dissemination in time
and space are sufficient to make a diagnosis, neurologists and neurologist with
interest in MS would require a baseline MRI to confirm diagnosis and for surveil-
lance. White matter lesions in the MRI are characteristic with typical juxtacortical,
cortical; periventricular, brainstem and spinal cord lesions are required. MRI
protocols used in MS are spin echo T2 weighted, fluid-attenuated inversion
recovery. The Consortium of MS Centres revised and updated guidelines for MRI
([24], ww.mscare.org/mri).
3.4.1 MRI protocols adapted from the Consortium of MS Centers
Baseline studies for patients with a clinically isolated syndrome (CIS) and/or
suspected MS:
• Brain MRI protocol with gadolinium at baseline and to establish dissemination
in time
• Spinal cord MRI if myelitis, insufficient features on brain MRI to support
diagnosis, or age > 40 years with nonspecific brain MRI findings
• A cervical cord MRI performed simultaneously with the brain MRI could
have prognostic value in the evaluation of CIS patients with or without myelitis
and would reduce the number of patients requiring a subsequent MRI
appointment
• Orbital MRI if severe optic neuritis with poor recovery
Timing of a follow-up brain MRI protocol for patients with a CIS and/or
suspected MS to look for evidence of dissemination in time (i.e. new T2 lesions or
gadolinium-enhancing lesions):
• 6–12 months for high-risk CIS (e.g. ≥ 2 ovoid lesions on first MRI)
• 12–24 months for low-risk CIS (i.e. normal brain MRI) and/or uncertain
clinical syndrome with suspicious brain MRI features (e.g. radiologic isolated
syndrome [RIS])
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• When clinical and MRI evidence is inadequate to make diagnosis of multiple
sclerosis, especially if treatment is considered
• When there are atypical features of clinically isolated syndrome and in
population where MS is less common such as children, older individuals, or
non-white populations
The Panel on Diagnosis of Multiple Sclerosis [5] cautions diagnosis of multiple
sclerosis early on in the disease and in children when OCB is negative in atypical
clinical, radiological, or OCB findings.
There are two methods of analysing the CSF for oligoclonal band agarose gel
electrophoresis/Coomasie Blue Staining and isoelectric focus/silver staining [22].
Oligoclonal bands are positive in up to 95% of patients with clinically definite
multiple sclerosis.
3.3 Evoked potentials
Evoked potentials are electrophysiological tests done to look for evidence of
silent lesions [23]. Abnormal or slowing of electrical conduction along the central
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nervous system pathway can be detected even when there are no obvious clinical
features seen. Visual evoked potentials are visual stimulation, which consists high
contrast black and white checkerboard where these squares, are changed places and
response to this reversal is recorded. Delayed waveform depicts an optic nerve
lesion. Brainstem evoked potentials are when auditory stimulations in the form of
clicks are given for a response obtained from the brainstem. It assesses lower
brainstem auditory pathway. The BAEP are abnormal when demyelination involves
brainstem. Somatosensory evoked potentials are obtained when stimulation from
the peripheral nerves in the upper limbs produces a response. An abnormal
response could translate to demyelination within the central fibres of dorsal
column-medial lemniscal pathways. Evoked potentials may not be useful with
advances in MRI techniques and oligoclonal band, and they have not been included
in McDonald criteria 2017.
3.4 Magnetic resonance imaging
Magnetic resonance imaging (MRI) is a neuroimaging of choice for diagnosis of
MS and plays a key role in research, surveillance, and treatment. Although the
McDonald criteria denote that two clinical attacks depicting dissemination in time
and space are sufficient to make a diagnosis, neurologists and neurologist with
interest in MS would require a baseline MRI to confirm diagnosis and for surveil-
lance. White matter lesions in the MRI are characteristic with typical juxtacortical,
cortical; periventricular, brainstem and spinal cord lesions are required. MRI
protocols used in MS are spin echo T2 weighted, fluid-attenuated inversion
recovery. The Consortium of MS Centres revised and updated guidelines for MRI
([24], ww.mscare.org/mri).
3.4.1 MRI protocols adapted from the Consortium of MS Centers
Baseline studies for patients with a clinically isolated syndrome (CIS) and/or
suspected MS:
• Brain MRI protocol with gadolinium at baseline and to establish dissemination
in time
• Spinal cord MRI if myelitis, insufficient features on brain MRI to support
diagnosis, or age > 40 years with nonspecific brain MRI findings
• A cervical cord MRI performed simultaneously with the brain MRI could
have prognostic value in the evaluation of CIS patients with or without myelitis
and would reduce the number of patients requiring a subsequent MRI
appointment
• Orbital MRI if severe optic neuritis with poor recovery
Timing of a follow-up brain MRI protocol for patients with a CIS and/or
suspected MS to look for evidence of dissemination in time (i.e. new T2 lesions or
gadolinium-enhancing lesions):
• 6–12 months for high-risk CIS (e.g. ≥ 2 ovoid lesions on first MRI)
• 12–24 months for low-risk CIS (i.e. normal brain MRI) and/or uncertain
clinical syndrome with suspicious brain MRI features (e.g. radiologic isolated
syndrome [RIS])
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Timing of brain MRI protocol for patients with an established diagnosis of MS:
• No recent prior imaging available (e.g. patient with established diagnosis
of MS and new to your clinical practice)
• Postpartum to establish a new baseline
• Prior to starting or switching disease-modifying therapy
• Approximately 6–12 months after switching disease-modifying therapy to
establish a new baseline on the new therapy
• Every 1–2 years while on disease-modifying therapy to assess for
subclinical disease activity (i.e. new T2 lesions or gadolinium-enhancing
lesions). Less frequent MRI scans required in clinically stable patients
after 2–3 years of stable treatment (gadolinium-based contrast optional)
• Unexpected clinical deterioration or reassessment of original diagnosis
(gadolinium-based contrast recommended)
• The use of gadolinium-based contrast agents is helpful but not essential
for detecting subclinical disease activity because new T2 MS lesions can be
identified on well-performed standardized MR imaging unless there is a
large T2 lesion burden, which may obscure new T2 lesion activity.
4. Diagnosis of MS with McDonald criteria
The International Panel on Diagnosis of Multiple Sclerosis consists of 30 mem-
bers of European, American, and Asian representatives who are experts in their
field, met in 2016 and 2017 to revise and formulate a new guideline based on
advances on MS. The criteria are to be used only in the setting of clinically isolated
syndrome to diagnose MS and progressive MS [5].
4.1 Optical coherence tomography
Optical coherence tomography (OCT) is a noninvasive cross-sectional imaging
in biological systems [26]. OCT assesses the peripapillary area of the retina. Retinal
nerve fibre layer and ganglion cell layer thickness loss affects visual function,
disability, and magnetic resonance imaging. OCT angiography is a new technique
under study in MS [27]. Retinal nerve fibre thinning is seen in multiple sclerosis,
and OCT is able to measure the loss. Fundoscopy is the clinical parallel of OCT.
5. Common differential diagnosis
Clinicians should bear in mind multiple sclerosis mimickers to ensure there is no
other possible explanation. Common differentials are connective tissue disease such
as systemic lupus erythematosus and antiphospholipid antibody syndrome.
Neuromyelitis optical spectrum disorder, which was previously known as Devic’s
disease, is an immune-mediated disorder that can be distinguished, from MS by
typical MRI lesions and/or anti-aquaporin 4 antibody. Other conditions are acute
disseminated meningoencephalitis, small vessel disease, and Susac’s syndrome.
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5.1 Neuromyelitis optica spectrum disorder
Neuromyelitis optica spectrum disorder is often considered as a differential of
MS. It was considered as a part and spectrum of Multiple sclerosis, till Aquaporin 4
antibody serum antibodies [28, 29] that target the water channel aquaporin 4 was
considered in the pathogenesis of NMOSD. It is essential to differentiate multiple
sclerosis and NMOSD as the treatment differs in both, and some treatment could be
harmful.
Diagnostic criteria for NMOSD[30].
Diagnostic criteria for NMOSD with AQP4-IgG
1. At least one core clinical characteristic
2. Positive test for AQP4-IgG using best available detection method (cell-based
assay strongly recommended)
3. Exclusion of alternative diagnoses
Diagnostic criteria for NMOSD without AQP4-IgG or unknown AQP4-IgG status:
1. At least two core clinical characteristic occurring as a result of one or more
clinical attacks and meeting all of the following requirement:
2. At least one core clinical characteristic must be optic neuritis, acute myelitis
with LETM, or area postrema syndrome
3.Dissemination in space (two or more core clinical characteristics)
4.Fulfilment of additional MRI requirements, as applicable
5. Negative test for AQP4-IgG using the best available detection method or
testing unavailable




3.Area postrema syndrome: episode of otherwise unexplained hiccups or nausea
and vomiting
4.Acute brainstem syndrome
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with
NMOSD-typical diencephalic MRI lesions
Symptomatic cerebral syndrome with NMOSD-typical brain lesions
Additional MRI requirements for NMOSD without AQP4-IgG or unknown
AQP4-IgG status:
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Timing of brain MRI protocol for patients with an established diagnosis of MS:
• No recent prior imaging available (e.g. patient with established diagnosis
of MS and new to your clinical practice)
• Postpartum to establish a new baseline
• Prior to starting or switching disease-modifying therapy
• Approximately 6–12 months after switching disease-modifying therapy to
establish a new baseline on the new therapy
• Every 1–2 years while on disease-modifying therapy to assess for
subclinical disease activity (i.e. new T2 lesions or gadolinium-enhancing
lesions). Less frequent MRI scans required in clinically stable patients
after 2–3 years of stable treatment (gadolinium-based contrast optional)
• Unexpected clinical deterioration or reassessment of original diagnosis
(gadolinium-based contrast recommended)
• The use of gadolinium-based contrast agents is helpful but not essential
for detecting subclinical disease activity because new T2 MS lesions can be
identified on well-performed standardized MR imaging unless there is a
large T2 lesion burden, which may obscure new T2 lesion activity.
4. Diagnosis of MS with McDonald criteria
The International Panel on Diagnosis of Multiple Sclerosis consists of 30 mem-
bers of European, American, and Asian representatives who are experts in their
field, met in 2016 and 2017 to revise and formulate a new guideline based on
advances on MS. The criteria are to be used only in the setting of clinically isolated
syndrome to diagnose MS and progressive MS [5].
4.1 Optical coherence tomography
Optical coherence tomography (OCT) is a noninvasive cross-sectional imaging
in biological systems [26]. OCT assesses the peripapillary area of the retina. Retinal
nerve fibre layer and ganglion cell layer thickness loss affects visual function,
disability, and magnetic resonance imaging. OCT angiography is a new technique
under study in MS [27]. Retinal nerve fibre thinning is seen in multiple sclerosis,
and OCT is able to measure the loss. Fundoscopy is the clinical parallel of OCT.
5. Common differential diagnosis
Clinicians should bear in mind multiple sclerosis mimickers to ensure there is no
other possible explanation. Common differentials are connective tissue disease such
as systemic lupus erythematosus and antiphospholipid antibody syndrome.
Neuromyelitis optical spectrum disorder, which was previously known as Devic’s
disease, is an immune-mediated disorder that can be distinguished, from MS by
typical MRI lesions and/or anti-aquaporin 4 antibody. Other conditions are acute
disseminated meningoencephalitis, small vessel disease, and Susac’s syndrome.
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5.1 Neuromyelitis optica spectrum disorder
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antibody serum antibodies [28, 29] that target the water channel aquaporin 4 was
considered in the pathogenesis of NMOSD. It is essential to differentiate multiple
sclerosis and NMOSD as the treatment differs in both, and some treatment could be
harmful.
Diagnostic criteria for NMOSD[30].
Diagnostic criteria for NMOSD with AQP4-IgG
1. At least one core clinical characteristic
2. Positive test for AQP4-IgG using best available detection method (cell-based
assay strongly recommended)
3. Exclusion of alternative diagnoses
Diagnostic criteria for NMOSD without AQP4-IgG or unknown AQP4-IgG status:
1. At least two core clinical characteristic occurring as a result of one or more
clinical attacks and meeting all of the following requirement:
2. At least one core clinical characteristic must be optic neuritis, acute myelitis
with LETM, or area postrema syndrome
3.Dissemination in space (two or more core clinical characteristics)
4.Fulfilment of additional MRI requirements, as applicable
5. Negative test for AQP4-IgG using the best available detection method or
testing unavailable




3.Area postrema syndrome: episode of otherwise unexplained hiccups or nausea
and vomiting
4.Acute brainstem syndrome
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with
NMOSD-typical diencephalic MRI lesions
Symptomatic cerebral syndrome with NMOSD-typical brain lesions
Additional MRI requirements for NMOSD without AQP4-IgG or unknown
AQP4-IgG status:
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• Acute optic neuritis
• Requires brain MRI showing
• Normal findings or only nonspecific white matter lesions, OR
• Optic nerve MRI with T2-hyperintense lesion, or T1-weighted
gadolinium-enhancing lesion extending over 1/2 optic nerve length or
involving optic chiasm
• Acute myelitis: requires associated intramedullary MRI lesion extending over
three or more contiguous segments (LETM) OR three or more contiguous
segments of focal spinal cord atrophy in patients with history compatible with
acute myelitis
• Area postrema syndrome: requires associated dorsal medulla/area postrema
lesions
• Acute brainstem syndrome: requires associated periependymal brainstem
lesions.
5.2 MOG antibody disease
Seronegative NMOSD patients have been associated with MOG antibody
disease, which is a myelin oligodendrocyte glycoprotein and which is found only
in the central nervous system. Myelin oligodendrocyte glycoprotein is a small
part of myelin [31]. MOG can be found in extracellular surface of myelin
sheaths and oligodendrocytes. MOG antibodies were seen in several
demyelinating diseases of the central nervous system disorders [32, 33].
MOG antibody disease tends to favour women, which is one third of
patients (Figure 1).
B-cell activation is the strongest element seen in central nervous system of
multiple sclerosis patients. Central nervous system-directed antibodies are pro-
duced in the periphery in neuromyelitis optica and myelin oligodendrocyte glyco-
protein antibody disease. MRZ reaction is antibodies against measles, rubella, and
varicella zoster (Tables 1–3).
5.3 Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis (ADEM) is a central nervous system-
demyelinating disease predominantly involving children and young adults. It has
been noted in adults and elderly; it follows vaccination and postinfectious state. It is
commonly monophasic and rarely multiphasic in nature, and it can involve the
brain, spinal cord, and optic nerves as in multiple sclerosis. Fever, malaise, myal-
gias, headache, nausea, and vomiting can precede neurological symptoms of
ADEM, which can begin 4–21 days after the antecedent event. Clinical features of
ADEM are the development of a focal or multifocal neurological disorder which
could be encephalopathy, coma, and focal and multifocal neurological signs like
hemiparesis, cranial nerve palsies, paraparesis, meningismus, ataxia, movement
disorders, and seizure [36]. The International Paediatric Multiple Sclerosis Study
Group (IPMSSG) [37] proposed consensus definitions for paediatric-acquired
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demyelinating disorders of the CNS to clarify the terminology for demyelination
disease, and this was further updated in 2013 [38]. ADEM criteria require the
following:
Monophasic ADEM:
i. A first polyfocal clinical neurological event with presumed inflammatory cause
ii. Encephalopathy that cannot be explained by fever is present
iii. No new clinical or radiological evidence of a new event suggestive of ADEM
after 3 months
Multiphasic ADEM
i. A new onset of ADEM in 3 or more months after the primary event
ii. A new onset or reappearance of ADEM linked to previous clinical or
radiological event involving the central nervous system
iii. Time of symptom onset in relation to steroids has no relevance
ADEM should be a diagnosis of exclusion and should be differentiated from
multiple sclerosis from its clinical and radiological profile.
Figure 1.
Biomarkers in Multiple sclerosis, Neuromyelitis Optica Spectrum Disorder and MOG antibody disease. MRZ
reaction are antibodies against measles, rubella and varicella zoster. (Adapted from [34]).
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5.3 Acute disseminated encephalomyelitis
Acute disseminated encephalomyelitis (ADEM) is a central nervous system-
demyelinating disease predominantly involving children and young adults. It has
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commonly monophasic and rarely multiphasic in nature, and it can involve the
brain, spinal cord, and optic nerves as in multiple sclerosis. Fever, malaise, myal-
gias, headache, nausea, and vomiting can precede neurological symptoms of
ADEM, which can begin 4–21 days after the antecedent event. Clinical features of
ADEM are the development of a focal or multifocal neurological disorder which
could be encephalopathy, coma, and focal and multifocal neurological signs like
hemiparesis, cranial nerve palsies, paraparesis, meningismus, ataxia, movement
disorders, and seizure [36]. The International Paediatric Multiple Sclerosis Study
Group (IPMSSG) [37] proposed consensus definitions for paediatric-acquired
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demyelinating disorders of the CNS to clarify the terminology for demyelination
disease, and this was further updated in 2013 [38]. ADEM criteria require the
following:
Monophasic ADEM:
i. A first polyfocal clinical neurological event with presumed inflammatory cause
ii. Encephalopathy that cannot be explained by fever is present
iii. No new clinical or radiological evidence of a new event suggestive of ADEM
after 3 months
Multiphasic ADEM
i. A new onset of ADEM in 3 or more months after the primary event
ii. A new onset or reappearance of ADEM linked to previous clinical or
radiological event involving the central nervous system
iii. Time of symptom onset in relation to steroids has no relevance
ADEM should be a diagnosis of exclusion and should be differentiated from
multiple sclerosis from its clinical and radiological profile.
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Biomarkers in Multiple sclerosis, Neuromyelitis Optica Spectrum Disorder and MOG antibody disease. MRZ
reaction are antibodies against measles, rubella and varicella zoster. (Adapted from [34]).
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Protocol 1: Standardised brain MRI protocol (diagnosis and routine follow-up of MS)
Field strength Scans should be of good quality, with adequate signal-noise ratio (SNR) and
spatial resolution (in-slice pixel resolution of ≤1  1 mm)
Scan prescription Use the subcallosal plane to prescribe or reformat axial oblique slices
Coverage Whole brain coverage
Slice thickness and
gap
≤ 3 mm, no gap (for 2D acquisition Or 3D1 reconstruction)
Core sequences 2D/3D sagittal and Axial FLAIR1,2. 2D/3D axial T21
Axial 2D DWI3
3D IR-Prep GE4 T1
Gadolinium5 (as
required)
Post-gad 2D/3D axial T1
Additional sequences Susceptibility-weighted imaging (SWI). Pre-gad 2D/3D axial T1
Axial proton density
1. 3D acquisition should be isotropic ≤1  1  1 mm
2. Fluid attenuated inversion recovery (FLAIR)
3. Diffusion-weighted imaging (DWI)
4. Inversion recovery-prepared gradient echo (IR-Prep GE); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo Or TFE
5. Single dose of gadolinium-based contrast agent as required (note that the FLAIR Or T2 may be
performed during the 5-minute minimum delay after gadolinium injection before acquiring the
post-gadolinium T1)
Protocol 2: PML surveillance brain MRI protocol
Field strength Scans should be of good quality, with adequate signal-noise ratio (SNR) and
resolution (in-slice pixel resolution of ≤1  1 mm)
Scan prescription Use the subcallosal plane to prescribe or reformat axial oblique slices
Coverage Whole brain coverage
Core sequences1 2D/3D sagittal and axial FLAIR2 axial 2D DWI3
Gadolinium (can be
helpful) 4
Post-gad 2D/3D axial T1
Additional sequences DWI
2D/3D axial T2
3D IR-Prep GE5 T1
Pre-gad 2D/3D axial T1. Axial proton density
Slice thickness and
gap
< 3 mm, no gap (for 2D acquisition or 3D reconstruction)
1. Typical PML lesions may appear hyperintense on FLAIR, hypointense on T1, and high signal
intensity on DWI
2. Fluid attenuated inversion recovery (FLAIR)
3. Diffusion-weighted imaging (DWI)
4. Less than 50% of PML lesions will show contrast enhancement
5. Inversion recovery-prepared gradient echo (IR-Prep GE); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo or TFE
Protocol 3: Spinal cord MRI protocol
Field strength Scans should be of good quality, with adequate signal-noise ratio (SNR) and
resolution (in-slice pixel resolution of ≤1  1 mm)
Coverage Cervical cord coverage1





Axial T2/T2* through lesions
Slice thickness and
gap
Sagittal: <3 mm, no gap. Axial: <5 Mm, no gap
Additional sequences Sagittal T1
Post-gad T14 (sag, axial)
Axial T2/T2* entire cervical cord 3D IR-Prep GE5 T1
1. Thoracic and conus coverage recommended if symptoms localize to this region to rule out an
alternate diagnosis
2. Short tau inversion recovery (STIR)
3. Phase-sensitive T1 inversion recovery (PSIR)
4. No additional gadolinium necessary if cord examination immediately follows gadolinium-
enhanced brain MRI
5. IR-Prep GE (inversion recovery-prepared gradient echo); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo or TFE
Protocol 4: Orbit MRI protocol
• May be clinically indicated to confirm optic neuritis and rule out compressive lesions
• Recommended sequences include coronal STIR or fat-suppressed T2 and a post-gadolinium fat-
suppressed T1 with a section thickness of ≤2 Mm, with coverage to include the optic chiasm
• Optional sequences may include axial/coronal pre-gadolinium fat-sat T1, axial fat-sat T2 or STIR,
and axial post-gad fat-sat T1
Recommendations for communication
MRI requisition:
The clinician should provide on the request for the standardized MRI brain and/or spinal cord protocol:
• Clinical questions to be addressed *diagnosis
*Monitoring for management decision
• Relevant clinical history and physical examination findings
• Current MS disease-modifying treatment and JC virus status if on natalizumab
• If known, date and place of previous examinations
MRI report:
Standardised nomenclature/terminology should be used and include:
1. Description of findings
• *Lesion type, location, size, shape, character, number for diagnostic
Scan
• *CIS diagnostic scan: whether meets current MRI dissemination in
space or dissemination in time criteria
• *Qualitative assessment of T2 and brain volume/atrophy
2. MS monitoring or CIS follow-up: comparison with previous studies (new lesions, atrophy)
3. Interpretation (typical for MS, atypical for MS, not MS) and differential diagnosis, if appropriate
Note: structured reports can be helpful (Alessandrino et al., Ajr, 2018; Dickerson et al., J Am Coll
Radiol 2017).
Recommendations:
*Studies should be stored in a DICOM format.
*Copies of MRI studies should be retained permanently and be available.
*It is strongly recommended for patients to keep their own studies on
Portable digital media
Table 1.
MRI protocols (Adapted from [25]).
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Protocol 1: Standardised brain MRI protocol (diagnosis and routine follow-up of MS)
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4. Inversion recovery-prepared gradient echo (IR-Prep GE); magnetization-prepared rapid
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5. Single dose of gadolinium-based contrast agent as required (note that the FLAIR Or T2 may be
performed during the 5-minute minimum delay after gadolinium injection before acquiring the
post-gadolinium T1)
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resolution (in-slice pixel resolution of ≤1  1 mm)
Scan prescription Use the subcallosal plane to prescribe or reformat axial oblique slices
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Core sequences1 2D/3D sagittal and axial FLAIR2 axial 2D DWI3
Gadolinium (can be
helpful) 4
Post-gad 2D/3D axial T1
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2D/3D axial T2
3D IR-Prep GE5 T1
Pre-gad 2D/3D axial T1. Axial proton density
Slice thickness and
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1. Typical PML lesions may appear hyperintense on FLAIR, hypointense on T1, and high signal
intensity on DWI
2. Fluid attenuated inversion recovery (FLAIR)
3. Diffusion-weighted imaging (DWI)
4. Less than 50% of PML lesions will show contrast enhancement
5. Inversion recovery-prepared gradient echo (IR-Prep GE); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo or TFE
Protocol 3: Spinal cord MRI protocol
Field strength Scans should be of good quality, with adequate signal-noise ratio (SNR) and
resolution (in-slice pixel resolution of ≤1  1 mm)
Coverage Cervical cord coverage1





Axial T2/T2* through lesions
Slice thickness and
gap
Sagittal: <3 mm, no gap. Axial: <5 Mm, no gap
Additional sequences Sagittal T1
Post-gad T14 (sag, axial)
Axial T2/T2* entire cervical cord 3D IR-Prep GE5 T1
1. Thoracic and conus coverage recommended if symptoms localize to this region to rule out an
alternate diagnosis
2. Short tau inversion recovery (STIR)
3. Phase-sensitive T1 inversion recovery (PSIR)
4. No additional gadolinium necessary if cord examination immediately follows gadolinium-
enhanced brain MRI
5. IR-Prep GE (inversion recovery-prepared gradient echo); magnetization-prepared rapid
acquisition gradient echo or MP-RAGE; turbo field echo or TFE
Protocol 4: Orbit MRI protocol
• May be clinically indicated to confirm optic neuritis and rule out compressive lesions
• Recommended sequences include coronal STIR or fat-suppressed T2 and a post-gadolinium fat-
suppressed T1 with a section thickness of ≤2 Mm, with coverage to include the optic chiasm
• Optional sequences may include axial/coronal pre-gadolinium fat-sat T1, axial fat-sat T2 or STIR,
and axial post-gad fat-sat T1
Recommendations for communication
MRI requisition:
The clinician should provide on the request for the standardized MRI brain and/or spinal cord protocol:
• Clinical questions to be addressed *diagnosis
*Monitoring for management decision
• Relevant clinical history and physical examination findings
• Current MS disease-modifying treatment and JC virus status if on natalizumab
• If known, date and place of previous examinations
MRI report:
Standardised nomenclature/terminology should be used and include:
1. Description of findings
• *Lesion type, location, size, shape, character, number for diagnostic
Scan
• *CIS diagnostic scan: whether meets current MRI dissemination in
space or dissemination in time criteria
• *Qualitative assessment of T2 and brain volume/atrophy
2. MS monitoring or CIS follow-up: comparison with previous studies (new lesions, atrophy)
3. Interpretation (typical for MS, atypical for MS, not MS) and differential diagnosis, if appropriate
Note: structured reports can be helpful (Alessandrino et al., Ajr, 2018; Dickerson et al., J Am Coll
Radiol 2017).
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5.4 Antiphospholipid antibody syndrome
The antiphospholipid syndrome (APS) is a systemic autoimmune disorder with
arterial and venous thromboses; recurrent foetal loss, often accompanied by
thrombocytopenia; raised antiphospholipid antibodies, namely, lupus
anticoagulant; and anticardiolipin antibodies [39]. Common presentations
that can mimic MS are stroke-like presentations such as transient ischemic attack,
ischemic stroke, venous thrombosis, epilepsy, headache, movement disorder,
transverse myelitis, cognitive impairment, and other neuropsychiatric
manifestations.
5.5 Systemic lupus erythematous
Systemic lupus erythematous is an autoimmune condition that is frequency






Multiple sclerosis can be challenging to make a diagnosis unless a clinician is
familiar with the disease. No better explanation for the condition is essential to
come to a conclusion regarding the diagnosis. A good history, elaborate and exten-
sive clinical examination, lumbar puncture, magnetic resonance examination, and
blood investigations are required. The McDonald criteria have facilitated the
diagnosis of multiple sclerosis for precision and allowing earlier diagnosis.
Author details
Joyce Pauline Joseph
Department of Neurology, Hospital Kuala Lumpur, Malaysia
*Address all correspondence to: jpjmy@yahoo.com
©2019 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
Table 3.
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Multiple sclerosis can be challenging to make a diagnosis unless a clinician is
familiar with the disease. No better explanation for the condition is essential to
come to a conclusion regarding the diagnosis. A good history, elaborate and exten-
sive clinical examination, lumbar puncture, magnetic resonance examination, and
blood investigations are required. The McDonald criteria have facilitated the
diagnosis of multiple sclerosis for precision and allowing earlier diagnosis.
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Features of MOG antibody disease, NMOSD and MS. (Adapted from [34]).
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Abstract
Although cognitive difficulties are not frequently reported by patients among
the initial symptoms of Multiple Sclerosis (MS), there is sufficient evidence that
cognitive impairment is present from the early stage of the disease. Today it is
commonly accepted that roughly one-half of individuals with MS will experience
cognitive dysfunction over the course of the disease. Though MS was originally
considered a disease of white matter, more recent investigations with advanced
immunohistochemistry techniques have revealed that demyelination of gray matter
is a common neuropathological feature in MS contributing significantly to cognitive
impairment. However, despite now been recognized as a core symptom of MS,
evidence up till now is only modest regarding the efficacy of pharmacological
agents on cognitive dysfunction and non-pharmacological interventions such as
cognitive rehabilitation also provide incomplete evidence on whether they might
improve or stabilize cognitive impairment and especially over long follow up
periods. Despite this general consensus, there are studies that have reported the
efficacy of cognitive neurorehabilitation in reducing MS associated cognitive defi-
cits. In this chapter we provide a selective review of the most relevant features
related to this topic.
Keywords: multiple sclerosis, neuropsychological functions, cognition,
cognitive neurorehabilitation
1. Introduction
Historically the disease today known as multiple sclerosis (MS) has been
referred to in the historical medical literature with a variety of terms, including,
disseminated sclerosis and sclerose en plaque [1]. Lidwina van Schiedam, was the
first potential case of MS dating as far back as 1421, when Jan van Berieren
commented on her illness. Records showed that she had difficulties walking,
paralysis of the right arm, decreased sensation and visual difficulties [2].
Today we know that MS is a chronic inflammatory autoimmune degenerative
disease of the central nervous system (CNS). It is the most common non-traumatic
neurological disorder among young adults leading to disability. The etiology of
MS involves white matter pathology, cortical atrophy, cortical lesions, and micro-
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1. Introduction
Historically the disease today known as multiple sclerosis (MS) has been
referred to in the historical medical literature with a variety of terms, including,
disseminated sclerosis and sclerose en plaque [1]. Lidwina van Schiedam, was the
first potential case of MS dating as far back as 1421, when Jan van Berieren
commented on her illness. Records showed that she had difficulties walking,
paralysis of the right arm, decreased sensation and visual difficulties [2].
Today we know that MS is a chronic inflammatory autoimmune degenerative
disease of the central nervous system (CNS). It is the most common non-traumatic
neurological disorder among young adults leading to disability. The etiology of
MS involves white matter pathology, cortical atrophy, cortical lesions, and micro-
structural abnormalities in deep gray matter that impact structural and functional
59
connectivity [3]. Cognitive impairment in MS appears to be a result of this diffuse
disruption in brain networks [4]. These patients may also present sensorimotor [5],
visual [6], bladder, cerebellar [7] and emotional difficulties leading to functional
disability [8] and poorer quality of life [9].
Environmental factors and especially geographical latitude may significantly
influence the development of MS. However, genetic susceptibility as is evident
from twin studies and familial cases, suggests that MS disease causality is due to a
complex interaction between multiple genes and environmental factors, eventually
leading to inflammatory-mediated central nervous system deterioration [10].
Genomic studies, with specific HLA antigens (HLA-DR2), have confirmed the
genetic susceptibility of MS [10]. Numerous other environmental factors have been
evaluated that may be associated with MS, but methodological caveats have casted
doubts on their validity. On average, MS patients contracted common childhood
illnesses at later ages than healthy controls [11]. A biomarker of Epstein-Barr virus
(anti-EBNA IgG seropositivity), infectious mononucleosis, and smoking have
shown the strongest consistent evidence of an association. However, additional data
and better-designed studies are needed to establish robust evidence [12].
MS disease course is heterogeneous in nature and several types have been
described: Relapsing remitting MS (RRMS), Active (with relapses and/or new
lesions on MRI), Not Active (no relapses or MRI activity), Progressive MS (Sec-
ondary Progressive MS (SPMS) and Primary Progressive MS (PPMS), Active with
Progression (relapses/MRI activity and clinical deterioration not due to relapses),
Active but without Progression (relapses but no clinical deterioration), Not Active
but with Progression, Not Active and without Progression (stable disease) [13]. The
use of these terms is primarily for descriptive purposes and for setting reasonable
expectations for treatment.
This chapter is not a comprehensive review of the extensive literature on neu-
ropsychological functions and cognitive rehabilitation in multiple sclerosis, but
rather a selective review of the most relevant features related to this topic.
2. Neuropsychological functions in multiple sclerosis
Dating back to the seminal writings on MS, Charcot’s observations of the adverse
effects that MS exerts on memory, concept formation, and the intellect [14], were
underestimated for many decades in the neurology literature. It was only with the
emergence of the comprehensive care model in the early 1980s, that the nature and
significance of cognitive dysfunction in MS became appreciated. The medical com-
munity, due to the often-subtle nature of cognitive deficits in MS, and the difficulty
in detecting these deficits during routine clinical practice, was initially slow to
appreciate them as a core clinical symptom of MS. Instead, they believed that
cognitive impairment was a relatively rare entity in MS, occurred only in advanced
cases with a high level of physical disability and was associated with subcortical
dementia [15].
Cognitive difficulties are not frequently reported by patients among the initial
symptoms of MS, although there is sufficient evidence that cognitive impairment is
present from the early stage of the disease (see for e.g., the study by [16], which
assessed MS patients neuropsychologically, not more than 2 years after experienc-
ing their first neurological symptoms, and [17], who presents three cases evaluated
at different stages of the disease). Moreover, cognitive impairment may be present
in the early stages of the disease in patients with relatively low or mild physical
disability (see for e.g. the studies by [18, 19] who found cognitive deficits in
patients with an EDSS disability score of ≤3.5, that had not yet been influenced
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significantly in their daily functional abilities and employment status). A recent
anatomofunctional study utilizing diffusion imaging and resting state functional
MRI, revealed that disconnection in the default mode network (DMN) and atten-
tional networks (ATT), may deprive the brain of the necessary compensatory
mechanisms required to face the widespread structural damage during the early
course of MS, providing a possible explanation for the cognitive dysfunction in
these early stages of the disease [20].
Although it is now commonly accepted that roughly one-half of individuals with
MS [21, 22], will experience clinical deficits over the course of the disease, preva-
lence rates are highly variable and depend to a large extent on the type of MS
population studied, the clinical, demographic and sociodemographic characteristics
and the year conducted. A recent study that included RRMS and SPMS patients
attending an outpatient neurology clinic reported an overall cognitive dysfunction
prevalence rate of 53.7% [23]. Moreover, the study by [22], reported that 47% of
their MS patients recruited from an outpatient clinical setting, diagnosed with the
revised McDonald criteria [24], the majority with RRMS and mean duration of
illness at 9.6 years, assessed with a brief cognitive measure (BICAMS), performed
below the 1SD cutoff set for impairment on at least one of the three tests that
comprise this brief neuropsychological battery. In an interesting cross-sectional
study that evaluated the patterns of cognitive impairment in patients with disease
duration of up to 30 years, 20.9% performed below the 1SD cutoff for impairment
by the 5th year from disease onset, by 10 years this had reached 29.3%. By utilizing
regression modeling the authors suggested that cognitive impairment may precede
MS onset by 1.2 years [25].
Most of the evidence suggests that cognitive impairment in MS patients is
present during all disease stages and across all disease clinical subtypes [26–28],
including, RRMS, PPMS, SPMS, Clinically Isolated Syndrome (CIS) and “benign
MS” [29, 30], and even Radiologically Isolated Syndrome—(RIS) [31]. Based on the
majority of studies that have compared cognitive functions across disease subtype,
deficits appear to be more frequent and more widespread in the progressive type
rather than in the relapsing form of the disease [23, 29, 31–32].
The dissemination of lesions in cerebral white matter including their affinity for
periventricular regions provides the basis for some cognitive dysfunction common-
alities [33]. In this respect, some cognitive domains appear to be more commonly
compromised than others. Information processing efficiency, episodic memory,
attention, and executive functioning are the domains found predominantly to be
detrimentally affected in MS [21, 34, 35]. Among these domains the most common
pattern involves circumscribed deficits as a combination of one or two of the above-
mentioned domains (e.g., attention/processing speed, learning/memory, and or
executive functions [11, 15, 21].
Symptoms like cognitive and physical fatigue, which are often accompanied by
depression and anxiety, may negatively influence cognition in MS patients. This is
especially true when extended periods are required to complete and appear more
relevant for the patient’s daily life than what may be assumed by many physicians
treating MS patients [11].
Although cognitive impairment is highly prevalent among MS patients, some
have a tendency to withstand severe disease burden (e.g., white matter lesions and
cerebral atrophy), and present with overall lower levels of cognitive decline. One
possible explanation for this protective mechanism is the brain reserve hypothesis
and the cognitive reserve theory [36]. Recently, it has been verified that highly
significant protection for cognitive impairment is provided by brain reserve,
defined as the maximal lifetime brain growth (MLBG), and estimated with intra-
cranial volume or head circumference. Larger MLBG a proxy for neuronal and
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significantly in their daily functional abilities and employment status). A recent
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cerebral atrophy), and present with overall lower levels of cognitive decline. One
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defined as the maximal lifetime brain growth (MLBG), and estimated with intra-
cranial volume or head circumference. Larger MLBG a proxy for neuronal and
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synaptic count has been linked to lower risk for cognitive impairment in MS [37].
This larger MLBG appears to be associated with more robust neural networks
resistant to disease-related disruption and also provides more potential degrees of
freedom for the brain to plastically reorganize in the face of MS disease related
challenges.
2.1 Assessment of neuropsychological functions in MS
The multidimensional nature of cognitive dysfunction in MS necessitates an
assessment of numerous cognitive domains. The challenge until recently was to
find the optimal combination of cognitive tests that would provide an accurate
picture of the deficits whilst avoiding the use of unnecessary and time-consuming
measures [15].
In order to overcome some of the limitations in assessing cognition in MS, and
considering the fact that not all neuropsychological measures are appropriate for
the MS population, a number of neuropsychological assessment tools (brief
screening batteries and comprehensive neuropsychological batteries), have been
utilized specifically for this population in routine clinical care and for research
purposes. Table 1 provides a summary of the most important neuropsychological
tools utilized in MS patients.
2.2 Neuropsychological functions and neuroimaging
Although MS was originally considered to be a disease of White Matter (WM),
more recently with the development and utilization of advanced immunohisto-
chemistry techniques investigators have begun to appreciate that demyelination
of gray matter (GM) is a common neuropathological feature in MS patients.
Demyelination of GM appears to be more common in the cerebellum, spinal cord
and hippocampus. Essentially, however, no areas within the CNS are actually
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GM structure, but lesions have been identified within the putamen, pallidum,
caudate, amygdale, substantia nigra and hypothalamus [39].
Considering the above, clinicians and researchers investigating neuropsycholog-
ical functions in MS patients have realized that cognitive dysfunction in this
population cannot be explained by WM pathology alone. GM pathology appears to
have a significant impact on cognitive impairment, but requires novel neuroimag-
ing technology in order to detect and visualize these types of lesions. Due to these
visualization difficulties in current imaging technologies, research in MS has shifted
its focus primarily to comparing WM and GM measures of atrophy [39]. In this
respect, [40], noted a similar increase in WM atrophy across disease stages (three-
fold), whereas, atrophy of the GM increased proportionally according to disease
stage, i.e. three-fold in CIS converting to RRMS, versus 14-fold in SPMS patients.
Another important issue is that GM atrophy has been reported to be regionally
specific, involving early volume loss of the basal ganglia, corpus callosum and
thalamus. Recent studies have outlined the significance of thalamic volume in
relation to cognitive impairment. One such report by [41] found lower thalamic
volumes in MS patients compared to healthy participants, with the lowest volumes
found in severely cognitive impaired patients. In one of our recent studies, we
provide evidence that thalamic atrophy was the best predictor of cognitive dys-
function in RRMS patients and was also highly associated with activities of daily
living and employment status [42]. Moreover, in a similar study that recruited late
stage SPMS patients, we found that corpus callosum atrophy was associated with
deficits in cognitive flexibility, processing speed, episodic memory, executive func-
tions, reaction time and phonological verbal fluency. Processing speed and com-
posite memory were the most sensitive markers for predicting employment status.
Corpus callosum atrophy was the most sensitive MRI marker for episodic memory
and processing speed deficits. Moreover, corpus callosum atrophy predicted a clin-
ically meaningful cognitive decline, affecting employment status in our SPMS
patients [43]. Thus, it appears that irreversible tissue loss, as measured by brain
atrophy of the white and gray matter, is strongly associated to cognitive function in
the MS population. While white matter atrophy has also been reported to contribute
significantly to impairment in mental processing speed and working memory,
gray matter atrophy was highly predictive for verbal memory status, but addition-
ally predicted neuropsychiatric symptoms such as disinhibition and euphoria [44].
3. Interventions for cognitive dysfunction in multiple sclerosis
Recent evidence from empirical research has indicated that cognitive dysfunc-
tion in MS patients is highly related to everyday functioning abilities [45]. One
such study that evaluated associations between cognitive functions and objective
performance on measures of everyday functioning in MS, [46], reported that MS
patients had significantly more difficulties in simple and more complex cooking
abilities, using the phone, taking medication, and paying the bills, compared to
healthy participants. An interesting study by O’Brien et al. [47] and a more ecolog-
ically valid study by Goverover et al [48], utilizing an actual reality (AR) approach
through the use of everyday tasks requiring the internet (e.g. booking an airline
ticket, purchasing cookies and ordering pizza), the authors report significant cor-
relations between these tasks and performance on mental processing speed
(SDMT), concluding that this measure contributes significantly to predicting
everyday functioning capacity in MS. A more recent study, [48], examined the
ability of MS patients to manage their finances. The authors found that MS patients
demonstrated and reported more difficulties in managing their finances compared
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to healthy controls. Moreover, MS patient’s difficulties in handling their finances
were associated with the severity of cognitive dysfunction. As this important every-
day task requires intact mental processing ability and executive-attentional abilities,
domains usually impaired in MS individuals, these findings may serve as potential
intervention indicators when planning cognitive rehabilitation interventions.
From the findings reported by the studies mentioned previously, it becomes
obvious that interventions to alleviate, stabilize, reduce or compensate for cognitive
impairment are of an extremely high priority, in order to provide MS individuals
with the necessary mechanisms to better handle their everyday functioning disabil-
ities. The evidence up till now is only modest regarding the efficacy of pharmaco-
logical agents on cognitive dysfunction [49, 50], and non-pharmacological
interventions such as cognitive rehabilitation also provide incomplete evidence on
whether they might improve or stabilize cognitive impairment and especially over
long follow up periods [51]. Despite this general consensus, there are studies that
have reported the efficacy of pharmacological agents [52] and cognitive rehabilita-
tion [28, 53, 54] in reducing MS associated cognitive deficits.
3.1 Cognitive neurorehabilitation in multiple sclerosis
The goals of non-pharmacological treatments for MS-related cognitive deficits
are similar to those of the immune-modulating drugs. In other words, these inter-
ventions are used with the intent of preventing the progression of cognitive dys-
function and promoting a therapeutic ‘milieu’ in which optimal cognitive
functioning can occur, and include specific approaches which are known to be
effective in remediating cognitive disorders of any etiology [15]. Cognitive rehabil-
itation or ‘rehabilitation of individuals with cognitive impairment’ [55] include
specific approaches designed to assist the MS patient to better cope with existing
cognitive impairments or to improve a specific cognitive skill. It focuses on two
main approaches: the restorative or functional training approach (i.e. ameliorating
patients’ deficits in processing and interpreting information—e.g. when cognitive
training is used to enhance attention or memory performance). The restorative
approach depends on the brains capability of cortical reorganization following
injury (i.e. that the brain possesses some degree of plasticity). The second is the
compensatory or strategy training approach (e.g. modifying the patient’s environ-
ment, using a calendar and set phone reminders). These approaches have different
goals and limitations, and may be used in isolation or in combination. For example,
in patients with extensive tissue loss, neural plasticity might be hampered and no
or little effect will result from restorative or functional training. In that particular
patient, compensatory or strategy training might help the patient to work around
the problems that are present. As for most MS patients, especially those with a
relapsing disease course, it is expected that restorative or functional training will
lead to improved cognitive functioning on neuropsychological measures, improved
functioning in everyday life activities, and ultimately will lead to an improvement
in network efficiency [56].
Several studies have investigated the effectiveness of cognitive rehabilitation
interventions in patients with MS, including computer-based training and neuro-
psychological counseling, but with inconsistent results. The majority of studies
found improvements in specific cognitive domains, but the evidence provided in
the literature remains inconclusive [57]. A significant limitation in providing evi-
dence on the efficacy of studies involving cognitive rehabilitation is the great
variability in the methods or strategies utilized for treatment, the measures used to
assess cognition and other secondary outcome variables and the lack of ecologically
64
Multiple Sclerosis
valid outcome measures in order to assess the efficiency of these interventions
in everyday functioning ability.
Applying a technique known as the Story Memory Technique (SMT), [58]
provided class 1 evidence that this technique applied for 5 weeks/twice weekly
(10 sessions) with an emphasis on teaching context and imagery to facilitate learn-
ing, improved episodic memory in MS patients relative to controls and moreover
produced increased f-MRI activation during a memory task in frontal and parietal
regions. Positive effects were additionally observed for objective measures of
everyday memory function, general contentment, and executive functioning. These
positive outcomes were sustained for a period of 6 months.
Clinical trials utilizing the RehaCom computerized software in MS patients with
cognitive impairments have also shown positive outcomes. Bonavita et al. [59],
noted significant pre-to post treatment improvements in a RehaCom treated MS
cohort, on mental information processing, executive functions and attention. This
and other similar studies have reported positive outcomes in MS patients treated
with this software, and moreover, associations between functional neuroimaging
(f-MRI) findings with changes in neurocognitive measures have been reported
[59–61]. In a multicenter Italian study, RehaCom was utilized to provide specific
intensive cognitive training for 12 months. Results showed that MS patients treated
with this modality had improved scores post treatment on the SDMT, PASAT, and
episodic memory measures relative to MS patients who received aspecific psycho-
logical therapy for the same period of time [62].
In 2017, our group, [53], conducted a multicenter randomized controlled trial
with 58 clinically stable RRMS patients utilizing computer-assisted (RehaCom)
functional cognitive training with an emphasis on episodic memory, information
processing speed/attention, and executive functions for 10 weeks. Our findings
revealed that only the group that had received functional cognitive training showed
significant improvements in verbal and visuospatial episodic memory, processing
speed/attention, and executive functioning from pre—to postassessment. More-
over, the improvement obtained on attention was retained over 6 months providing
evidence on the long term benefits of this intervention. Treated patients rated the
intervention positively and were more confident about their cognitive abilities
following treatment.
While the previously mentioned positive results regarding the efficacy of cogni-
tive rehabilitation interventions in MS individuals cannot be overstated, it is
important to note that a recently published Cochrane Review that included 15
studies and 989 MS participants regarding the efficacy of memory retraining tech-
niques with or without the assistance of computer software, concluded that there
is only limited evidence on the effectiveness of memory rehabilitation in this popu-
lation. The authors further suggest that more RCTs of high methodological quality
be conducted with the utilization of ecologically valid outcome assessments [63].
Another Cochrane Review that included 20 studies and 966 MS participants
evaluating the effectiveness of neuropsychological rehabilitation in MS [64],
reported low-level evidence for the positive effects of neuropsychological rehabili-
tation in this population. However, the authors reported that the comparability of
the 20 studies reviewed was limited due to heterogeneity of interventions and
outcome measures. It should be noted however, that the majority of studies
included in this review did show some evidence of positive effects on cognitive
outcome measures.
Despite the limitations noted by the previously mentioned Cochrane reviews,
a growing body of literature supports the efficacy of cognitive rehabilitation for
individuals with MS and more randomized controlled trials are needed to support
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existing and new rehabilitation techniques. Cognitive rehabilitation appears to be
useful for all patients with MS regardless of disease course and level of cognitive
impairment, although studies including exclusively MS patients with progressive
disease course are limited. Future clinical trials utilizing cognitive rehabilitation
interventions in progressive MS patients should become a priority.
4. Conclusions
Cognitive impairment is frequently encountered in MS individuals, irrespective
of disease duration, severity of physical disability, and at both the earlier and later
disease stages. Moreover, cognitive dysfunction in this population may have a
significant negative impact on quality of life, activities of daily living and employ-
ment status. Furthermore, past and current pharmacological treatments have
shown inconsistent findings in alleviating cognitive impairment in individuals with
MS requiring further clarification. This inconsistency regarding the effects of
pharmacological interventions on cognition, coupled with the reduced ability to
effectively handle everyday tasks, loss of employment and social interaction
capacity, prioritizes the need for utilizing potentially more effective
non-pharmacological, neurobehavioral interventions to address cognitive dysfunc-
tion and everyday functioning abilities. Neurobehavioral interventions utilizing
cognitive rehabilitation have shown favorable effects on MS patients cognitive
performance and other related skills, and in some cases, have managed to generalize
these positive effects to MS individual’s everyday life functioning ability. In this
respect it becomes obvious that there is a need for rigorous new cognitive
neurorehabilitation studies that may overcome some of the methodological limita-
tions of older studies, and provide robust evidence regarding the efficiency of such
cognitive interventions for the MS population.
Conflict of interest
The authors have no conflict of interest.
Declarations
Parts of this chapter originate from my Doctoral Dissertation entitled:
Neuropsychological functions and association with Single Photon Emission Com-
puted Tomography (SPECT) in Greek Multiple Sclerosis patients: Efficacy of a
Computerized Cognitive Rehabilitation Intervention (2017). Department of Neu-




Lambros Messinis1*, Grigorios Nasios2 and Panagiotis Papathanasopouos3
1 Neuropsychology Section, Departments of Psychiatry and Neurology,
University Hospital of Patras and University of Patras Medical School, Greece
2 Department of Speech and Language Therapy, School of Health Sciences,
University of Ioannina, Greece
3 University of Patras Medical School, Greece
*Address all correspondence to: lmessinis@upatras.gr
© 2019 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
67
Neuropsychological Functions and Cognitive Neurorehabilitation in Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.85511
existing and new rehabilitation techniques. Cognitive rehabilitation appears to be
useful for all patients with MS regardless of disease course and level of cognitive
impairment, although studies including exclusively MS patients with progressive
disease course are limited. Future clinical trials utilizing cognitive rehabilitation
interventions in progressive MS patients should become a priority.
4. Conclusions
Cognitive impairment is frequently encountered in MS individuals, irrespective
of disease duration, severity of physical disability, and at both the earlier and later
disease stages. Moreover, cognitive dysfunction in this population may have a
significant negative impact on quality of life, activities of daily living and employ-
ment status. Furthermore, past and current pharmacological treatments have
shown inconsistent findings in alleviating cognitive impairment in individuals with
MS requiring further clarification. This inconsistency regarding the effects of
pharmacological interventions on cognition, coupled with the reduced ability to
effectively handle everyday tasks, loss of employment and social interaction
capacity, prioritizes the need for utilizing potentially more effective
non-pharmacological, neurobehavioral interventions to address cognitive dysfunc-
tion and everyday functioning abilities. Neurobehavioral interventions utilizing
cognitive rehabilitation have shown favorable effects on MS patients cognitive
performance and other related skills, and in some cases, have managed to generalize
these positive effects to MS individual’s everyday life functioning ability. In this
respect it becomes obvious that there is a need for rigorous new cognitive
neurorehabilitation studies that may overcome some of the methodological limita-
tions of older studies, and provide robust evidence regarding the efficiency of such
cognitive interventions for the MS population.
Conflict of interest
The authors have no conflict of interest.
Declarations
Parts of this chapter originate from my Doctoral Dissertation entitled:
Neuropsychological functions and association with Single Photon Emission Com-
puted Tomography (SPECT) in Greek Multiple Sclerosis patients: Efficacy of a
Computerized Cognitive Rehabilitation Intervention (2017). Department of Neu-




Lambros Messinis1*, Grigorios Nasios2 and Panagiotis Papathanasopouos3
1 Neuropsychology Section, Departments of Psychiatry and Neurology,
University Hospital of Patras and University of Patras Medical School, Greece
2 Department of Speech and Language Therapy, School of Health Sciences,
University of Ioannina, Greece
3 University of Patras Medical School, Greece
*Address all correspondence to: lmessinis@upatras.gr
© 2019 TheAuthor(s). Licensee IntechOpen. This chapter is distributed under the terms
of theCreativeCommonsAttribution License (http://creativecommons.org/licenses/
by/3.0),which permits unrestricted use, distribution, and reproduction in anymedium,
provided the original work is properly cited.
67
Neuropsychological Functions and Cognitive Neurorehabilitation in Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.85511
References
[1] Murray TJ. The history of multiple
sclerosis. In: Burks JS, Johnson KP,
editors. Multiple Sclerosis: Diagnosis,
Medical Management and
Rehabilitation. New York: Demos
Medical Publishing Murray; 2000
[2] Kesselring J. History of multiple
sclerosis. In: Raine CS, McFarland HF,
Hohlfeld R, editors. Multiple Sclerosis: A
Comprehensive Text. Philadelphia, PA:
Elsevier Limited. Kesselring; 2008
[3] Massimiliano DF, Portaccio E,
Mancini A, et al. Multiple sclerosis and
cognition: Synaptic failure and network
dysfunction. Nature Reviews.
Neuroscience. 2018;19:599-609
[4] Schoonheim MM, Meijer KA, Geurts
JJ. Network collapse and cognitive
impairment in multiple sclerosis.
Frontiers in Neurology. 2015;6:82-86
[5] Peterson DS, Fling BW. How changes
in brain activity and connectivity are
associated with motor performance in
people with MS. NeuroImage: Clinical.
2018;17:153-162
[6] Balcer LJ, Balk LJ, Brandt AU, et al.
The international multiple sclerosis
visual system consortium: Advancing
visual system research in multiple
sclerosis. Journal of Neuro-
Ophthalmology. 2018;38:494-501
[7] Doty RL, MacGillivray MR, Talab H,
et al. Balance in multiple sclerosis:
Relationship to central brain regions.
Experimental Brain Research. 2018;236:
2739-2750
[8] Uitdehaag BM. Disability outcome
measures in phase III clinical trials in
multiple sclerosis. CNS Drugs. 2018;1:
1-16
[9] Kefaliakos A, Pliakos I, Diomidous
M. Managing the quality of life in
patients with multiple sclerosis: A
literature review. Studies in Health
Technology and Informatics. 2016;226:
220-221
[10] Hawkes CH, Macgregor AJ. Twin
studies and the heritability of MS: A
conclusion. Multiple Sclerosis. 2009;15:
661-667
[11] Lezak MD, Howieson DB, Bigler ED,
Tranel D. Neuropsychological
Assessment. 5th ed. New York: Oxford
University Press; 2012. pp. 290-303
[12] Belbasis L, Bellou V, Evangelou E,
Ioannidis JPA, Tzoulaki I.
Environmental risk actors and multiple
sclerosis: An umbrella review of
systematic reviews and meta-analyses.
Lancet Neurology. 2015;14:263-273
[13] Lublin FD, Reingold SC, Cohen JA,
et al. Defining the clinical course of
multiple sclerosis: The 2013 revisions.
Neurology. 2014;83:278-286
[14] Charcot JM. Lectures on the
Diseases of the Nervous System.
London: New Sydenham Society; 1877
[15] Messinis L, Kosmidis MH, Lyros E,
Papathanasopoulos P. Assessment and
rehabilitation of cognitive impairment
in multiple sclerosis. International
Review of Psychiatry. 2010;22:22-34
[16] Schulz D, Kopp B, Kunkel A, Faiss
JH. Cognition in the early stage of
multiple sclerosis. Journal of Neurology.
2006;253:1002-1010
[17] Faiss JH. Cognitive dysfunction in
different stages in multiple sclerosis—
presentation of 3 cases. Journal of
Neurology. 2007;254(supp. 2):77-79
[18] Ruggieri RM, Palermo R, Vitello G,
Gennuso M, Settipani N, Picolli F.
Cognitive impairment in patients
suffering from relapsing-remitting





[19] Messinis L, Anyfantis E, Paschali A,
Papathanasopoulos P. Cognitive deficits
in relapsing remitting multiple sclerosis
patients with low disability status. In:
Proceedings of the 7th International
Congress on the Improvement of the
Quality of life on Dementia, Parkinson’s
disease, Epilepsy, MS, Muscular
Disorders and Neuroethics. 2009.
pp. 31-35
[20] Louapre C, Perlbarg V. Garcia-
Lorenzo, et al., Brain networks
disconnection in early multiple sclerosis:
An anatomofunctional study. Human
Brain Mapping. 2014;35:4706-4717
[21] Chiaravalloti ND, DeLuca J.
Cognitive impairment in multiple
sclerosis. Lancet Neurology. 2008;7:
1139-1151
[22] Polychroniadou E, Bakirtzis C,
Langdon D, et al. Validation of the Brief
International Cognitive Assessment for
Multiple Sclerosis (BICAMS) in Greek
population with multiple sclerosis.
Multiple Sclerosis and Related
Disorders. 2016;9:68-72
[23] Papathanasiou A, Messinis L,
Georgiou LV, Papathanasopoulos P.
Cognitive impairment in relapsing
remitting and secondary progressive
multiple sclerosis patients: Efficacy of a
computerized cognitive screening
battery. ISRN Neurology. 2014;2014:
151379. DOI: 10.1155/2014/151379
[24] Polman CH, Reingold SC, Banwell
B, et al. Diagnostic criteria for multiple
sclerosis: 2010 revisions to the
McDonald criteria. Annals of
Neurology. 2011;69:292-302
[25] Achiron A, Chapman J, Magalashvili
D, et al. Modeling of cognitive
impairment by disease duration in
multiple sclerosis: A cross–sectional
study. PLoS One. 2013;8(8):e71058
[26] Prakash RS, Snook EM, Lewis JM,
et al. Cognitive impairments in relapsing
remitting multiple sclerosis: A meta-
analysis. Multiple Sclerosis. 2008;14:
1250-1261
[27] Langdon DW. Cognition in multiple
sclerosis. Current Opinion in Neurology.
2011;24:244-249
[28] Rosti-Otajarvi E, Ruutianen J,
Huhtala H, Hamalainen P. Cognitive
performance profile in different
phenotypes of MS with cognitive
complaints. Multiple Sclerosis and
Related Disorders. 2014;3:463-472
[29] Potagas C, Giogkaraki E, Koutsis G,
Mandellos D, Tsirempolou E, Sfagos C,
et al. Cognitive impairment in different
MS subtypes and clinically isolated
syndromes. Journal of the Neurological
Sciences. 2008;267:100-106
[30] Panou T, Mastorodemos V,
Papadaki E, Simos PG, Plaitakis A. Early
signs of memory impairment among
multiple sclerosis patients with clinically
isolated syndrome. Behavioural
Neurology. 2012;25:311-326
[31] Forslin Y, Granberg T, Jumah AA,
et al. Incidence of radiologically isolated
syndrome: A population-based study.
American Journal of Neuroradiology.
2016;37:1017-1022
[32] Ntoskou A, Messinis L, Nasios G,
Martzoukou M, Makris G,
Panagiotopoulos E, et al. Cognitive and
language deficits in multiple sclerosis:
Comparison of relapsing remitting and
secondary progressive subtypes. The
Open Neurology Journal. 2018;12:19-30
[33] Fischer JS. Cognitive impairments in
multiple. In: Cook SD, editor. Handbook
of Multiple Sclerosis. New York, USA:
Marcel Dekker; 2001. pp. 233-256
[34] Rao SM, Leo GJ, Bernardin L,
Unverzagt F. Cognitive dysfunction in
multiple sclerosis: I Frequency, patterns,
69
Neuropsychological Functions and Cognitive Neurorehabilitation in Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.85511
References
[1] Murray TJ. The history of multiple
sclerosis. In: Burks JS, Johnson KP,
editors. Multiple Sclerosis: Diagnosis,
Medical Management and
Rehabilitation. New York: Demos
Medical Publishing Murray; 2000
[2] Kesselring J. History of multiple
sclerosis. In: Raine CS, McFarland HF,
Hohlfeld R, editors. Multiple Sclerosis: A
Comprehensive Text. Philadelphia, PA:
Elsevier Limited. Kesselring; 2008
[3] Massimiliano DF, Portaccio E,
Mancini A, et al. Multiple sclerosis and
cognition: Synaptic failure and network
dysfunction. Nature Reviews.
Neuroscience. 2018;19:599-609
[4] Schoonheim MM, Meijer KA, Geurts
JJ. Network collapse and cognitive
impairment in multiple sclerosis.
Frontiers in Neurology. 2015;6:82-86
[5] Peterson DS, Fling BW. How changes
in brain activity and connectivity are
associated with motor performance in
people with MS. NeuroImage: Clinical.
2018;17:153-162
[6] Balcer LJ, Balk LJ, Brandt AU, et al.
The international multiple sclerosis
visual system consortium: Advancing
visual system research in multiple
sclerosis. Journal of Neuro-
Ophthalmology. 2018;38:494-501
[7] Doty RL, MacGillivray MR, Talab H,
et al. Balance in multiple sclerosis:
Relationship to central brain regions.
Experimental Brain Research. 2018;236:
2739-2750
[8] Uitdehaag BM. Disability outcome
measures in phase III clinical trials in
multiple sclerosis. CNS Drugs. 2018;1:
1-16
[9] Kefaliakos A, Pliakos I, Diomidous
M. Managing the quality of life in
patients with multiple sclerosis: A
literature review. Studies in Health
Technology and Informatics. 2016;226:
220-221
[10] Hawkes CH, Macgregor AJ. Twin
studies and the heritability of MS: A
conclusion. Multiple Sclerosis. 2009;15:
661-667
[11] Lezak MD, Howieson DB, Bigler ED,
Tranel D. Neuropsychological
Assessment. 5th ed. New York: Oxford
University Press; 2012. pp. 290-303
[12] Belbasis L, Bellou V, Evangelou E,
Ioannidis JPA, Tzoulaki I.
Environmental risk actors and multiple
sclerosis: An umbrella review of
systematic reviews and meta-analyses.
Lancet Neurology. 2015;14:263-273
[13] Lublin FD, Reingold SC, Cohen JA,
et al. Defining the clinical course of
multiple sclerosis: The 2013 revisions.
Neurology. 2014;83:278-286
[14] Charcot JM. Lectures on the
Diseases of the Nervous System.
London: New Sydenham Society; 1877
[15] Messinis L, Kosmidis MH, Lyros E,
Papathanasopoulos P. Assessment and
rehabilitation of cognitive impairment
in multiple sclerosis. International
Review of Psychiatry. 2010;22:22-34
[16] Schulz D, Kopp B, Kunkel A, Faiss
JH. Cognition in the early stage of
multiple sclerosis. Journal of Neurology.
2006;253:1002-1010
[17] Faiss JH. Cognitive dysfunction in
different stages in multiple sclerosis—
presentation of 3 cases. Journal of
Neurology. 2007;254(supp. 2):77-79
[18] Ruggieri RM, Palermo R, Vitello G,
Gennuso M, Settipani N, Picolli F.
Cognitive impairment in patients
suffering from relapsing-remitting





[19] Messinis L, Anyfantis E, Paschali A,
Papathanasopoulos P. Cognitive deficits
in relapsing remitting multiple sclerosis
patients with low disability status. In:
Proceedings of the 7th International
Congress on the Improvement of the
Quality of life on Dementia, Parkinson’s
disease, Epilepsy, MS, Muscular
Disorders and Neuroethics. 2009.
pp. 31-35
[20] Louapre C, Perlbarg V. Garcia-
Lorenzo, et al., Brain networks
disconnection in early multiple sclerosis:
An anatomofunctional study. Human
Brain Mapping. 2014;35:4706-4717
[21] Chiaravalloti ND, DeLuca J.
Cognitive impairment in multiple
sclerosis. Lancet Neurology. 2008;7:
1139-1151
[22] Polychroniadou E, Bakirtzis C,
Langdon D, et al. Validation of the Brief
International Cognitive Assessment for
Multiple Sclerosis (BICAMS) in Greek
population with multiple sclerosis.
Multiple Sclerosis and Related
Disorders. 2016;9:68-72
[23] Papathanasiou A, Messinis L,
Georgiou LV, Papathanasopoulos P.
Cognitive impairment in relapsing
remitting and secondary progressive
multiple sclerosis patients: Efficacy of a
computerized cognitive screening
battery. ISRN Neurology. 2014;2014:
151379. DOI: 10.1155/2014/151379
[24] Polman CH, Reingold SC, Banwell
B, et al. Diagnostic criteria for multiple
sclerosis: 2010 revisions to the
McDonald criteria. Annals of
Neurology. 2011;69:292-302
[25] Achiron A, Chapman J, Magalashvili
D, et al. Modeling of cognitive
impairment by disease duration in
multiple sclerosis: A cross–sectional
study. PLoS One. 2013;8(8):e71058
[26] Prakash RS, Snook EM, Lewis JM,
et al. Cognitive impairments in relapsing
remitting multiple sclerosis: A meta-
analysis. Multiple Sclerosis. 2008;14:
1250-1261
[27] Langdon DW. Cognition in multiple
sclerosis. Current Opinion in Neurology.
2011;24:244-249
[28] Rosti-Otajarvi E, Ruutianen J,
Huhtala H, Hamalainen P. Cognitive
performance profile in different
phenotypes of MS with cognitive
complaints. Multiple Sclerosis and
Related Disorders. 2014;3:463-472
[29] Potagas C, Giogkaraki E, Koutsis G,
Mandellos D, Tsirempolou E, Sfagos C,
et al. Cognitive impairment in different
MS subtypes and clinically isolated
syndromes. Journal of the Neurological
Sciences. 2008;267:100-106
[30] Panou T, Mastorodemos V,
Papadaki E, Simos PG, Plaitakis A. Early
signs of memory impairment among
multiple sclerosis patients with clinically
isolated syndrome. Behavioural
Neurology. 2012;25:311-326
[31] Forslin Y, Granberg T, Jumah AA,
et al. Incidence of radiologically isolated
syndrome: A population-based study.
American Journal of Neuroradiology.
2016;37:1017-1022
[32] Ntoskou A, Messinis L, Nasios G,
Martzoukou M, Makris G,
Panagiotopoulos E, et al. Cognitive and
language deficits in multiple sclerosis:
Comparison of relapsing remitting and
secondary progressive subtypes. The
Open Neurology Journal. 2018;12:19-30
[33] Fischer JS. Cognitive impairments in
multiple. In: Cook SD, editor. Handbook
of Multiple Sclerosis. New York, USA:
Marcel Dekker; 2001. pp. 233-256
[34] Rao SM, Leo GJ, Bernardin L,
Unverzagt F. Cognitive dysfunction in
multiple sclerosis: I Frequency, patterns,
69
Neuropsychological Functions and Cognitive Neurorehabilitation in Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.85511
and prediction. Neurology. 1991;41:
685-691
[35] Guimares J, Jose SA. Cognitive
dysfunction in multiple sclerosis.
Frontiers in Neurology. 2012;3:74
[36] Sumowski JF, Leavitt VM. Cognitive
reserve in multiple sclerosis. Multiple
Sclerosis. 2013;19:1122-1127
[37] Sumowski JF, Rocca MA, Leavitt
VM, et al. Brain reserve and cognitive
reserve protect against cognitive decline
over 4.5 years in MS. Neurology. 2014;
82:1776-1178
[38] Gilmore CP, DeLuca GC, Bo L, et al.
Spinal cord neuronal pathology in
multiple sclerosis. Brain Pathology.
2009;19:642-649
[39] Benedict RHB, DeLuca J, Enzinger
C, Geuts JG, Krupp LB, Rao M.
Neuropsychology of multiple sclerosis:
Looking back and moving forward.
Journal of the International
Neuropsychological Society. 2017;23:
832-842
[40] Fisher E, Lee JC, Nakamura K,
Rudick RA. Gray matter atrophy in
multiple sclerosis: A longitudinal study.
Annals of Neurology. 2008;64:255-265
[41] Schoonheim MM, Hulst HE, Brandt
RB, et al. Thalamus structure and
function determine severity of cognitive
impairment in multiple sclerosis.
Neurology. 2015;84:776-783
[42] Papathanasiou A, Messinis L,
Zampakis P, et al. Thalamic atrophy
predicts cognitive impairment in
relapsing remitting multiple sclerosis.
Effect on instrumental activities of daily
living and employment status. Journal
of the Neurological Sciences. 2015;358:
236-242
[43] Papathanasiou A, Messinis L,
Zampakis P, Papathanasopoulos P.
(2017). Corpus Callosum atrophy as a
marker of clinically meaningful
cognitive decline in Secondary
Progressive multiple sclerosis. Impact
on employment status. Journal of
Clinical Neuroscience. 2017;43:170-175
[44] LanzM, HahnHK, Hildebrandt H.
Brain atrophy and cognitive impairment
inmultiple sclerosis: a review. Journal of
Neurology. 2007;254(Supp. 2):II/43-II/48
[45] Goverover Y, Chiaravalloti N,
DeLuca J. Brief international cognitive
assessment for multiple sclerosis
(BICAMS) and performance of
everyday life tasks: Actual reality.
Multiple Sclerosis. 2016;22:544-550
[46] Goverover Y, Kalmar J, Gaudino-
Goering E, et al. The relation between
subjective and objective measures of
everyday life activities in persons with
multiple sclerosis. Archives of Physical
Medicine and Rehabilitation. 2005;86:
2303-2308
[47] O’Brien A, Gaudino-Goering E,
Shawaryn M, Komaroff E, Moore NB,
DeLuca J. (2007). Relationship of
multiple sclerosis neuropsychological
questionnaire (MSNQ) to functional,
emotional, and neuropsychological
outcomes. Archives of Clinical
Neuropsychology. 2007;22:933-948
[48] Goverover Y. Cognition and
everyday functional activity in persons
with multiple sclerosis. In: Presented at
the 5th Conference of the International
MS Cognition Society. 2016
[49] Roy S, Benedict RH, Drake AS,
Weinstock-Guttman B. Impact of
pharmacotherapy on cognitive
dysfunction in patients with multiple
sclerosis. CNS Drugs. 2016;30(3):
209-225. DOI: 10.1007/s40263-016-
0319-6
[50] Miller E, Morel A, Miller I, Saluk J.
Pharmacological treatment and non-
pharmacological therapies of cognitive





[51] Mitolo M, Venneri A, Wilkinson ID,
Sharrack B. Cognitive rehabilitation in
multiple sclerosis: A systematic review.
Journal of Neurological Sciences. 2015;
354:1-9
[52] Mokhber N, Azarpazhooh A, Orouji
E. Cognitive dysfunction in patients
with multiple sclerosis treated with
different types of interferon beta: A
randomized clinical trial. Journal of the
Neurological Sciences. 2014;342:16-20
[53] Messinis L, Nasios G, Kosmidis MH,
Zampakis P, Malefaki S, Ntoskou, et al.
Efficacy of a computer—assisted
cognitive rehabilitation intervention in
relapsing remitting multiple sclerosis
patients—a randomized controlled trial.
Behavioural Neurology. 2017;2017:
5919841
[54] Dardiotis E, Nousia A, Siokas V,
Tsouris Z, Andravizou A, Fotios A, et al.
Efficacy of computer-based cognitive
training in neuropsychological
performance of patients with multiple
sclerosis: A systematic review and meta-
analysis. Multiple Sclerosis and Related
Disorders. 2018;20:58-66
[55] Sohlberg MM, Mateer CA. Cognitive
Rehabilitation: An Integrative
Neuropsychological Approach. New
York: Guilford Press; 2001
[56] Hulst HE, Langdon DW. Functional
training is a senseless strategy in MS
cognitive rehabilitation: Strategy
training is the only useful approach—
NO. Multiple Sclerosis. 2017;23:930-932
[57] Bakirtzis C, Ioannidis P, Messinis L,
Nasios G, Grigoriadis N. (2018). The
rationale for monitoring cognitive
function in multiple sclerosis: practical
issues for clinicians. The Open
Neurology Journal. 2018;12:31-40
[58] Chiaravalloti ND, Moore NB,
Nikelshpur OM, DeLuca J. An RCT to
treat learning impairment in multiple
sclerosis. Neurology. 2013;81:2066-2072
[59] Bonavita S, Sacco R, Della Corte M,
et al. Computer-aided cognitive
rehabilitation improves cognitive
performances and induces brain
functional connectivity changes in
relapsing remitting multiple sclerosis
patients: An exploratory study. Journal
of Neurology. 2015;262:91-100
[60] Cerasa A, Gioia MC, Valentino P,
et al. Computer assisted cognitive
rehabilitation of attention deficits for
multiple sclerosis: A randomized trial
with fMRI correlates.
Neurorehabilitation and Neural Repair.
2013;27:284-295
[61] Mattioli F, Stampatori C, Bellomi F,
et al. A RCT comparing specific
intensive cognitive training to aspecific
psychological intervention in RRMS:
The SMICT study. Frontiers in
Neurology. 2015;5:278
[62] Mattioli F, Bellomi F, Stampatori C,
et al. Two years follow up of domain
specific cognitive training in relapsing
remitting multiple sclerosis: A
randomized clinical trial. Frontiers in
Behavioral Neuroscience. 2016;10:28
[63] Das Nair R, Martin K, Lincoln NB.
Memory rehabilitation for people with
multiple sclerosis. Cochrane Database of
Systematic Reviews. 2016;3:CD008754.
DOI: 10.1002/14651858.CD008754.pub3
[64] Rosti-Otajarvi EM, Hamalainen PI.
Neuropsychological rehabilitation for
multiple sclerosis. The Cochrane
Database of Systematic Reviews. 2014;
11:CD009131
71
Neuropsychological Functions and Cognitive Neurorehabilitation in Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.85511
and prediction. Neurology. 1991;41:
685-691
[35] Guimares J, Jose SA. Cognitive
dysfunction in multiple sclerosis.
Frontiers in Neurology. 2012;3:74
[36] Sumowski JF, Leavitt VM. Cognitive
reserve in multiple sclerosis. Multiple
Sclerosis. 2013;19:1122-1127
[37] Sumowski JF, Rocca MA, Leavitt
VM, et al. Brain reserve and cognitive
reserve protect against cognitive decline
over 4.5 years in MS. Neurology. 2014;
82:1776-1178
[38] Gilmore CP, DeLuca GC, Bo L, et al.
Spinal cord neuronal pathology in
multiple sclerosis. Brain Pathology.
2009;19:642-649
[39] Benedict RHB, DeLuca J, Enzinger
C, Geuts JG, Krupp LB, Rao M.
Neuropsychology of multiple sclerosis:
Looking back and moving forward.
Journal of the International
Neuropsychological Society. 2017;23:
832-842
[40] Fisher E, Lee JC, Nakamura K,
Rudick RA. Gray matter atrophy in
multiple sclerosis: A longitudinal study.
Annals of Neurology. 2008;64:255-265
[41] Schoonheim MM, Hulst HE, Brandt
RB, et al. Thalamus structure and
function determine severity of cognitive
impairment in multiple sclerosis.
Neurology. 2015;84:776-783
[42] Papathanasiou A, Messinis L,
Zampakis P, et al. Thalamic atrophy
predicts cognitive impairment in
relapsing remitting multiple sclerosis.
Effect on instrumental activities of daily
living and employment status. Journal
of the Neurological Sciences. 2015;358:
236-242
[43] Papathanasiou A, Messinis L,
Zampakis P, Papathanasopoulos P.
(2017). Corpus Callosum atrophy as a
marker of clinically meaningful
cognitive decline in Secondary
Progressive multiple sclerosis. Impact
on employment status. Journal of
Clinical Neuroscience. 2017;43:170-175
[44] LanzM, HahnHK, Hildebrandt H.
Brain atrophy and cognitive impairment
inmultiple sclerosis: a review. Journal of
Neurology. 2007;254(Supp. 2):II/43-II/48
[45] Goverover Y, Chiaravalloti N,
DeLuca J. Brief international cognitive
assessment for multiple sclerosis
(BICAMS) and performance of
everyday life tasks: Actual reality.
Multiple Sclerosis. 2016;22:544-550
[46] Goverover Y, Kalmar J, Gaudino-
Goering E, et al. The relation between
subjective and objective measures of
everyday life activities in persons with
multiple sclerosis. Archives of Physical
Medicine and Rehabilitation. 2005;86:
2303-2308
[47] O’Brien A, Gaudino-Goering E,
Shawaryn M, Komaroff E, Moore NB,
DeLuca J. (2007). Relationship of
multiple sclerosis neuropsychological
questionnaire (MSNQ) to functional,
emotional, and neuropsychological
outcomes. Archives of Clinical
Neuropsychology. 2007;22:933-948
[48] Goverover Y. Cognition and
everyday functional activity in persons
with multiple sclerosis. In: Presented at
the 5th Conference of the International
MS Cognition Society. 2016
[49] Roy S, Benedict RH, Drake AS,
Weinstock-Guttman B. Impact of
pharmacotherapy on cognitive
dysfunction in patients with multiple
sclerosis. CNS Drugs. 2016;30(3):
209-225. DOI: 10.1007/s40263-016-
0319-6
[50] Miller E, Morel A, Miller I, Saluk J.
Pharmacological treatment and non-
pharmacological therapies of cognitive





[51] Mitolo M, Venneri A, Wilkinson ID,
Sharrack B. Cognitive rehabilitation in
multiple sclerosis: A systematic review.
Journal of Neurological Sciences. 2015;
354:1-9
[52] Mokhber N, Azarpazhooh A, Orouji
E. Cognitive dysfunction in patients
with multiple sclerosis treated with
different types of interferon beta: A
randomized clinical trial. Journal of the
Neurological Sciences. 2014;342:16-20
[53] Messinis L, Nasios G, Kosmidis MH,
Zampakis P, Malefaki S, Ntoskou, et al.
Efficacy of a computer—assisted
cognitive rehabilitation intervention in
relapsing remitting multiple sclerosis
patients—a randomized controlled trial.
Behavioural Neurology. 2017;2017:
5919841
[54] Dardiotis E, Nousia A, Siokas V,
Tsouris Z, Andravizou A, Fotios A, et al.
Efficacy of computer-based cognitive
training in neuropsychological
performance of patients with multiple
sclerosis: A systematic review and meta-
analysis. Multiple Sclerosis and Related
Disorders. 2018;20:58-66
[55] Sohlberg MM, Mateer CA. Cognitive
Rehabilitation: An Integrative
Neuropsychological Approach. New
York: Guilford Press; 2001
[56] Hulst HE, Langdon DW. Functional
training is a senseless strategy in MS
cognitive rehabilitation: Strategy
training is the only useful approach—
NO. Multiple Sclerosis. 2017;23:930-932
[57] Bakirtzis C, Ioannidis P, Messinis L,
Nasios G, Grigoriadis N. (2018). The
rationale for monitoring cognitive
function in multiple sclerosis: practical
issues for clinicians. The Open
Neurology Journal. 2018;12:31-40
[58] Chiaravalloti ND, Moore NB,
Nikelshpur OM, DeLuca J. An RCT to
treat learning impairment in multiple
sclerosis. Neurology. 2013;81:2066-2072
[59] Bonavita S, Sacco R, Della Corte M,
et al. Computer-aided cognitive
rehabilitation improves cognitive
performances and induces brain
functional connectivity changes in
relapsing remitting multiple sclerosis
patients: An exploratory study. Journal
of Neurology. 2015;262:91-100
[60] Cerasa A, Gioia MC, Valentino P,
et al. Computer assisted cognitive
rehabilitation of attention deficits for
multiple sclerosis: A randomized trial
with fMRI correlates.
Neurorehabilitation and Neural Repair.
2013;27:284-295
[61] Mattioli F, Stampatori C, Bellomi F,
et al. A RCT comparing specific
intensive cognitive training to aspecific
psychological intervention in RRMS:
The SMICT study. Frontiers in
Neurology. 2015;5:278
[62] Mattioli F, Bellomi F, Stampatori C,
et al. Two years follow up of domain
specific cognitive training in relapsing
remitting multiple sclerosis: A
randomized clinical trial. Frontiers in
Behavioral Neuroscience. 2016;10:28
[63] Das Nair R, Martin K, Lincoln NB.
Memory rehabilitation for people with
multiple sclerosis. Cochrane Database of
Systematic Reviews. 2016;3:CD008754.
DOI: 10.1002/14651858.CD008754.pub3
[64] Rosti-Otajarvi EM, Hamalainen PI.
Neuropsychological rehabilitation for
multiple sclerosis. The Cochrane
Database of Systematic Reviews. 2014;
11:CD009131
71








Communicating ability is one of the necessary social needs in human, and 
language is a critical part of daily connections and communications. Language is 
impaired by different central nervous system (CNS) diseases such as multiple scle-
rosis (MS). MS leads to a language disorder by creating some plaques in subcortical 
constructions such as naming problems, semantic errors, and circumlocutory nam-
ing errors, semantic paraphasia, nonfluent speech, and grammatical and syntactic 
problems such as reduced mean maximum length of sentences and the number of 
spoken words and impairment in high-level language skills.
Keywords: multiple sclerosis, language, language disorder
1. Introduction
Communicating ability is one of the necessary social needs in human, and 
language is a critical part of daily connections and communications. Hence, any 
disorders in language result in inappropriate transferring of thoughts, idea, needing 
others, and finally inappropriate communication. According to studies, language 
is disrupted in different ways through the central nervous system (CNS), including 
Parkinson’s, Alzheimer’s, amyotrophic lateral sclerosis (ALS), and multiple sclerosis 
[1–6]. MS leads to language disorder by creating some plaques in language-related 
areas. If not treated, these disorders limit social life, professional life, mental life, 
and quality of life [7, 8]. If language disorders not treated, these disorders limit 
social, professional, mental, and quality of life. It is necessary to get involved with 
language interventions at the early stages of the disease and immediately after the 
detection of language disorders if life quality of MS patients is to be protected. 
Early detection and intervention in language disorders in these patients result in 
fast improvements in language functions, preventing the development of these 
disorders and finally preserving daily communication, social, functional, and 
professional life quality. Language interventions at the early stages of MS disease 
require accurate awareness of every kind of language disorders and the detection 
of various language disorders. Therefore, given the importance of language in daily 
communications, and social, professional, and functional lives, it is necessary to 
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2. What is language?
Language is a social code or a conventional system to reflect concepts through 
using conventional symbols and the rules related to combining these symbols [9]. 
As shown in Figure 1, language is complex, and a multiple-level phenomenon con-
sisted of three main aspects; form, content, and use [10]. In other words, language 
is a complex cognitive function including pragmatic, semantic, syntax, morphol-
ogy, and phonology subsystems (more information in Table 1).
Ref. [55].
Table 1. Description of language measures. Ref. [55].
Figure 1. 
The three main aspects.
75
Language Disorders in Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.85766
3. What is language disorder?
The American Speech-Language-Auditory Association (ASHA) considers any 
disorder in comprehension and applying symbolic speech, writing, and another 
symbolic system as a language disorder. This may occur in any of the three main 
language aspects (form, content, use) in semantic, syntax, morphology, phonology, 
and pragmatic subsystems (Table 1).
4. Language disorders in MS disease
Multiple sclerosis (MS) is a type of progressive central nervous system disease 
in which myelin sheaths are destroyed, and plaques are created in some parts of 
the brain and spinal cord’s white material [11]. MS is the most common neurologic 
disease in people aging 20–45, and its prevalence is four times more in women than 
in men. Depending on the country and its special population, its prevalence is 
2–150 individuals per 100,000 individuals [12]. According to the Multiple Sclerosis 
International Federation report in 2015, 2,300,000 million people in the world 
suffer from the MS disease [3]. Common symptoms of the disease include physical 
and sensory movement problems, speech disorders such as dysarthria, cognitive 
disorders, and language disorders [11].
5. Language disorder history in MS
In the recent two decades, researchers believed that MS harms subcortical areas, 
and cortical disorder causes language deficits [7, 13]. For this, no research was done 
on MS cognitive functions in the language field. However, along with brain imag-
ing developments, it is proved that not only are subcortical structures such as the 
thalamus, caudate nucleus, globus pallidus, subthalamic nucleus, substantia nigra, 
and cerebellum effective in adjusting and coordinating the movement aspects of 
speech, but also they play a role in the processing of cognitive and language func-
tions [14]. Using PET scan, some researchers showed that the thalamus and basal 
ganglia start to work during doing language assignments like picture naming [15] 
and word repeating [14, 16]. Using FMRI, Crosson et al. found a remarkable activ-
ity in subcortical structures while doing some language skills [14, 17]. Therefore, 
considering the researches, we can conclude that not only brain cortical but also 
subcortical structures, including the thalamus and its other structures and cerebel-
lum, play a role in language processing and cause language disorders in MS patients 
[14, 18]. Another issue showing the possibility of language deficits in MS patients is 
cognitive deficits, as cognitive skills (memory and attention) are related to language 
skills [19, 20]. Memory disorder is one of the MS’s common symptoms causing 
problems in information retrieving and decoding [20, 21]. In addition, memory 
disorder affects language assignments including verbal fluency [22], naming [23], 
and language comprehension [21, 24].
6. Language disorder types in MS
Studies show that individuals with progressive neurologic diseases such as MS 
experience not only have speech production deficits but also language problems [7]. 
Although some researchers confirm various language disorders in MS, they believe 
that these disorders are prevalent [3].
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Language disorder means any disorder to the semantic, syntax, morphology, 
phonology, and pragmatic abilities appearing in different forms with different 
severities.
Among the existing language disorders, naming problems [1, 23, 25–27], verbal 
fluency [1, 8, 23, 28] in language production, and syntax skills including maximum 
sentence length mean reduction, word number reduction [18, 29], and deficiency 
in high-level language skills [7, 18, 30] are disorders seen in MS patients. Thus, 
regarding the special definition of each language disorder, we discuss each language 
disorder in MS separately.
7. Naming problem and verbal fluency deficit
The naming process is one of the basic lingual processes related to speech 
content and concept transfer. Naming is the person’s ability to comprehend a visual 
symbol and retrieve its name correctly [31].
Naming deficit is one of the language disorders resulted from deficit in message 
content production [32] causing individual disability in achieving phonology and 
semantic characteristics from mental lexical storage [33]. Naming ability disorder 
is caused by different diseases [34], one of which is MS [1, 23, 25–27, 35]. In struc-
tural and functional changes in the brain and language path disorder, MS results in 
naming deficit [21], semantic error, circumlocution [36], and semantic paraphasia 
[24]. There are different reasons for justifying the naming ability deficit. Some 
researchers found insufficient memory [23], depression, and medicine intake. 
However, a particular relationship between medicine and language disorder is 
not confirmed yet [21]. Murdoch et al. found that the naming deficit is related to 
semantic disorders [21]. Le Dorze et al. pointed that retrieving semantic informa-
tion deficit is related to cognitive problems like attention and memory in these 
patients [37]. However the relationship between cognitive and naming disorders is 
a challenge [21].
The naming disorder’s severity can be different depending on the disease prog-
ress; sometimes a more severe disease may cause a more severe naming disorder and 
directly affect individual’s daily functions [21].
There are various tasks to evaluate naming disorders, including confrontational 
naming, naming semantic levels, automatic serial naming, repetition, and verbal 
fluency [38].
Verbal fluency is a cognitive function facilitating information retrieval from the 
memory. It is also sensitive to cognitive disorders caused by the brain’s dysfunc-
tion [39], involving the evaluation of the related processes in the naming process, 
including accessing lexical and semantic information [40]. Verbal fluency is 
disrupted after various diseases such as MS [1, 8, 23, 28]. MS results in verbal flu-
ency disorder through caudate nuclei atrophy [39, 41], thalamus disorder, and basal 
ganglia [7, 42]. Henry and Beatty consider verbal fluency disorder as a common 
language disorder in MS patients [43].
8. Language production and syntax skill deficit
As mentioned earlier, language consisted of three main aspects: form, content, 
and use. Form includes grammar. Grammar refers to the knowledge of examining 
a language structure. Grammar has two components: morphology and syntax. 
Morphology studies words and phrase construction and is related to words’ inner 
structures. Syntax is related to the order of elements in speech.
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The evaluation proposed for the syntax structure of sentences in neurologic 
patients provides important information about neural instantiation and the organi-
zation of language [44]. Any disorder in grammar affects an individual’s ability in 
transferring concepts in an exact sentence form [45].
There are various methods to study morpho-syntax skills, such as studying 
continuous speech and the elicitation procedure.
In most studies, continuous speech and sentence completion analysis methods 
are used to examine morpho-syntax skills so far. The continuous speech method can 
be administered in two ways: soliloquy and conversation. Researchers believe that 
soliloquy is better, as speech-language pathologists speak less and soliloquy writing 
is easier [18]. Being able to define language problems through this method, solilo-
quy needs a high degree of linguistic-cognitive interactions [29, 46].
Some clinical measures for syntactic complexity are used to analyze continu-
ous speech in these studies, including the mean length of utterance in morphemes 
(MLU), mean clauses per utterance (MCU), developmental sentence scoring 
(DSS), remediation and screening procedure analysis (LARSP), the syntactic 
complexity score (SCS), and the picture-elicited scoring procedure for LARSP 
(PSL). MLU is one of the informal measures in continuous speech analysis applied 
in several studies to examine adults’ syntax complexity [47–50]. Some scholars 
reported a meaningful difference between patients and healthy people’s syntax 
skills. These measures are also used to study syntax skills in MS patients compared 
to healthy people [18, 29]. Some mentioned no deficit in syntax skills [51, 52]. In the 
following, we will discuss this in more details.
MCU is a useful measure and shows the number of conjoined and embedded 
clauses in a speech used to study syntax complexity in speaking in adults [48–51].
DSS is a valuable tool to evaluate grammar growth, help diagnostic judgments, 
help plan treatment, and evaluate treatment results [53]. This measure is used to 
examine syntax complexity skills in adults in various studies [48–50]. Another group 
of researchers applied this measure to study syntax skills in MS patients [51, 52]. This 
is mentioned in MLU findings.
Being useful for kids and adults, LARSP is a method to describe syntax com-
plexity in a language sample, ability on the clauses, subordinate clause, phrase and 
word levels, and grammatical abilities [54]. Two scales, SCS and PSL, are used in 
this method. SCS calculates the number of grammatical categories (subject, verb, 
object, and complement) in a speech. Single-word speech does not include syntax 
skills, and syntax is composed of the relationship between morphemes. SCS is only 
used to calculate multiword utterances [51]. PSL is another measure of syntax com-
plexity applied to facilitate the scoring of the Renfrew Action Picture Test (RAPT) 
[51]. Only one study used the LARSP profile and SCS and PSL to examine syntax 
skills in MS patients and showed no deficit in these patients [51].
The investigations showed that grammar deficit is one of the language disor-
ders in MS patients [18, 29, 55, 56]. In defining syntax deficits, they also showed 
that MS patients demonstrate a combination of syntax-semantic disorders [55]. 
Morphology is one of the language components playing an important role in 
syntax phrase, since there is a relationship between morphology and syntactic 
components and they can appear as syntax [55]. To show this, various studies 
demonstrated that MS patients have syntactic errors resulted from morphologic 
errors [29, 55]. Studies on grammar in MS patients each showed a type of deficit 
in syntax skills. One of these deficits was shorter sentences, decrease in the word 
number mean, and the most spoken words in a sentence. Researchers pointed 
that MS patients have language structure deficits related to cognitive impairment, 
especially administrative function impairment. However, the role of aphasia on 
such disorders cannot be denied [18]. In another study, researchers showed that 
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the number of sentences mean and the length of the longest sentence decrease. 
However, there was not a meaningful difference in sentence length mean between 
MS patients and healthy people. This is because of mild severity of the disease and 
no cognitive impairment [57] .
The elicitation procedure is another method to investigate morpho-syntax skill, 
one of which is sentence repetition skill being a fast method to provide information 
from an individual speech. The individual is asked to repeat whatever the patholo-
gist says [58]. Although this method is criticized, evidence shows that with a high 
compatibility in their sentence repetition function with their self-motivated gram-
mar level, if kids or adults have brain impairment, they will have better progress in 
the treatment. In cases where there is time limitation in evaluation and detection 
of patients’ abilities, sentence repetition is a useful strategy for pathologist to gain 
information about individual ability in a short time [58].
Another advantage of sentence repetition is that it is easily implemented. 
Moreover, control, implementation, and analysis are more allowed in this method 
[59]. This method allows concentration on special grammar and phonology aspects, 
and they can be studied accurately. Researchers believe that sentence repetition 
assignment is a method with a high validity and reliability to evaluate general gram-
mar knowledge (morphology, syntax) [59], and it is a valid language-psychology 
representation to detect language impairments [60]. So, we should use easy-imple-
mented methods and immediately detect speech and language disorders to evaluate 
grammar structure. Based on this, among studies on syntax skill investigation, a 
study was implemented on MS patients using the long sentences repetition test 
(the first subtest of the Persian test of investigating high-level language skills). The 
results showed that, compared to a healthy person, the number of spoken words by 
an MS patient decreases meaningfully, and a meaningful decrease in the number of 
functional words (proposition, conjunction, and plural sign) and of content words 
(noun and verb) is a syntax deficit in MS patients. Compared to healthy people, 
they omit these words more often [61].
However, some researchers concluded that MS patients are not different with the 
ordinary people in using syntax structures [51, 52]. It is because of MS mild sever-
ity or being in recover period. Meanwhile, if a deficit is seen in complex language 
structures in MS, it is approvable through natural language measurement tools [51].
9. High-level language skills
High-level language skills mean language production in sentence or discourse 
level compared to single-word level [62]. These skills include several assignments, 
ambiguous sentences, sarcastic comprehension and explanation, proverb, conclu-
sion, sentence making, long sentence repetition, celebrity naming, word definition, 
complex grammatical sentence comprehension, and comprehension and explana-
tion of differences and similarities, and they use many language fields and cognitive 
processes [30].
Another aspect affected by neurologic diseases is high-level language skills. 
These skills are created following the amount of myelin decrease and subcorti-
cal paths impairment. In addition, a possible reason of high-level language skill 
deficit in MS is disconnection of cortical and subcortical areas [30]. The primary 
symptoms of high-level language skills in MS patients are comprehension and 
explanation deficits. They are along with deficit symptoms in ambiguous sentences 
comprehension, sarcastic comprehension and explanation, proverb, conclusion, 
sentence making, long sentence repetition, celebrity naming, word definition, com-
plex grammatical sentence comprehension, and comprehension and explanation of 
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differences and similarities [7, 63]. Deficit in these skills may be predictive of brain 
impairments and certain degenerative dementias [64, 65].
There are a few studies on MS that influence on high-level language skills so 
far. Primary studies evaluate high-level language skills based on standard aphasia 
tests. Although these tests investigate language skills, they are not complex and 
sensitive enough to exactly define language disorders and high-level language skills 
in MS patients [27, 66]. Thus, high-level language skills were studied using the 
test of language competence (TLC) and the word test (TWT). The results showed 
that, compared to healthy people, MS patients had lower scores in these skills, and 
there are more severe language problems in chronic progressive MS patients than 
in recrudescent-recovering one [30]. It is worth noting that TCL and TWT only 
study four high-level language skills, including the comprehension of ambiguous 
sentences, conclusion, proverb, and sentence making, and are useful for the ages 
of 9–11/18 [7, 30, 66]. A test named BESS was used in another study in Sweden 
showing impairment in high-level language skills. This is the only Swedish test 
investigating all high-level language skills and is complex and sensitive enough 
to evaluate all high-level language skills in MS patients with no age limitation [7]. 
Laakso et al. investigated high language functions in Swedish MS patients. They 
found that MS patients have language difficulties in repetition of long sentences, 
inference, metaphor, logico-grammatical sentence comprehension, comprehension 
of ambiguous sentences, and word definition. BESS validity was investigated in 
the Persian language in 2017. Rahimifar et al. studied its Persian version’s validity 
and reliability. After confirming this test as a valid and matched tool with racial, 
linguistic, cultural, social, and geographical features in Persian people, they study 
high-level language skills in Persian MS patients and found out that, like other lan-
guages, high-level language skills were impaired in MS patients [56]. These studies 
show that we can use BESS test for clinical goals and we can detect language deficits 
sooner. As a result, language deficits of patients with progressive diseases will be 
treated faster [7, 56].
10. Conclusion
The study conducted on MS patients shows that the linguistic skills of these 
patients are damaged. Language disorders in MS include naming, verbal fluency 
disorder, syntax skills, and lack of high-level language skills. Researchers have 
focused more on the naming and verbal fluency, which are related to semantic 
component of language, and other areas of the language, including the form and 
language use, have been neglected. Therefore, it is imperative that all language 
skills, including high-level language skills, be addressed in MS patients.
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structures in MS, it is approvable through natural language measurement tools [51].
9. High-level language skills
High-level language skills mean language production in sentence or discourse 
level compared to single-word level [62]. These skills include several assignments, 
ambiguous sentences, sarcastic comprehension and explanation, proverb, conclu-
sion, sentence making, long sentence repetition, celebrity naming, word definition, 
complex grammatical sentence comprehension, and comprehension and explana-
tion of differences and similarities, and they use many language fields and cognitive 
processes [30].
Another aspect affected by neurologic diseases is high-level language skills. 
These skills are created following the amount of myelin decrease and subcorti-
cal paths impairment. In addition, a possible reason of high-level language skill 
deficit in MS is disconnection of cortical and subcortical areas [30]. The primary 
symptoms of high-level language skills in MS patients are comprehension and 
explanation deficits. They are along with deficit symptoms in ambiguous sentences 
comprehension, sarcastic comprehension and explanation, proverb, conclusion, 
sentence making, long sentence repetition, celebrity naming, word definition, com-
plex grammatical sentence comprehension, and comprehension and explanation of 
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differences and similarities [7, 63]. Deficit in these skills may be predictive of brain 
impairments and certain degenerative dementias [64, 65].
There are a few studies on MS that influence on high-level language skills so 
far. Primary studies evaluate high-level language skills based on standard aphasia 
tests. Although these tests investigate language skills, they are not complex and 
sensitive enough to exactly define language disorders and high-level language skills 
in MS patients [27, 66]. Thus, high-level language skills were studied using the 
test of language competence (TLC) and the word test (TWT). The results showed 
that, compared to healthy people, MS patients had lower scores in these skills, and 
there are more severe language problems in chronic progressive MS patients than 
in recrudescent-recovering one [30]. It is worth noting that TCL and TWT only 
study four high-level language skills, including the comprehension of ambiguous 
sentences, conclusion, proverb, and sentence making, and are useful for the ages 
of 9–11/18 [7, 30, 66]. A test named BESS was used in another study in Sweden 
showing impairment in high-level language skills. This is the only Swedish test 
investigating all high-level language skills and is complex and sensitive enough 
to evaluate all high-level language skills in MS patients with no age limitation [7]. 
Laakso et al. investigated high language functions in Swedish MS patients. They 
found that MS patients have language difficulties in repetition of long sentences, 
inference, metaphor, logico-grammatical sentence comprehension, comprehension 
of ambiguous sentences, and word definition. BESS validity was investigated in 
the Persian language in 2017. Rahimifar et al. studied its Persian version’s validity 
and reliability. After confirming this test as a valid and matched tool with racial, 
linguistic, cultural, social, and geographical features in Persian people, they study 
high-level language skills in Persian MS patients and found out that, like other lan-
guages, high-level language skills were impaired in MS patients [56]. These studies 
show that we can use BESS test for clinical goals and we can detect language deficits 
sooner. As a result, language deficits of patients with progressive diseases will be 
treated faster [7, 56].
10. Conclusion
The study conducted on MS patients shows that the linguistic skills of these 
patients are damaged. Language disorders in MS include naming, verbal fluency 
disorder, syntax skills, and lack of high-level language skills. Researchers have 
focused more on the naming and verbal fluency, which are related to semantic 
component of language, and other areas of the language, including the form and 
language use, have been neglected. Therefore, it is imperative that all language 
skills, including high-level language skills, be addressed in MS patients.
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The aim of this chapter is to assess the effectiveness of non-pharmacologic 
therapies like progressive muscle relaxation therapy (PMRT) as an adjunctive 
therapy for reducing level of depression for multiple sclerosis (MS) patients. One 
of the most common mood disorders is major depressive disorder (MDD) that 
MS patients experience it during their lives. MDD can exacerbate the symptoms 
of the MS disease. Non-pharmacologic therapies were held for the MS patients, 
twelve sessions of PMRT using Bernstein and Borkovec’s method in spring 2010. 
According to the results, PMRT is effective in reducing depression. This therapy 
enables patients to reach relaxation quickly and thus can cope with depression 
reactions effectively.
Keywords: non-pharmacologic therapies, multiple sclerosis, depression,  
progressive muscle relaxation therapy
1. Introduction
These days the goal of all current and emerging therapeutic strategies for 
multiple sclerosis (MS) patients is to return them to a normal life despite of the 
disease [1].
Currently there is not any definitive treatment for MS disease and medications 
only reduce relapse rate, prolong remission, limit the onset of new MS lesions, and 
postpone the development of long-term disability [2].
Pharmacologic therapies (modafinil, dalfampridine, baclofen, diazepam, gaba-
pentin, opioids) are used for symptomatic treatment of disability and symptoms, 
but these do not improve disease outcome [2].
The cause and cure is unknown; appearing, removing and even relapsing of 
symptoms occurs without any signs warning [3] and the onset of the disease may be 
acute or gradual [1]. Strong evidence for irreversible neurological disability in MS 
patients indicates that MS disease is an autoimmune disease against central nervous 
system myelin or neuron degeneration [4].
MS disease may prevent from some patients activities such as; employment, 
relationships (social, familial), goals and long term plans and activities of daily 
living [3]. Therefore these disabilities will challenge persons with MS disease, when 
they are attempting to pursue an active and compatible lifestyle [5].
Variable courses in MS disease are common. Within two to three decades, this 
disease changes from recoverable to unrecoverable neurological disorder and stable 
disability [6].
One million people in the world suffer from MS disease that has been reported 
1.8 times more in females than males. MS is co morbid with psychiatric disorders 






The aim of this chapter is to assess the effectiveness of non-pharmacologic 
therapies like progressive muscle relaxation therapy (PMRT) as an adjunctive 
therapy for reducing level of depression for multiple sclerosis (MS) patients. One 
of the most common mood disorders is major depressive disorder (MDD) that 
MS patients experience it during their lives. MDD can exacerbate the symptoms 
of the MS disease. Non-pharmacologic therapies were held for the MS patients, 
twelve sessions of PMRT using Bernstein and Borkovec’s method in spring 2010. 
According to the results, PMRT is effective in reducing depression. This therapy 
enables patients to reach relaxation quickly and thus can cope with depression 
reactions effectively.
Keywords: non-pharmacologic therapies, multiple sclerosis, depression,  
progressive muscle relaxation therapy
1. Introduction
These days the goal of all current and emerging therapeutic strategies for 
multiple sclerosis (MS) patients is to return them to a normal life despite of the 
disease [1].
Currently there is not any definitive treatment for MS disease and medications 
only reduce relapse rate, prolong remission, limit the onset of new MS lesions, and 
postpone the development of long-term disability [2].
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pentin, opioids) are used for symptomatic treatment of disability and symptoms, 
but these do not improve disease outcome [2].
The cause and cure is unknown; appearing, removing and even relapsing of 
symptoms occurs without any signs warning [3] and the onset of the disease may be 
acute or gradual [1]. Strong evidence for irreversible neurological disability in MS 
patients indicates that MS disease is an autoimmune disease against central nervous 
system myelin or neuron degeneration [4].
MS disease may prevent from some patients activities such as; employment, 
relationships (social, familial), goals and long term plans and activities of daily 
living [3]. Therefore these disabilities will challenge persons with MS disease, when 
they are attempting to pursue an active and compatible lifestyle [5].
Variable courses in MS disease are common. Within two to three decades, this 
disease changes from recoverable to unrecoverable neurological disorder and stable 
disability [6].
One million people in the world suffer from MS disease that has been reported 
1.8 times more in females than males. MS is co morbid with psychiatric disorders 
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The psychosocial factors are closely associated with MS onset and may play 
important roles in the development of the disease [9].
MS disease usually indicates disparate disease periods and interaction between 
medical and psychological variables in MS disease is complex [7].
People with multiple sclerosis (MS) often report depression, poor sleep, fatigue, 
sleepiness and cognitive dysfunction. Interrelationships between symptoms are 
poorly understood [10].
For example findings suggest that treatment for depression is associated with 
reductions in the severity of fatigue symptoms [11] and many patients with mul-
tiple sclerosis (MS) report that stress can exacerbate disease [12].
Cognitive impairment is common in this disease [13]. Prevalence of cognitive 
impairment is about 30.5% and affects attention, concentration, performance, 
processing speed and visual perception [14].
These data point out the importance of orienting therapeutic interventions. For 
managing the symptoms of MS disease and improving or maintaining function and 
preserving the patient’s quality of life are recommended careful clinical monitoring 
and pharmacologic and non-pharmacologic therapies [15].
Non-pharmacologic therapeutic strategies include psychotherapy, cognitive 
behavioral therapy, strengthen of coping, progressive muscle relaxation therapy 
(PMRT), etc. [16].
Non-pharmacologic therapies are used widely by MS patients and progressive 
muscle relaxation therapy (PMRT) is a form of complementary therapies [17].
For the first time Jacobson in 1934 recognized that the mind and selected 
muscles (16 muscle groups) work together in a united way. It means body can be 
relaxed with mental relaxation and mind can be relaxed with progressive muscle 
relaxation therapy (PMRT) [18].
This procedure was suited by Wolpe (1948) for systematic desensitization therapy 
and by Bernstein and Borkovec for stress management in cognitive-behavioral 
therapy in 1973. The Bernstein and Borkovec forms are brief and adapted that these 
are used generally (7 or 4 muscles groups) [18, 19].
In fact, relaxation therapy is several methods to show patients how they can 
achieve relaxation. Most programs include training special breathing and progressive 
muscle relaxation (tension-release cycles) to reduce physical and mental tension [20].
The relaxation response is a physiological state and incompatible response 
against stress response [21] and has a significant psychological impact on specific 
aspects of our personality and changing unwanted habits and attitudes [22].
Muscle tension is associated with stress and anxiety, which are related with 
depression strongly [20]. Depression had a negative impact on all quality of life 
domains and anxiety impact on mental domains [23].
It seems that unpredictable courses of disease activity influence in many differ-
ent fields of their life. Unpredictable periods can make severe feelings of helpless-
ness and depression in patients with MS [7], also the hopelessness hypothesis states 
that unpredictable and negative events of life patients leads to depression [24].
Depression is the predominant psychological disturbance with lifetime prevalence 
around 50% and annual prevalence of 20%. With diagnosis of MS, anxiety increases 
and depression is commoner during relapses also increases the rate of suicidal ide-
ation and treating depression improves adherence to disease-modifying drugs [25].
MS patients often hide symptoms of depression and they complain from other 
symptoms [26]. Therefore treatment plans for depression among MS patients 
should be treated with individual and integrated approach [25].
According to the American Psychological Association (2018), people with 
depression may experience a lack of interest and pleasure in daily activities, 




thoughts of death or suicide (non-somatic symptoms), significant weight loss or 
gain, insomnia or excessive sleeping, lack of energy (somatic symptoms).
Significant results show that PMRT, helpfulness for human suffering from 
depression in groups with brain health (different patients, like: multiple somato-
form syndrome, cancer disease, pulmonary disease, cardiac disease, muscular pain, 
tinnitus disease and night eating syndrome) and brain lesion (MS patients).
Treatment by PMRT for depression is better than no-treatment or placebo treat-
ment or other behavioral methods treatment. The comparison between the first 
intervention and the follow up showed that the effect of the treatment remained 
(sometimes more) [27–39].
According to recent researches, it was assumed that PMRT may reduce the level 
of major depressive disorder in female MS patients in Shiraz Multiple Sclerosis Aid 
Society (SH.M.S.A.S).
2. Methods and materials
This study was an applied-experimental research with randomized controlled 
trial design plus pre and posttests.
Study included the independent variable (progressive muscle relaxation therapy 
PMRT) and dependent variable (depression).
This study compared two groups; experimental and control.
The first group received (PMRT) and the second group did not receive any treat-
ment for depression.
In spring 2010, from 2800 MS patients in SH.M.S.A.S 30 female volunteers 
participated in this study.
They answered the questionnaire before the intervention (Beck Depression 
Inventory BDI-II).
Criteria of MS and major depressive disorder (MDD) disease from minimal to 
severe were confirmed by the SHMSAS and BDI-II.
After the pretest, cases were matched in terms such as: degree of depression age, 
marital status, education and income then randomly divided in two groups.
The experimental group received standard care for MS disease plus 60 min of 
psychological intervention (PMRT) for each session (twice a week for six weeks) by 
M.A Clinical Psychology in Society of MS.
The control group received only standard care for MS disease.
Until the end of the treatment, drop out did not occur in the number of patients 
and two groups cooperated again in the posttest (answered the questionnaire for the 
second time).
2.1 Rights and criteria
Ethical considerations and rights were applied for this research (respect to basic 
rights of patients such as; privacy, cultural and social values, freedom of choice and 
honesty about characteristics of therapy and therapist’s competence).
Selection criteria:
1. Willing to attend in therapy meeting.
2. Having physical ability and minimal level of literacy was sufficient.
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2.2 The content of therapy sessions
The best way for muscle relaxation is for muscles to be contracted as much 
as possible, and then be relaxed suddenly (tension-release sequence). The released 
force from the treatment increases the excitability threshold. The released force 
is a big step toward deeper relaxation and patients can understand the feeling of 
tension and relaxation of muscles (comparative judgment). Relaxation therapy was 
divided to two parts:
1. The first six sessions: special breathing plus contraction and relaxation of 
muscles, with gradual reduction of the number of muscles involved.
2. The second six sessions: special breathing plus contraction and relaxation of 
mind [21].
2.3 Tools
In this intervention for therapy meetings, Progressive Muscle Relaxation, was 
used by method of Bernstein and Borkovec, 1973 [18], also the Beck Depression 
Questionnaire (Beck, Epstein, Brown and Steer, 1988) was used, with the reliability 
(0.91) and validity (0.87) of the Iranian valid [40].
The BDI-II was expanded based on criteria of diagnostic and statistical 
manual of mental disorders, fourth edition (DSM-IV) for diagnosing depressive 
disorders [41].
The BDI-II is a brief scale that it is suitable for researchers as a screening tool. It 
is a subjective paper and pencil questionnaire with ordinal scale. In addition cut-off 
points (0–13), (14–19), (20–28) and (29–63) show minimal, mild, moderate and 
severe depression [41].
2.4 Iranian validation
Based on Iranian Validation, validity was certified by positive correlation, 
between Beck Depression Inventory (BDI-II) and Brief Symptom Inventory (BSI), 
coefficient of Pearson was 0.87, and factor analysis showed physical factor, cogni-
tive factor and affective factor.
And reliability was certified by method of internal consistency, Cronbach’s alpha 
coefficient was 0.91 [40].
2.5 Analysis method of data
To remove covariate variable was applied Analysis of Covariance and to remove 
difference between two groups was applied Levine Test.
In this intervention, the variables were Progressive Muscle Relaxation Therapy 
as independent and Depression as dependent variable after that analysis of Variance 
was applied with technique of Repeated Measures.
3. Results
Thirty MS patients attended in this intervention that they were separated 
randomly in two groups (experimental and control). Tables 1 and 2 was designed 




Table 1, shows half of patients in this intervention were sick more than 5 years 
and they had tolerated symptoms from mild to severe and they were in the third 
decade of their life and in status of marital single patients were more than others. 
Also in education degree most of them had a bachelor’s degree.
All patients had depression and some of them had severe depression that in 
experimental group the mean value indicates mild depression (the results are rav-
eled in Table 2).
The intervention hypothesis explains that PMRT may reduce the level of depres-
sive disorder. This assumption was checked by Tables 3–5.
Table 3, was designed to measure the equality of variances between groups.
The results indicate that there was no significant difference in the variance of 
groups.
The purpose of Covariance Analysis in Table 4 was to eliminate of the covariate 
variable from the dependent variable and to estimate the central indexes.
After intervention, with notice to the significance level and after omitting the 
impact of pretest on posttest, finding revealed the mean and standard deviation 
has increased (reduce depression). A significant reduction in depression variable 
occurred in seven levels.
In Table 5, Analysis of Variance with Repeated Measures method reviewed the 
impact of intervention on depression.
Table 5 showed that the difference between pretest and posttest was significant 
(p = 0.0001) and this difference was 49% reduction in depression levels, it means 
that this reduction has occurred because of the relaxation therapy and statistical 
power was 99%.
Experimental group Control group
Frequency Percentage Frequency Percentage
Sick precedent Less than 2 years 4 0.26 4 0.26
2–5 years 2 0.13 3 0.20
5–10 years 7 0.46 8 0.53
More than 
10 years
2 0.13 0 0.00
Age Second decade 5 0.33 4 0.26
Third decade 5 0.33 6 0.40
Fourth decade 4 0.26 3 0.20
Fifth decade 1 0.60 2 0.13
Marital status Single 7 0.46 5 0.33
Married 5 0.33 6 0.40
Divorced 2 0.13 2 0.13
Widow 1 0.60 2 0.13
Education 
degree
High school 3 0.20 4 0.26
Diploma 4 0.26 5 0.33
Bachelor 8 0.53 6 0.40
Master 0 0.00 0 0.00
Table 1. 
Context variable in experimental and control groups.
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MS patients spent a lot of time to control emotional disorders, like depression. 
Levels of depression were studied by researchers and the results showed high levels 
of this variable and the effects of depression on MS disease exacerbation [42–59].
For example:
The possibility that the health status of negative mental can change period of 
MS disease since Charcot (1879, he was the first proposer), has been discussed, 
that shows grief and worry might influence on onset and exacerbation of disease 
symptoms [3].
F First-degree of freedom Second-degree of freedom Significant level
Depression 0.463 1 28 0.502
Table 3. 
Levine test results (about equal variances in the two groups).
Control Experimental Total
After Before After Before After Before
Mean 15.93 15.86 8.40 16.20 12.16 16.03
Median 13 13 5 16 10 14
Mode 10 11 5 11 5 11
Sum 239 238 126 243 365 481
Std. deviation 9.72 9.76 9.43 9.50 10.16 9.46
Variance 94.49 95.26 88.9 90.31 103.24 89.62
Range 31 31 40 36 40 37
Maximum 34 34 40 40 40 40
Table 2. 
Descriptive statistics of depression variable.






Before intervention 16.08 1.03 15 7.83 0.000
After intervention 8.24 1.03 15 −7.83 0.000
Table 4. 
The estimate of average depression variable.
Source of changes Sig Effect Statistical power
Effects Depression 0.0001 0.49 99
Interaction depression and group 0.0001 0.55 99
Error
Table 5. 




Negative emotions (like depression) in the MS patients correlated with their 
family troubles and social isolation [9].
Non-somatic symptoms of depression can predict cognitive performance [14] 
and on the other hand somatic and non-somatic symptoms of depression predict 
exacerbation of MS disease [60].
Depression is an important predictor parameter on psychological balance of MS 
patients [61] and studies have confirmed that there are the relationships between 
structural brain lesions with depression in MS patients [24] and may be lesion site has 
two function: increases in depression and sleep disturbance (fatigue symptoms) [62].
Previous studies have indicated that depression is prevalent in MS patients and 
affects treatment adherence and associates with the neurologic damage that results 
from multiple sclerosis [42–59].
This study was designed to purpose that with identifying and treating the first 
symptoms of depression, patients can increase the performance of themselves in 
the society.
This study was designed to assess hypothesis derived from the Gate Theory this 
theory states that psychological factors influence on physical factors of pain [physi-
cal pain and psychological pain]. It means, the same way that stress and discomfort 
can exacerbate pain, relief and relaxation can also reduce pain [63] and depression 
is an overwhelming psychological pain [64], therefore this randomized controlled 
study during twelve sessions was carried out to determine the effects of treatment 
on experimental group. The results showed that there was a significant relationship 
between treatment and depression. Table 4 shows mild depression in experimental 
group and after intervention average of depression reduction was seven levels; 
operationally it define that patients in experimental group indicated state of depres-
sion like normal people.
Analysis of Variance showed that these changes (it was 49%) in the group, were 
as a result of progressive muscle relaxation therapy.
Table 2 shows severe depression in some cases before and after treatment. They 
often hide symptoms of depression or cannot recognize between symptoms of 
depression and MS disease. Also previous treatments (like pharmacologic therapy) 
for severe depression were continued. These cases took less advantage from this 
treatment.
Measurement of depression in patients with MS is complicated because some of 
the symptoms are identical between depression and MS disease (excessive fatigue, 
cognitive difficulties, psychomotor retardation, mood changes, sleep changes and 
emotional changes) [65].
Findings of this study showed that the level of depression (first symptoms of 
depression), even in the short-term treatment has reduced, which were considered 
6 weeks (as a safe, inexpensive and effective intervention) and demonstrated the 
effectiveness of PMRT in reducing depression as non-pharmacologic treatment, 
when treatment was used systematically.
Findings of this short-term treatment were consistent with the research of 
Jorm and Morgan [20]. They confirmed that PMRT as psychological intervention 
for depression patients are more acceptable than other interventions (relaxation 
imagery, autogenic training) and finding of Annette and Jens’s study [66] demon-
strated both cognitive behavioral therapy (CBT) and PMRT appear to be effective 
treatments for depression in the normal human brain.
Based on the results of Sutherland and Andersen [3] and Artemiadis and 
Vervainioti [39] and Molina and Pérez in Spain [67] and Ghafari and Ahmadi in 
Iran [68], potentially, it could be stated that PMRT may provide benefits in differ-
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However in psychological interventions, therapist training is essential. In fact, 
relaxation technique is an acceptable psychological intervention, which this method 
requires less skill and training than other techniques.
Finally, rationale and supporting evidence, and techniques used in Progressive 
Muscle Relaxation Therapy was summarized in this article for intuitive understand-
ing of future researchers about influences of PMRT.
4.1 Suggestions
PMRT is effective treatment for depression in MS patients, although more stud-
ies should be done for investigating the relaxation therapy as a first-line treatment 
in a stepped care approach to managing depression in MS patients. Therefore, to 
obtain more accurate results, the following recommendations are given:
1. It is suggested that in future studies, should be used more objective clinical and 
laboratory studies.
2. More control of confounding variables can reduce the limitations of the study 
(such as: sex, social and cultural status and disease progression).
3. Quantity of therapy will be better by using tapes, movies or booklets and long-
term treatment.
4. Finally, it is recommended screening programs for depression in MS disease 
for facilitating access to services for all MS patients.
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Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system in which the body’s immune system is abnormally directed towards the 
myelin sheaths covering the nerve fibers. What triggers the neuroinflammation 
and autoimmune destruction of the myelin sheaths remains unknown. However, 
it is widely accepted that susceptibility depends on a combination of genetic and 
environmental factors and their interactions. With little chance of influencing 
genetic predisposition, the importance of identifying risk factors which could be 
modulated to either prevent the on-set of MS or to ameliorate the course of the 
disease, is an attractive alternative. An accumulating body of evidence, including 
our own recent study involving over 1000 MS and non-MS samples, indicates that 
Epstein-Barr virus (EBV), a common herpesvirus, could be involved. In this chap-
ter, we review the studies linking EBV to MS and propose an explanation by which 
this common virus could be involved in the pathogenesis of MS.
Keywords: multiple sclerosis, autoimmunity, neuroinflammation, Epstein-Barr 
virus, seroepidemiological evidence, postmortem studies
1. Introduction
Multiple sclerosis (MS) is a progressive disease in which multiple regions in the 
brain, spinal cord and optic nerve undergo myelin destruction or demyelination. It 
is believed that an aberrant immune response mistakenly attacks the myelin sheaths 
in the central nervous system (CNS) resulting in the formation of focal demyelin-
ated plaques; the hallmark of MS [1]. In spite of extensive search, the identity of 
the factor(s) that triggers the immune assault against the myelin remains elusive. 
It is generally accepted that MS is a complex disease and most likely involves both 
genetic and environmental factors [2]. Although no single gene has been identi-
fied to be responsible in the development of MS, certain HLA haplotypes, such as 
HLA-DRB1 have been shown be associated with MS susceptibility [3]. Furthermore, 
the fact that MS is more prevalent in certain races such as Caucasians [4, 5] and 
incidence rates are increasing in some ethnic groups such as blacks [6, 7] supports 
the involvement of genes in the development of MS. Although the risk of MS is 
significantly higher in individuals with first-degree relatives with MS, this still does 
not explain the occurrence of MS in majority of cases. In fact, MS concordance in 
monozygotic twins is only around 25% [8, 9]. This clearly indicates that environ-
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1.1 Environmental risk factors for MS
In support of the above observations, MS prevalence has been reported to be higher 
in the northern hemisphere, but lower towards the equator. However, recent studies 
indicate that this pattern of distribution, known as the latitudinal gradient, is chang-
ing in some countries such as Norway and USA [10–12]. Moreover, migration studies 
indicate that the increasing burden of MS is due to exposure to certain factors in the 
environment, which may account for a bigger proportion of MS risk than genetic 
factors. These studies show that leaving countries with high MS incidence prior to 
reaching adolescence, to regions with low MS incidence, confers protection against 
developing the disease [13]. Similarly, migrating in the opposite direction is linked to 
increased risk of developing MS [14–16]. These protective and MS predisposing effects 
have been shown to occur in a single generation, and this is highly unlikely to be due to 
effects of genes which usually manifest on longer periods of time [17].
Additionally, exposure to specific environmental agents at a young age seems to 
be critical in shaping the risk of developing MS [18]. The past few decades have seen 
a rapid accumulation of epidemiological data pointing to a number of different envi-
ronmental factors that could potentially be involved in MS pathogenesis. However, no 
single causative agent has yet been unequivocally shown to be central to MS develop-
ment [19]. Environmental risk factors associated with MS include sunlight exposure 
and serum levels of vitamin D, smoking, obesity, female sex hormones, and infection 
with Epstein-Barr virus (EBV) [20–22]. Among these factors, infection with EBV, 
particularly when manifested as infectious mononucleosis (IM), appears to have the 
most significant and consistent association with the risk of developing MS [23].
1.2 Infectious risk factors for MS: Hygiene hypothesis
The notion that an infectious agent is involved in the pathogenesis of MS is not 
new. A number of observations, including MS outbreak in the Faroes islands during 
World War II, which coincided with the British occupation of the islands [24], and 
MS occurrence in clustering fashion (e.g. familial clustering of MS), suggested 
an infectious cause for MS [17]. The hygiene hypothesis was used to provide an 
explanation for such involvement [21], assuming that certain infections occurring 
during the first few years of life can protect against MS, whereas exposure to the 
same infections later in life, predisposes to MS [25]. The hygiene hypothesis also 
partly explained the geographical distribution of MS, in that it is less common in 
tropical regions that are known to be endemic to certain microbial infections. In 
these areas, children tend to acquire infections very early in life [26, 27]. Similarly, 
MS incidence seems to rise in tropical regions [28] that have witnessed improved 
feasibility of vaccines and antibiotics and enhanced sanitary conditions which have 
led to decreased childhood infections [29–31]. However, some epidemiological 
observations such as the finding that the risk of MS in individuals who have never 
been exposed to EBV is 10 fold lower than in those who were exposed to childhood 
EBV infection [32], cannot be explained by the hygiene hypothesis.
2. Epstein-Barr virus (EBV)
EBV is a common human herpesvirus, infecting over 90% of the population 
worldwide [33]. Generally, EBV infection is considered to be one of the early asymp-
tomatic childhood infections and in the vast majority of the infected individuals, 
the virus persists for life without causing disease. Bizarrely, if primary infection is 
delayed until adolescence, as commonly noted in developed countries, the virus can 
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cause an acute self-limiting symptomatic infection known as infectious mononucleo-
sis (IM) [34]. Importantly, EBV has oncogenic properties and in a very small per-
centage of individuals, the virus can induce life-threatening lymphoid and epithelial 
malignancies, accounting for approximately 150,000 deaths annually [35, 36].
EBV is transmitted from person to person through salivary exchange. However, the 
details of the early steps in EBV infection remain unclear. Two models have been pro-
posed. In the first model, it is suggested that EBV initially infects tonsillar epithelial 
cells where it undergoes lytic replication with subsequent infection of B-lymphocytes. 
In the second model, it is suggested that EBV directly infects B-lymphocytes with-
out the involvement of epithelial cells [37, 38]. Whatever the initial cellular target, 
one thing is fairly well-established; the cellular site of long-term EBV persistence is 
B-lymphocytes [39, 40]. These cells can be transformed and immortalized by EBV 
when grown in in vitro cultures, forming what are known as lymphoblastoid cell lines 
(LCLs). In LCLs, a number of viral latent products, namely 2 EBV encoded RNAs 
(EBER 1 and 2), 6 EBV nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and LP) and 3 EBV 
latent membrane proteins (LMPs 1, 2A and 2B) are expressed [33]. The expression 
of these latent products in infected cells is referred to as EBV latency III program and 
is typically observed in EBV associated post-transplant lymphomas [41] and in IM 
[42]. When EBERs, EBNA-1, LMP1 and LMP2 are expressed, it is known as latency 
II, typically seen in EBV associated Hodgkin’s lymphoma. In latency I, only EBERs 
and EBNA-1 are expressed, as seen in Burkitt’s lymphoma. In latently infected asymp-
tomatic EBV carriers (>90% of the population), infected B cells express EBERs only 
[43]. Since no viral proteins are expressed in these cells, the virus can remain out of 
the radar of the host immune system. This strategy allows the virus to be dormant, but 
still dangerous. Moreover, the virus utilizes an array of viral encoded miRNAs to target 
immune associated mRNAs, aiding its escape from host defenses [44, 45]. Thus, EBV 
has evolved to be a master manipulator of the immune system, ensuring its persistence 
for the life of its host, even in the face of a competent immune system.
Beside the latent infection described above, a lytic infection can occasionally 
occur resulting in production of new virions. The expression of the immediate early 
lytic protein BZLF1 signals the beginning of the lytic cycle. Whether it is latent or 
lytic infection, an efficiently functioning immune system is essential to keep EBV 
infection under control and maintain a homeostatic virus-host relationship [46]. 
Thus, any disruption of the intricate connection between EBV and the immune 
system can lead to serious health conditions, for instance EBV-induced malignan-
cies and some autoimmune disorders such as MS. Based on an accumulating body 
of evidence from epidemiological, serological and postmortem studies, it is now 
widely believed that EBV is associated, directly or indirectly in the pathogenesis 
of MS [20–22]. However, the details of how EBV induces or promotes an aberrant 
immune response against myelin self-antigens in MS remain unknown.
3. Epidemiological link between EBV and MS
A considerable amount of literature has been published on the link between the 
epidemiology of MS and EBV infection. Early reports consistently showed higher 
prevalence of EBV infection in MS patients compared to the general population [47, 
48]. This difference was particularly pronounced in the pediatric cohort, where 
almost 100% of children with MS were EBV seropositive compared to 72% matched 
controls [49–52]. Consistent with these findings, MS risk was found to diminish in 
individuals who have never been exposed to EBV infection (the odds ratio of devel-
oping MS is 0.06 in a seronegative person compared to 13.5 in an EBV seropositive 
person). Furthermore, continuing to be EBV seronegative keeps MS risk to about 
Multiple Sclerosis
102
1.1 Environmental risk factors for MS
In support of the above observations, MS prevalence has been reported to be higher 
in the northern hemisphere, but lower towards the equator. However, recent studies 
indicate that this pattern of distribution, known as the latitudinal gradient, is chang-
ing in some countries such as Norway and USA [10–12]. Moreover, migration studies 
indicate that the increasing burden of MS is due to exposure to certain factors in the 
environment, which may account for a bigger proportion of MS risk than genetic 
factors. These studies show that leaving countries with high MS incidence prior to 
reaching adolescence, to regions with low MS incidence, confers protection against 
developing the disease [13]. Similarly, migrating in the opposite direction is linked to 
increased risk of developing MS [14–16]. These protective and MS predisposing effects 
have been shown to occur in a single generation, and this is highly unlikely to be due to 
effects of genes which usually manifest on longer periods of time [17].
Additionally, exposure to specific environmental agents at a young age seems to 
be critical in shaping the risk of developing MS [18]. The past few decades have seen 
a rapid accumulation of epidemiological data pointing to a number of different envi-
ronmental factors that could potentially be involved in MS pathogenesis. However, no 
single causative agent has yet been unequivocally shown to be central to MS develop-
ment [19]. Environmental risk factors associated with MS include sunlight exposure 
and serum levels of vitamin D, smoking, obesity, female sex hormones, and infection 
with Epstein-Barr virus (EBV) [20–22]. Among these factors, infection with EBV, 
particularly when manifested as infectious mononucleosis (IM), appears to have the 
most significant and consistent association with the risk of developing MS [23].
1.2 Infectious risk factors for MS: Hygiene hypothesis
The notion that an infectious agent is involved in the pathogenesis of MS is not 
new. A number of observations, including MS outbreak in the Faroes islands during 
World War II, which coincided with the British occupation of the islands [24], and 
MS occurrence in clustering fashion (e.g. familial clustering of MS), suggested 
an infectious cause for MS [17]. The hygiene hypothesis was used to provide an 
explanation for such involvement [21], assuming that certain infections occurring 
during the first few years of life can protect against MS, whereas exposure to the 
same infections later in life, predisposes to MS [25]. The hygiene hypothesis also 
partly explained the geographical distribution of MS, in that it is less common in 
tropical regions that are known to be endemic to certain microbial infections. In 
these areas, children tend to acquire infections very early in life [26, 27]. Similarly, 
MS incidence seems to rise in tropical regions [28] that have witnessed improved 
feasibility of vaccines and antibiotics and enhanced sanitary conditions which have 
led to decreased childhood infections [29–31]. However, some epidemiological 
observations such as the finding that the risk of MS in individuals who have never 
been exposed to EBV is 10 fold lower than in those who were exposed to childhood 
EBV infection [32], cannot be explained by the hygiene hypothesis.
2. Epstein-Barr virus (EBV)
EBV is a common human herpesvirus, infecting over 90% of the population 
worldwide [33]. Generally, EBV infection is considered to be one of the early asymp-
tomatic childhood infections and in the vast majority of the infected individuals, 
the virus persists for life without causing disease. Bizarrely, if primary infection is 
delayed until adolescence, as commonly noted in developed countries, the virus can 
103
Epstein-Barr Virus in Multiple Sclerosis
DOI: http://dx.doi.org/10.5772/intechopen.85222
cause an acute self-limiting symptomatic infection known as infectious mononucleo-
sis (IM) [34]. Importantly, EBV has oncogenic properties and in a very small per-
centage of individuals, the virus can induce life-threatening lymphoid and epithelial 
malignancies, accounting for approximately 150,000 deaths annually [35, 36].
EBV is transmitted from person to person through salivary exchange. However, the 
details of the early steps in EBV infection remain unclear. Two models have been pro-
posed. In the first model, it is suggested that EBV initially infects tonsillar epithelial 
cells where it undergoes lytic replication with subsequent infection of B-lymphocytes. 
In the second model, it is suggested that EBV directly infects B-lymphocytes with-
out the involvement of epithelial cells [37, 38]. Whatever the initial cellular target, 
one thing is fairly well-established; the cellular site of long-term EBV persistence is 
B-lymphocytes [39, 40]. These cells can be transformed and immortalized by EBV 
when grown in in vitro cultures, forming what are known as lymphoblastoid cell lines 
(LCLs). In LCLs, a number of viral latent products, namely 2 EBV encoded RNAs 
(EBER 1 and 2), 6 EBV nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and LP) and 3 EBV 
latent membrane proteins (LMPs 1, 2A and 2B) are expressed [33]. The expression 
of these latent products in infected cells is referred to as EBV latency III program and 
is typically observed in EBV associated post-transplant lymphomas [41] and in IM 
[42]. When EBERs, EBNA-1, LMP1 and LMP2 are expressed, it is known as latency 
II, typically seen in EBV associated Hodgkin’s lymphoma. In latency I, only EBERs 
and EBNA-1 are expressed, as seen in Burkitt’s lymphoma. In latently infected asymp-
tomatic EBV carriers (>90% of the population), infected B cells express EBERs only 
[43]. Since no viral proteins are expressed in these cells, the virus can remain out of 
the radar of the host immune system. This strategy allows the virus to be dormant, but 
still dangerous. Moreover, the virus utilizes an array of viral encoded miRNAs to target 
immune associated mRNAs, aiding its escape from host defenses [44, 45]. Thus, EBV 
has evolved to be a master manipulator of the immune system, ensuring its persistence 
for the life of its host, even in the face of a competent immune system.
Beside the latent infection described above, a lytic infection can occasionally 
occur resulting in production of new virions. The expression of the immediate early 
lytic protein BZLF1 signals the beginning of the lytic cycle. Whether it is latent or 
lytic infection, an efficiently functioning immune system is essential to keep EBV 
infection under control and maintain a homeostatic virus-host relationship [46]. 
Thus, any disruption of the intricate connection between EBV and the immune 
system can lead to serious health conditions, for instance EBV-induced malignan-
cies and some autoimmune disorders such as MS. Based on an accumulating body 
of evidence from epidemiological, serological and postmortem studies, it is now 
widely believed that EBV is associated, directly or indirectly in the pathogenesis 
of MS [20–22]. However, the details of how EBV induces or promotes an aberrant 
immune response against myelin self-antigens in MS remain unknown.
3. Epidemiological link between EBV and MS
A considerable amount of literature has been published on the link between the 
epidemiology of MS and EBV infection. Early reports consistently showed higher 
prevalence of EBV infection in MS patients compared to the general population [47, 
48]. This difference was particularly pronounced in the pediatric cohort, where 
almost 100% of children with MS were EBV seropositive compared to 72% matched 
controls [49–52]. Consistent with these findings, MS risk was found to diminish in 
individuals who have never been exposed to EBV infection (the odds ratio of devel-
oping MS is 0.06 in a seronegative person compared to 13.5 in an EBV seropositive 
person). Furthermore, continuing to be EBV seronegative keeps MS risk to about 
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10-fold lower than those who seroconvert [53] and about 20-fold less than those with 
a history of IM, the primary symptomatic EBV infection [32]. These reports suggest 
that the risk of MS rises in EBV-seronegative individuals soon after they seroconvert 
as confirmed by a nested case–control study on 305 MS cases and 610 controls [54].
Interestingly, IM has a strikingly similar distribution to that of MS [55]. Moreover, 
females report IM symptoms earlier (more prolonged), more frequently, and with 
more severity than their male counterparts. Females also tend to have higher anti-EBV 
titers and are believed to mount stronger response against EBV [56, 57]. In demon-
stration of the correlation between IM and the risk of MS, a case–control study found 
that history of IM increases the risk of developing a CNS demyelinating disease, 
particularly in genetically susceptible individuals who are HLA-DRB1*1501 positive 
[58]. In support of these results, a meta-analysis of 14 case–control and longitudinal 
studies reported that history of IM significantly increased the risk of MS by over 2 
folds [59]. Furthermore, this increased risk persists for at least 30 years post EBV 
infection [60], suggesting that symptomatic EBV infection manifested as IM may be a 
prerequisite to developing the autoimmune response associated with MS [61].
4. Serological link between EBV and MS
More evidence has been brought to light by serological studies investigating 
antibody response against EBV antigens in MS patients compared to that in controls. 
One of the most consist piece of evidence is the finding of elevated antibody titers 
against EBNA-1 antigen in the blood, both pre- and post-onset of the disease [62–65]. 
Indeed, individuals with clinically isolated syndromes (CIS) are more likely to develop 
definite MS when they experience elevated antibody response to EBNA-1 [66, 67]. 
Furthermore, serum levels of anti-EBV capsid antigen (VCA) together with anti-
EBNA-1 IgG antibodies seem to also correlate with the risk of MS [68]. In an attempt 
to understand how the humoral response towards EBNA-1 impacts the risk of devel-
oping MS, it was shown that the levels of circulating IgG against certain EBNA-1 epit-
opes, particularly those derived from EBNA-1: 385–420 domain, interact with MS risk 
gene, the HLA genotype DRB1*15 in amplifying MS risk [69]. These findings point to 
similarities between how HLA molecules influence response to EBV antigens and how 
they are involved in inducing autoimmune response [70]. Additionally, the humoral 
response to EBV antigens, specifically anti-EBNA-1 IgG vary between different forms 
of MS, namely CIS, relapsing–remitting and progressive MS [71], suggesting that 
the level of these antibodies is not only predictive of MS onset, but also of disease 
progression. However, it remains debatable whether the humoral level can correlate 
with markers of disease progression such as volumes of T2 MRI lesions, reflective of 
demyelinative disease activity and scores of Expanded Disability Status Scale (EDSS), 
reflective of the progression of physical disability [71–76]. Despite some of these 
inconsistencies in the serological link between EBV infection and MS, studies agree 
on the fact that serum antibody titers to EBNA-1 increase prior to developing MS, and 
hence predictive of MS. In other words, it seems that EBV acts early in provoking an 
immune (humoral) response towards promoting the onset of MS [77]. However, it 
is safe to argue that EBV may be a cofactor contributing with other factors, such as 
genetic susceptibility and vitamin D levels, to the pathogenesis of MS [78, 79].
5. Cellular immune response to EBV in MS
Forty years ago, it was shown that peripheral blood mononuclear cells (PBMCs) 
taken from patients with active MS, spontaneously transformed into LCLs in in vitro 
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culture more readily than PBMCs taken from healthy controls or patients with 
inactive MS [80]. These spontaneously immortalized LCLs were of B-cell origin and 
expressed EBV antigens, including VCA and EBNAs [80]. So, why do PBMCs from 
active MS patients transform more readily compared to those from healthy controls? 
One possible explanation is that the immune response to EBV in MS patients is less 
effective compared to healthy EBV seropositive individuals. Indeed, data from a 
number of different studies indicates that the T-cell response to EBV is aberrantly 
regulated in MS patients and it varies at different stages of the disease [81–83]. CD8+ 
T cells in the blood of MS patients with inactive disease, have been shown to express 
the immune inhibitory molecule, programmed death 1 (PD-1), making these cells 
less efficient in eliminating EBV infected cells [84]. This CD8+ T cell exhaustion is 
believed to be a common feature in many chronic viral infections [85–87], and could 
explain the conflicting results in EBV viral load detected in MS patients. Thus, the 
stage of the disease and the level of T cell exhaustion could account for the higher 
viral load reported in some studies [88, 89], whilst others showed no statistical dif-
ference between MS and controls [89–91]. Further support for an aberrant anti-viral 
immune response in MS comes from the observations that MS patients appear to be 
at increased risk of acquiring certain viral infections such as influenza [92, 93].
A more recent study investigated B cell transformation of PBMCs taken from 21 
MS patients and 21 healthy controls [94]. In order to minimize the effect of T cell 
control of EBV, which may vary from person to person, T cell activity in all PBMCs 
cultures was inhibited using cyclosporine A. Cultures obtained from MS patients 
resulted in significantly higher frequency of B cell transformation compared to 
healthy controls [94]. Whether this was due to MS patients having a higher fre-
quency of circulating EBV infected cells, or due to higher frequency of viral lytic 
replication occurring in MS patients is not clear.
There have also been some attempts to examine differences in the cell-mediated 
immune response against EBV and its antigens in the blood and cerebrospinal fluid 
(CSF) of MS patients [95, 96]. However, these investigations have also yielded 
inconsistent results. Whilst some have reported an increase in frequency of both 
intrathecal EBV reactive CD4+ and CD8+ T cells in MS [96], others have found that 
only CD8+ T cells and not CD4+ T cells are increased compared to controls [95]. 
Moreover, intrathecal CD4+ and CD8+ T cells from MS failed to react to a number 
of common autoantigens suspected to be targets of immune response in MS [97]. 
Thus, the identity of the target antigen for the autoreactive T cells remains elusive. 
A very recent study has reported that intrathecal CD4+ T cells from HLA-DRB3 
positive MS patients reacted with GDP-L-fucose synthase, an enzyme frequently 
expressed in human cells as well as in bacteria commonly present in the gastro-
intestinal track of MS patients [98]. This tantalizing finding warrants further 
investigations to determine if gut bacterial GDP-L-fucose synthase is indeed the 
primary trigger for the activation of autoreactive T-cells that subsequently migrate 
to the brain and lead to demyelination. It is plausible that EBV could also trigger 
autoreactive T-cells by molecularly mimicry [99–101]. In this context, certain 
epitopes of EBNA-1, EBNA-3A and LMP2 have been shown to be targets of CD8+ T 
cell responses and to cross-react with self-antigens associated with MS pathogenesis 
[102–104]. However, current evidence fails to clearly explain how cell-mediated 
immune responses to EBV antigens may lead to MS.
6. Direct demonstration of the presence of EBV in MS brains
Compared to the blood and CSF, access to brain tissues, particularly fresh tissues 
from MS patients has been difficult and limited. In spite of this, a number of studies 
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Compared to the blood and CSF, access to brain tissues, particularly fresh tissues 
from MS patients has been difficult and limited. In spite of this, a number of studies 
Multiple Sclerosis
106
have examined brain tissues to explore the link between EBV and the pathogenesis of 
MS. Most of these investigations have been conducted on formalin-fixed, paraffin-
embedded post-mortem tissues. Arguably, these studies have generated the strongest 
and most convincing data implicating EBV in the development of MS. Initial attempts 
aimed at directly demonstrating if EBV was present in MS lesions or not, reported 
either negative results or did not see any difference in EBV positivity between MS 
and control tissues [105, 106]. A subsequent study however, reported the presence of 
EBV in 21/22 MS, but not in non-MS inflammatory neurological conditions [107]. The 
virus was localized to B cells and plasma cells, most notably in the meninges and peri-
vascular infiltrates of active lesions. Additionally, infected cells were found to express 
a number of viral antigens, latent and lytic [107], making them a potential target of 
CD8+ T cells and triggering an inflammatory environment in the CNS [82]. Although 
these findings were confirmed by some subsequent studies [108, 109], others reported 
absence of EBV infection in the MS brain [110–112]. It was argued that the discrepan-
cies in the findings would be due to many different variables, including differences in 
the tissue samples examined, variation in tissue preservation and processing, type of 
fixatives and length of fixation, and the sensitivity and specificity of methods used 
for EBV detection [113]. Moreover, owing to the great heterogeneity of the brain, 
the molecular and cellular environment of one region does not necessarily represent 
another adjacent region, even in the same tissue block [113, 114]. Thus, the absence of 
EBV in one region of the brain, cannot be interpreted to mean that the virus is absent 
from all parts of the brain. Keeping some of these variables in mind, we recently 
conducted an extensive study examining the potential involvement of EBV in MS 
pathogenesis [115]. We analyzed over 1000 samples from MS cases and non-MS 
controls using our highly sensitive EBER-in situ hybridization, PCR, and immuno-
histochemistry methodologies [115]. Our findings indicated that EBV was present in 
most (90%) cases of MS and the virus could be detected in multiple tissue samples 
from each case. Surprisingly, we found EBV not only in B-cells, but also in astrocytes 
and some microglial cells. Significantly, the virus was transcriptionally active in these 
cells and expressed EBNA-1, and to a lesser extent the early lytic cycle protein BZLF1. 
Taken together, these findings support a role for EBV in the pathogenesis of MS.
7. Proposed model of EBV involvement in MS pathology
The data demonstrating the presence of EBV directly in the brain of MS cases 
is fairly robust and convincing evidence in support of a role for EBV in the patho-
genesis of MS. However, the presence of the virus in the brain cannot be simply 
interpreted to imply causality. Although it is possible that EBV infection could be 
a consequence of MS pathology, the observation that EBV seronegative individu-
als have an almost zero risk of developing MS is strong and compelling evidence 
supporting a role for EBV in initiating MS. Ironically, although it is believed that 
T-cells orchestrate and lead the pathogenesis of MS, treatment strategies that have 
been shown to be most effective in controlling disease activity, involve depleting 
B-cells [22, 116]. Moreover, depleting memory B-cells, the very cells that harbor 
EBV, appears to be the most effective [117]. How can these apparently contradic-
tory findings be reconciled? We propose that EBV infected memory B-cells act 
as antigen presenting cells (APC), resulting in the activation of helper T-cells, 
which in individuals carrying certain HLA haplotypes, activate autoreactive B and 
T-cells targeting antigens expressed on oligodendrocytes [102, 118]. In this model 
(Figure 1), disturbances in the integrity of the blood brain barrier (BBB) allows 
EBV carrying memory B-cells to cross into the CNS, triggering a cascade of events 
including, attraction of autoreactive B and T-cells, triggering pro-inflammatory 
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cytokines and microglial activation [118–120]. While most of the EBV infected 
B-cells infiltrating into the brain remain latently infected, a small percentage are 
triggered to undergo lytic replication [121, 122, 107], which could explain how CNS 
resident astrocytes and microglial cells get infected [115]. Infection of astrocytes can 
be reconciled by the fact that, like B-cells, they also express CD21, the receptor for 
EBV [123]. Astrocytes are the most abundant cells in the CNS, constituting around 
30% of the total cells. They play an important role in a number of homeostatic and 
neuroinflammatory processes within the CNS, including axon guidance, synaptic 
transmission and controlling BBB [124, 125]. An accumulating body of data now 
indicates that activated astrocytes also play a central role in neurodegenerative 
diseases such as MS [124–126]. Since astrocytes interact with blood vessels to form 
the BBB, any functional impact on these cells could also increase BBB permeability 
and exacerbate infiltration of peripheral immune cells into the CNS [120, 125, 127]. 
This could explain the characteristic perivascular cuffing and presence of inflam-
matory aggregates resembling germinal center (GC)-like structures commonly 
observed in the CNS in viral infections [22, 128]. Although the precise role of these 
tertiary lymphoid aggregates remains unknown, it is likely that they play a key role 
Figure 1. 
Model for EBV involvement in MS pathology. The pathogenesis of MS is no doubt very complex. This is a 
simplified outline of a potential model to explain some of the experimental findings linking EBV to MS. EBV 
persists in memory B-cells in peripheral circulation [39, 40] and in healthy seropositive individuals, they are 
tightly regulated by the immune system. In individuals genetically predisposed to MS, these cells cross the BBB 
and enter the CNS where they trigger an inflammatory response leading to the formation of GC-like structures 
[128, 129]. Most of the infected cells remain latently infected with limited viral gene expression [107, 108]. These 
infected cells could function as APC for the activation of helper T-cells [118] which in individuals carrying 
certain HLA haplotypes [89, 132], leads to the activation of autoreactive B and T-cells that recognize both EBV 
and self-antigens [99, 101, 118]. A small proportion of EBV infected memory B-cells, upon differentiation into 
plasma cells, initiate EBV replicative cycle [121, 122]. The new virions produced, infect other susceptible cells, 
including astrocytes and microglia [115, 123]. Microglia and astrocytes are two main types of cells typically 
providing a protective role against viral infection. In their activated form, they release various pro-inflammatory 
cytokines and immune mediators that activate the immune system to resolve the infection [125, 133]. In MS, 
these chronically activated cells switch from being neuroprotective to neurotoxic [133, 134]. Additionally, 
proinflammatory microglia can also induce activation of astrocytes, which can impact not only the BBB but also 
contribute to neurotoxicity [125, 126]. The combined effects of these multiple events result in MS pathology.
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in the immune response to CNS injury [129]. In contrast to previously held views, 
studies now indicate that B-cell differentiation and clonal expansion typically 
known to occur in secondary lymphoid organs, can also occur in the CNS [130]. This 
finding also provides an explanation for the source of oligoclonal immunoglobulin 
bands present in the CSF of most patients with MS. In MS, these GC-like aggregates, 
triggered by EBV infection of the brain, could be responsible for recruiting, activat-
ing and sustaining B and T-cells [119, 118] that inadvertently react to auto-antigens, 
such as myelin basic protein (MBP) and GDP-L-fucose synthase, expressed on 
oligodendrocytes (Figure 1) [98, 99, 101]. Moreover, cellular and viral components 
such miRNAs and EBERs, secreted in exosomes could also promote inflammatory 
and pathological changes that contribute to CNS injury in MS [108, 131].
8. Conclusion
The pathogenesis of MS appears to be a complex process, where both genetic and 
environmental risk factors interplay to promote the development of the disease. The 
evidence implicating EBV as a central player in MS development is substantial. For 
some critics, these pieces of evidence are still not sufficient to charge EBV as the mas-
termind behind the pathogenesis of MS. A very recent study by Pender and colleagues 
goes some way to proving the etiological association [135]. The study demonstrated that 
treating MS patients with autologous EBV-specific T cell therapy can improve symp-
toms and quality of life in most patients [135]. The only absolute and unequivocal proof 
that EBV is central to the development of MS, is to prevent EBV infection in the first 
place by vaccination and then see if the incidence of MS declines. Although a number of 
vaccine candidates have been tested, none have yet been approved for clinical use [136].
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provided the original work is properly cited. 
in the immune response to CNS injury [129]. In contrast to previously held views, 
studies now indicate that B-cell differentiation and clonal expansion typically 
known to occur in secondary lymphoid organs, can also occur in the CNS [130]. This 
finding also provides an explanation for the source of oligoclonal immunoglobulin 
bands present in the CSF of most patients with MS. In MS, these GC-like aggregates, 
triggered by EBV infection of the brain, could be responsible for recruiting, activat-
ing and sustaining B and T-cells [119, 118] that inadvertently react to auto-antigens, 
such as myelin basic protein (MBP) and GDP-L-fucose synthase, expressed on 
oligodendrocytes (Figure 1) [98, 99, 101]. Moreover, cellular and viral components 
such miRNAs and EBERs, secreted in exosomes could also promote inflammatory 
and pathological changes that contribute to CNS injury in MS [108, 131].
8. Conclusion
The pathogenesis of MS appears to be a complex process, where both genetic and 
environmental risk factors interplay to promote the development of the disease. The 
evidence implicating EBV as a central player in MS development is substantial. For 
some critics, these pieces of evidence are still not sufficient to charge EBV as the mas-
termind behind the pathogenesis of MS. A very recent study by Pender and colleagues 
goes some way to proving the etiological association [135]. The study demonstrated that 
treating MS patients with autologous EBV-specific T cell therapy can improve symp-
toms and quality of life in most patients [135]. The only absolute and unequivocal proof 
that EBV is central to the development of MS, is to prevent EBV infection in the first 
place by vaccination and then see if the incidence of MS declines. Although a number of 
vaccine candidates have been tested, none have yet been approved for clinical use [136].
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Multiple sclerosis is among the most frequent neurological diseases, which 
affect seriously the quality of life of a constantly increasing number of patients, 
inducing physical and mental invalidism with indefinite perspectives. The ongoing 
investigation of the pathogenetic background and the inconclusive analysis of many 
pathophysiological mechanisms and serious neuropathological alterations of the disease 
are dominant crucial topics in the field of neurosciences, aimed at tracing a definite 
way to a therapeutic approach. The authors of this volume attempt to throw light on 
the labyrinth of multiple sclerosis, approaching the disease from the viewpoint of 
epidemiology, autoimmune reactions, symptomatology, mental and physical decline, 
diagnostic procedures, prognosis, and treatment. The authors submit herein, along with 
scientific data, their hope of contributing effectively to ameliorating the quality of life of 
those suffering from multiple sclerosis who wait patiently for the day of recovery.
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